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What is Rheumatoid Arthritis? 
Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease, 
generally affecting the peripheral joints with a poly-articular distribution. The acute 
features of this disorder are painful, swollen and stiff joints, but it may include also 
systemic manifestations in organs other than the joint. Moreover, the role of 
fatigue as an RA related symptom is quite prominent, especially in established 
RA.  This disease has a worldwide prevalence in adults ranging between 0.2 to 
1.0 percent, with a higher prevalence in more developed countries. Exact 
population numbers for Belgium are unknown, although it is estimated that 
approximately 80 000 individuals are affected. The peak age of RA onset is 
situated in the fifth decade. Furthermore, the disease is three times more 
common in women than in men. [1, 2] 
Left insufficiently treated, RA can lead to bone and cartilage destruction, to loss 
of physical function and impairment of quality of life and participation. However, 
the course of disease is different per individual and hard to predict. Traditionally 
also an increase in morbidity and mortality is associated with RA. [3] Yet, a recent 
study demonstrated a decrease in excess mortality over time in patients with RA 
compared with the general population. [4] The frequency of comorbidities ranges 
between 25-60%, depending on the type of study, the type of evaluated 
comorbidity and the geographical region. Typical comorbidities cited are 
cardiovascular problems, infections and malignancy. Aside of these conditions, 
RA can also have an important psychological impact, with symptoms of anxiety 
and depression[5]. By consequence, often patients with RA have difficulties to 
participate actively in family life and social activities. Hence, management of RA 
should not only focus on the disease itself, but also on managing the frequent 
comorbidities and the mental and social wellbeing of the patient. [6]  
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Overlooking the description of this chronic condition above, it is not surprising 
that the management of RA generates high healthcare related and 
socioeconomic costs. Moreover, on top of these high medical costs, many 
patients with RA are hit by work loss and reduced productivity, not only affecting 
individual but also societal expenditures. [7]  
The etiology of Rheumatoid Arthritis  
Although the exact pathogenesis of RA is not yet completely unraveled, genetic 
and environmental aspects have been comprehensively investigated, giving rise 
to an improved understanding of the dysregulation of the immune system 
involved in RA. [2] 
It is estimated based on evidence from twin studies that over 50% of the risk for 
the development of RA can be attributed to genetic factors. [8, 9] Patients with 
RA more frequently have relatives with RA or other immune-mediated disorders.  
Until recently, only few genetic risk factors for RA have been identified. [10] The 
first genetic risk factor is the human leucocyte antigens (HLA) region which 
seems at the moment the most significant genetic region linked to RA. The HLA 
molecules are encoded by the major histocompatibility complex on chromosome 
6 region 6p21.31 for RA. These molecules are expressed on the surface of 
antigen presenting cells (APCs), activating the T-cells of the immune system. 
Most HLA-DR alleles with an increased risk for RA susceptibility have a common 
amino acid motif, the so-called ‘shared epitope’, in the β chain of the HLA-DR 
molecules. [11, 12] Most research in this field is performed on Caucasian 
populations and slight differences in this genotypic background in other 
ethnicities seems to lead to less severe phenotypes. [13, 14] 
Another well studied genetic risk factor for RA is protein tyrosine phosphatase, 
non-receptor type 22 (PTPN22). The tyrosine phosphatase coded by this gene 
affects the responsiveness of the T- and B-cell receptors. Hence, mutations in 
PTPN22 can be related to an increased risk of RA. [15]  
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A last genetic risk factor we discuss in this introduction is cytotoxic the T 
lymphocyte-associated antigen 4 (CTLA4). CTLA4 codes is a protein receptor on 
the surface of T-cells and can act as a down regulator of the immune system, 
which makes it a prime target in auto immune diseases. [15] Nowadays, genome 
wide association studies identify constantly new genetic regions related to RA, 
although the modest effects of these individual loci limit the use of all these 
genetic risk factors in daily clinical practice. [10] 
Being an autoimmune disease, RA can be characterized in most cases by the 
production of autoantibodies. Rheumatoid Factor (RF) and Anti-Citrullinated 
Peptide-Antibodies (ACPA) are until now the most important autoantibodies in 
RA detection, diagnosis and research. [16]  
RF is an immunoglobulin type M, directed against the Fc component of 
immunoglobulin G (IgG). Lymphocytes secreting RF are present in the peripheral 
blood, synovial fluids and bone marrow in patients with RA. [17] The immune 
complexes formed by RF and IgG activate the immune system. Macrophages are 
activated, releasing pro-inflammatory cytokines like tumor necrosis factor (TNF) 
and interleukins (ILs). On their turn, these proteins enhance the production of 
cartilage- and bone-destructive molecules and the release of other pro-
inflammatory cytokines. 
ACPA, historically also called anti-keratin antibodies or anti-perinuclear factor, 
are increasingly important autoantibodies. The ACPA-producing B-lymphocytes 
and the target of ACPA, citrullinated proteins are present in the synovial tissue 
and fluids of patients with RA. Immune complex formation again activates 
macrophages leading to the production of TNFs and ILs. A close link is found 
between the presence of HLA-DR shared epitope and an increase in ACPA-
production. 
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RF and ACPA are the two most-used markers for the detection and diagnosis of 
RA. Both proteins show similar sensitivity but RF tends to be less specific for RA.  
Detecting and diagnosing RA is improved by measuring both autoantibodies, 
although it is to be noted that neither RF nor ACPA are decisive in the diagnosis 
of RA. [18] 
In addition to ACPA and RF, anti-carbamylated protein antibodies recently appear 
to be a promising target in RA research. These antibodies are associated with 
the future onset of RA and with increased disease severity in early RA [19-21]. 
Aside of genetic variations, environmental risk factors can also increase the risk 
of developing RA. The most established risk factor is smoking. It doubles the risk 
of developing RA but this effect seems restricted to patients who are ACPA 
positive.  There seems to be a strong relationship between smoking, ACPA and 
the HLA-DR risk allele. [22] Alcohol intake, coffee intake, vitamin D status, oral 
contraceptive use, and low socioeconomic status are other suspected risk 
factors, although decisive evidence is lacking. [23] 
Seeing the evidence above, RA can be seen more as a clinical syndrome than 
as one specific disease. Different genetic and environmental risk factors are at 
the basis of different RA subsets with distinct cellular and subcellular 
pathophysiological backgrounds, all converging to a similar type of dysregulation 
of the biological homeostasis, leading to RA as a clinical syndrome. This 
hypothesis can explain the variations in disease course between patients with RA 
and the failure of certain anti-rheumatics in individual patients. 
Clinical Assessment of Rheumatoid Arthritis 
The hallmark of RA, joint inflammation, is also the focus of clinical assessment in 
RA. [24] Nowadays, swollen and tender joint counts should systematically be 
performed in daily clinical practice. The standard joint count in trials focuses on 
28 joints in the knees, upper limbs and hands and might be used also in clinical 
practice.  An important issue is that the feet are neglected in this limited joint 
count. Therefore, physicians might prefer total joint counts, including the feet, 
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specifically in daily practice. Additionally, serum inflammation markers such as 
erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) status should 
regularly be measured. Furthermore, the patient is sometimes asked on a scale 
to rate his perceived global health, his pain level and his fatigue level on a visual 
analogue scale (VAS) ranging from 0 to 100. The physician can also give his 
estimation of the patient’s global health on a VAS scale. [24] Another important 
and widely used measure is the health assessment questionnaire (HAQ), which 
gives an idea of the patient’s physical function. [1, 24, 25] 
In the late nineties, some of the measurements mentioned above were grouped 
to give a general appraisal of disease activity status or treatment response [26]. 
Such Disease Activity Scores (DAS), combining joint counts, serum inflammation 
markers and the patient’s estimation of his/her global health or his/her disease 
activity are now routinely used in daily practice. [27] New disease activity 
measures were developed such as the clinical disease activity index (CDAI) the 
SDAI and the 2010 Boolean remission criteria of the American College of 
Rheumatologists (ACR). [28] Limitations of these scores are the use of the 28 
joint count - hence without counting swelling and pain in the lower limbs - in some 
of the disease algorithms and the use of ESR of CRP status, which are not always 
readily available in daily practice. 
Diagnosis of a patient with RA is left to the discretion of the rheumatologist. 
However, classification criteria were developed to aid the physician in this 
challenging task. These criteria are based on the characteristics of RA as 
mentioned above. The first criteria distinguished between a more established RA 
and other types of established musculoskeletal disorders. [29, 30] However, 
these criteria have difficulty identifying very early rheumatoid arthritis. Erosive 
joint damage and extra-articular disease, two ACR 1987 criteria, are for example 
more frequent in established RA and can be prevented by current treatment 
possibilities. Hence in 2010, the ACR and European League Against 
Rheumatism (EULAR) constructed new criteria, facilitating the classification of 
patients with a more early form of RA. [31] 
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How to treat Rheumatoid Arthritis? 
A little history 
Only a century ago, no effective treatment for RA existed. Patients suffered pain 
and discomfort on a daily base and could only hope that one day something 
effective could aid them. In such conditions, quack remedies are prone to 
develop. It just shows how desperate people are when being confronted with a 
disabling disorder as RA. These ‘cures and treatments’ for RA range from 
reasonable actions such as a diet and anti-infectious agents to more remarkable 
steps taken such as standing inside the carcass of a whale as witnessed on the 
coasts of Australia, applying an obscure sort of oil, secreted by the earthworm as 
seen in Scotland to even electric convulsion therapy in some cases. Placebo 
effect of course played a major role in the perceived efficacy of such remedies. 
[32] However, it is in these circumstances that the first seeds of effective RA 
treatment were planted. For example,  gold salts were introduced in RA treatment 
around 1930 because it was believed that tuberculosis and other infectious 
diseases were potentially the cause of RA and gold was fairly effective in 
tuberculous disease. Hence, a false hypothesis could render a good result. 
Furthermore, in the 1950 glucocorticoids (GCs) made their appearance in RA 
treatment. Stress was than seen as a possible cause for RA and patients were 
prescribed stays at spas and other stress-relieving therapies. It was then believed 
that anti-stress treatments were successful because of adrenocortical stimulation 
and increase in GCs production. Hence, synthetic GCs were developed and they 
proved indeed very successful for RA treatment. Unfortunately GC’s were given 
initially in dosages of 300mg/day, leading rapidly to severe adverse events and 
giving rise to their infamous reputation until today. Moreover, sometimes the 
discovery of a drug is helped by careful patient observation. Anecdotal reports in 
the South Pacific war stage in World War II described the improvement of RA 
symptoms in Allied soldiers on long-term anti-malarial therapy. Hence, 
chloroquine and hydroxychloroquine were introduced in the treatment of RA. As 
a side note, these anti-malarial agents originate from the ‘fever tree’ in South 
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America and this tree was already found to be a miraculous remedy for many 
diseases in the era of the Inca’s. [33]  
This very short and incomplete history illustrates the difficulty physicians had 
treating RA patients without many means. However, it is in this period that the 
first steps towards an effective RA treatment were taken. [32, 33] 
Pharmacological treatments for RA 
Today, patients with RA have fortunately access to more effective treatment 
options. For symptomatic treatment of RA, non-steroidal anti-inflammatory drugs 
(NSAIDs) can be used to  suppress the pain. These drugs work by inhibiting the 
production of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), which 
are responsible for the activation of the pathways of pain sensation by 
prostaglandins or thromboxanes. It is believed that the inhibition of COX-2 leads 
to the anti-inflammatory and analgesic effects, while inhibiting COX-1 may cause 
gastrointestinal bleeding and ulcers. Therefore, specific COX-2 inhibitors were 
developed, pairing efficacy in reducing symptoms of RA with reduced 
gastrointestinal toxicity in comparison with more traditional NSAIDs. [34] 
Unfortunately all NSAIDs share an unfavorable cardiovascular and renal risk 
profile. [35] Therefore their use should be restricted to short periods of time and 
specific clinical situations. 
Disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone in the 
treatment of RA. [36-38] The term originates from the capability of these drugs to 
prevent bone erosions. This broad group of DMARDs can roughly be divided into 
two groups.  
Firstly, the synthetic DMARDs are small molecules modulating and suppressing 
the immune system. This type of DMARDs consists of conventional and recently 
also more targeted synthetic DMARDs. Currently, the most used conventional 
DMARDs are Methotrexate (MTX), Sulphasalazine (SSZ),Leflunomide (LEF) and 
Hydroxychloroquine (HCQ). These ‘traditional’ drugs all have proven their 
effectiveness in treating patients with RA, with an acceptable safety profile. The 
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new class of targeted synthetic DMARDs comprises the Janus Kinase (JAK) 
inhibitors, which were recently introduced to the pharmaceutical market.  This oral 
compound might have its merits, but the long-term results and the efficacy/safety 
balance are not yet clear. [39]  
Secondly, the biological DMARDs, also called biologics, are biotechnological 
drugs with a very specific target, located in one of the pathways of inflammation 
or auto-immunity. [40] These drugs have a tendency to work more rapidly than 
conventional synthetic DMARDs. Roughly, two groups can be distinguished. A 
first group of biologics consists of the anti-TNF drugs. As described above, TNF-
alpha is a key cytokine in the pathophysiology of RA and by its inhibition 
inflammation is suppressed. The following biologicals belong to this group: 
Adalimumab, Certolizumab pegol, Etanercept, Golimumab and Infliximab. More 
recently biologicals with other mechanisms of action were introduced, including 
Abatacept, Rituximab and Tocilizumab. Abatacept acts by modulating T-cell 
function, Rituximab lowers the amount of specific types of B-cells and 
Tocilizumab inhibits IL-6. All these targets are again determining elements of the 
inflammation cascade. A substantial drawback of the biologicals is their high cost. 
Nowadays however, the patents on some of the drugs in this class have expired 
or are expiring soon. Hence, biosimilars, expressing a highly similar quality and 
efficacy profile in comparison with the original biologicals, are currently entering 
the market. This drastic economic change could influence the future affordability 
and use of biologic therapy in the treatment of RA. [41] 
GCs are already commonly used from the fifties in the treatment of RA.  Also this 
class of drugs can be considered as DMARDs, albeit somewhat atypical. GCs 
bind to the glucocorticoid receptor, which among other things regulates genes 
controlling the  immune system. Thus, GCs rapidly suppress the over-active 
immune system and as a result, inflammation will be reduced. Besides 
suppression of inflammation and immune modulation, GCs have a range of other 
biologic effects in different organ systems, raising concerns because of the 
potential adverse events related to this. However, decisive evidence on safety is 
lacking [42, 43].  
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An important side remark to this list of pharmacological treatment is the speed of 
treatment response after medication intake. Roughly, two categories exist. The 
first category consists of the slow acting anti-rheumatic drugs. For example, 
Methotrexate reaches its maximum potency after three to four months of 
treatment. Logically, the second group consists of fast acting anti-rheumatic 
drugs, quickly suppressing pain and inflammation. Biologicals are an example, 
but the most known members of this family are GCs. In that respect, GCs are 
useful for bridging the interval between initiation of DMARD therapy and onset of 
their therapeutic effect. A further discussion point can consist of whether GCs can 
be regarded as DMARDs or not. Some physicians regard GCs as pure 
symptomatic treatment, while most studies show that GCs have the ability to 
prevent bone erosions, the definition of a DMARD. In this discussion, GC dosage 
and duration should be taken into account. These two factors probably influence 
its DMARD-like abilities. [43-45] 
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Treatment strategies for RA 
Pharmacological treatment strategies for patients with early RA have changed in 
recent history. Only two decades ago, physicians would act on a ‘go low, go slow’ 
base. Patients were to be treated conservatively and mainly symptomatically. The 
paradigm was to first initiate treatment with symptom relieving drugs, such as 
NSAIDs and analgesics, and if insufficiently effective, to add a DMARD like SSZ 
or MTX. This approach embodied the classical pyramid strategy. As a 
consequence of this slow approach, the burden of disease for patients with RA 
was high, not only short-term but also in the long run. Important structural damage 
and disability were very common in patients with established RA. Many drugs for 
RA were used with a suboptimal strategy and some older therapeutics are now 
considered inadequate. At the end of the 20th century, the armamentarium to 
combat this condition was enlarged and strengthened, not only by a new range 
of therapeutic agents, with the introduction of the biologicals, but foremost by new 
therapeutic regimens based on existing drugs. It became clear that intensive and 
early treatment with optimized medication schedules often combining different 
anti rheumatic drugs, including traditional DMARDs but also GCs, in a treat to 
target approach, resulted in much better clinical outcomes than held possible. 
[46-50] In the current era of increasing therapeutic choices, rheumatologists are 
challenged to choose the treatment strategy that guarantees the best possible 
disease outcome for every individual patient, ideally fulfilling both clinicians’ and 
RA patients’ treatment goals. Moreover, these goals should be achieved within 
reasonable cost boundaries. [51] Current international guidelines recommend 
treating RA patients early, intensively and to target. [36-38] However, these 
treatment recommendations still leave much room for interpretation by the 
treating rheumatologist. 
The first principle is to treat a patient early. The time elapsed between RA 
symptom onset and treatment initiation influences treatment outcome, particularly 
if DMARD monotherapy or a slow step-up strategy is chosen as initial therapeutic 
approach. [52-54] A better treatment outcome is expected when treatment is 
initiated earlier than 12 weeks after symptom onset. Hence, treatment delay is of 
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interest for the rheumatologic community. However, treatment delay is found to 
be too long in many countries. [55] This total treatment delay is influenced by 
patient, General Practitioner (GP) and rheumatologist-related factors and 
strongly dependent on the healthcare system. At these different levels there are 
opportunities to minimize delay and optimize early RA treatment. There is 
evidence that the longer it takes to start a treatment, the more important it is to 
start a combination therapy. [56] 
Given the evidence above, the treatment focus is sometimes even shifted to 
undifferentiated arthritis (UA), which can be partly viewed as a precursor of RA 
or even a very early stage of RA itself, especially in case ACPA is positive. [57] 
The rationale is to tackle the disease before RA can fully develop. Treating these 
patients indeed postpones the evolution to classical RA and inhibits radiographic 
damage as shown in the PROMPT study. [58, 59] However, treating all patients 
with UA holds a danger for overtreatment, because the majority of UA patients 
do not develop RA. 
The second principle is to treat intensively with DMARDs as the basis of 
treatment. [36-38] All international guidelines recommend MTX as gold standard 
in RA treatment at present, because of its effectiveness and safety profile. [60] 
The question that many physicians encounter in daily practice is if combinations 
of slow and fast acting anti-rheumatic drugs are more effective than plain MTX 
monotherapy in patients with early RA. In the late nineties, the effectiveness of 
combination therapy with DMARDs versus monotherapy was studied. No benefit 
of the combination of MTX and SSZ compared to only MTX or SSZ is observed 
in early RA. [48] Other trials however showed that combination therapy was more 
effective than monotherapy in refractory RA. [61, 62] At the same time, the 
potential advantage of adding a low dose of GCs to the anti-rheumatic therapy 
was studied in more detail, showing that GCs could effectively inhibit radiographic 
damage. [63] The indications found in these studies were a source of inspiration 
for one of the hallmarks of early RA trials: the COBRA trial. This study showed 
that a combination of DMARDs with a remission induction scheme of GCs was 
superior over DMARD monotherapy. [46] Other concurrent trials demonstrated 
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similar results. [47, 49]  However, SSZ monotherapy was chosen as the 
comparator in the COBRA study, and it remained unclear if MTX monotherapy 
was less effective than DMARD combination therapy with GCs as well. In 2007, 
the BEST trial showed that DMARD combination therapies, supplemented with a 
remission induction scheme with GCs or a biological, were superior to MTX 
monotherapy, even in the context of a treat to target strategy. Moreover, 
combination strategies with a TNF blocker as fast acting compounds showed 
similar efficacy as a DMARD combination with GC remission induction. [64] 
The last but certainly not the least principle is treating a patient to a certain 
predefined clinical target. This important principle emerged at the beginning of 
the 21th century. The TICORA and CAMERA trials showed that adapting therapy 
in case the goal set for disease outcome was not reached, gave superior 
treatment results. [50, 65] Hence, patients with early RA should be treated to 
target and as a consequence followed in a tight control setting. This standard 
indicates that a patient should be monitored regularly to control if the outcome 
aims are reached and alter the treatment schedule if necessary [36-38]. Treating 
to target but with too long stretches of time in between clinical evaluations 
unfortunately nullifies the advantage of rapidly adapting the treatment to an 
individual patient’s needs. The adagio ‘you cannot manage what you do not 
measure’ should be honored [6]. 
Starting from treatment initiation, the primary goal should be clinical remission or 
at least low disease activity, which is most easily achieved with a ‘hit hard, hit 
fast’ approach. In the field of rheumatology, physicians theoretically have the 
choice between GCs or an array of biological DMARDs in combination with MTX 
to aim for remission. The BEST trial compared remission induction with GCs and 
with biological therapy and found comparable efficacy. [64] In practice however 
the choice is restricted by economic and other constraints incorporated in 
guidelines and reimbursement criteria. Expensive biological therapy combined 
with MTX gave superior effects versus MTX monotherapy in several pivotal RCTs 
mostly without a treat to target approach, and this with remission rates ranging 
between 20-60%. [66-74] Trials using the cheaper GCs combined with MTX 
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showed remission rates ranging between 30-70%. [46, 59, 64, 75-78] Yet, most 
of these trials touched only upon low dose GC use, while increasing attention is 
given to GCs in moderate or high doses as part of remission induction at 
treatment initiation. Induction therapies including GCs are often perceived as 
complicated because of concerns about the broad spectrum of potential adverse 
reactions. [79] However, evidence for increased numbers of adverse events when 
using low-dose or high-dose GCs in the short term is scarce [42, 43]. 
Furthermore, GCs and biological therapy have even been combined for remission 
induction, with excellent clinical results. [80, 81] In conclusion, remission 
induction with GCs seems to be a very effective initial therapy choice without 
economic restraints and with good feasibility in daily clinical practice. [51, 82] 
Patients who are refractory to this initial therapeutic approach with synthetic 
DMARDS and GCs currently have several options with biologicals. To note is that 
this vast and expensive array of biological DMARDs performs better when 
combined with a traditional DMARD such as MTX. [40] Economic constraints 
might influence optimal treatment choices and interfere sometimes with 
guidelines. Inequities in access to treatment are seen for example in countries 
with lower socioeconomic welfare. These countries tend to have also stricter 
eligibility criteria for biologicals. [83] 
The window of opportunity 
According to the window of opportunity theory, in the first months after diagnosis 
of RA, intensive treatment should be initiated as soon as possible to achieve 
remission rapidly, to prevent radiographic progression and to increase the chance 
of long-term remission. [84, 85] This period in which therapy is more successful 
seems to be limited by rather stringent boundaries. Recent studies have shown 
that patients are more responsive to RA treatment only within the first 20 weeks 
after symptom onset. [86, 87] Furthermore, to benefit maximally from the window 
of opportunity, following prompt treatment initiation any sign of RA disease activity 
should be treated and controlled as soon as possible with regular adjustment of 
treatment in case of insufficient response. [50, 88] 
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In contrast to the evidence above, the SWEFOT and the recent TEAR trial 
showed that add-on therapies, starting with MTX monotherapy but rapidly adding 
synthetic or biological DMARDs after MTX failure yield  comparable efficacy rates 
after one year compared to initial combination therapy. [89, 90] However, the 
burden of disease for patients over time was not considered in these exercises. 
Every extra week, or even day, it takes to achieve remission counts in terms of 
the individual patients’ quality of life. From our point of view choosing a treatment 
strategy that leads to a delay in disease control compared to the optimal 
therapeutic approach cannot be defended, even if it ultimately results in a 
comparable disease activity level at a cross-sectional measurement point later 
on in the disease course, i.e. after one year of treatment. The way a patient 
reaches an endpoint is at least as important as the endpoint as such, certainly 
taking into account the patient perspective. Furthermore, the initial response is 
shown to be probably the driver for good clinical outcomes in the long run. [84, 
85] 
Nevertheless, some questions remain unanswered regarding the optimal initial 
therapy for early RA. The COBRA and BEST trial showed that MTX and SSZ 
combined with a GC remission induction scheme starting at 60mg/day 
prednisone was superior compared to MTX or SSZ monotherapy. [46, 64] The 
added effect of SSZ in this regimen and the initial high dose of prednisone are 
however up for discussion. The Cobra-light study first explored the original 
COBRA scheme versus an attenuated scheme leaving out SSZ and using less 
prednisone in the remission induction scheme, starting at 30 mg/day, tapered to 
7.5 mg/day in 9 weeks. This trial provided the first clues that an attenuated Cobra 
scheme could possibly give similar results. [78, 91] However, it was 
underpowered, administered a different suboptimal dose of MTX at baseline in 
the comparison group, used a comparable total cumulative prednisone dosage in 
both groups and had rapid add-on of anti-TNF therapy build in the protocol. The 
results were thus ambiguous. Other trials such as CARDERA, tREACH and 
IMPROVED also used some form of an attenuated Cobra scheme with excellent 
clinical results. [59, 76, 92, 93] 
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The CareRA trial 
Because strong evidence regarding the optimal composition of RA treatment 
regimens based on the Cobra scheme was still lacking and the feasibility in daily 
practice was often questioned, the Care in early RA (CareRA) trial was initiated. 
This trial has served as the backbone of my thesis. 
The CareRA study is a two year prospective, multicenter, investigator-initiated, 
randomized clinical trial. In total, thirteen Flemish rheumatology practices have 
actively participated: two academic centers, seven general hospitals and four 
private practices. DMARD naive patients with RA, as defined by the ACR 1987 
revised classification criteria were recruited between January 2009 and May 
2013. These adult patients were included if their disease duration, the period 
between RA diagnosis and treatment initiation, was less than or equal to one 
year. Patients having contra indications for the applied treatments as judged by 
their rheumatologist were excluded. These patients with early RA were then 
stratified into a high or low-risk group based on the presence of erosions, RF 
and/or ACPA; and low or high disease activity. Subsequently, the high-risk 
patients were randomized to one of three possible intensive treatment strategies 
with a high or moderate initial dosed GC remission induction scheme. On the 
other hand, the low-risk patients were randomized in a conservative step up or 
an intensive step down approach. This rough description of the CareRA trial will 
be put into more detail further in this thesis.  
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Aims of the thesis 
In summary, treatment prospects for patients with RA have improved greatly 
compared to the past. However, still many questions regarding the optimal 
strategy for identification, stratification and treatment initiation in early RA patients 
remain unanswered. In this PhD project, we aim to optimize the management for 
every patient with early RA, irrespective of the clinical presentation. Therefore, 
we put forward three research questions: 
1. How long does it currently take before treatment can be initiated in early RA 
and what are the determinants of a potential delay? 
 Chapter 1: Treatment delay in RA care 
2. Is a personalized treatment approach feasible with the current prognostic 
biomarkers? 
 Chapter 2: Therapeutic prognostic factors: value and future 
3. What is the optimal intensive treatment regimen for early RA?  
 Chapter 3: Optimal intensive treatment 
 
 
 
 
 
 
 
 
 18 
 
REFERENCES 
1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376 9746: 1094-108. 
2. Tobon GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: 
Rheumatoid arthritis. Autoimmun Rev 2010;9 5: A288-92. 
3. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 
2007;21 5: 885-906. 
4. Norton S. Excess mortality in rheumatoid arthritis: gains in life expectancy over 25 years. British 
Society for Rheumatology 2014: Rheumatology 2014 Abstracts. 2014:i69-i70. 
5. Smedstad LM, Moum T, Vaglum P, Kvien TK. The impact of early rheumatoid arthritis on 
psychological distress. A comparison between 238 patients with RA and 116 matched controls. Scand J 
Rheumatol 1996;25 6: 377-82. 
6. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P et al. Treating 
rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann 
Rheum Dis 2015. 
7. Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 2004;71 6: 
518-24. 
8. van der Woude D, Houwing-Duistermaat JJ, Toes RE, Huizinga TW, Thomson W, Worthington J 
et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein 
antibody-negative rheumatoid arthritis. Arthritis Rheum 2009;60 4: 916-23. 
9. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K et al. Characterizing the 
quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43 1: 
30-7. 
10. Messemaker TC, Huizinga TW, Kurreeman F. Immunogenetics of rheumatoid arthritis: 
Understanding functional implications. J Autoimmun 2015. 
11. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D et al. 
Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope 
for antibodies to citrullinated proteins. Arthritis Rheum 2005;52 11: 3433-8. 
12. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to 
understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30 11: 
1205-13. 
 19 
 
13. Malemba JJ, Mbuyi-Muamba JM, Mukaya J, Bossuyt X, Emonds MP, Deiteren K et al. The 
phenotype and genotype of rheumatoid arthritis in the Democratic Republic of Congo. Arthritis Res Ther 
2013;15 4: R89. 
14. Chun-Lai T, Padyukov L, Dhaliwal JS, Lundstrom E, Yahya A, Muhamad NA et al. Shared epitope 
alleles remain a risk factor for anti-citrullinated proteins antibody (ACPA)--positive rheumatoid arthritis in 
three Asian ethnic groups. PLoS One 2011;6 6: e21069. 
15. Mohan VK, Ganesan N, Gopalakrishnan R. Association of susceptible genetic markers and 
autoantibodies in rheumatoid arthritis. J Genet 2014;93 2: 597-605. 
16. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373 9664: 659-72. 
17. Panush RS, Bittner AK, Sullivan M, Katz P, Longley S. IgM rheumatoid factor elaboration by 
blood, bone marrow, and synovial mononuclear cells in patients with rheumatoid arthritis. Clin Immunol 
Immunopathol 1985;34 3: 387-91. 
18. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al. Meta-analysis: 
diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid 
arthritis. Ann Intern Med 2007;146 11: 797-808. 
19. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA et al. 
Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis 
and predict joint damage. Proc Natl Acad Sci U S A 2011;108 42: 17372-7. 
20. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D et al. Anti-
carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 
2014;73 4: 780-3. 
21. Gan RW, Trouw LA, Shi J, Toes RE, Huizinga TW, Demoruelle MK et al. Anti-carbamylated 
protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J 
Rheumatol 2015;42 4: 572-9. 
22. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J et al. A new model for 
an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune 
reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54 1: 38-46. 
23. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J et al. Environmental risk 
factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated 
peptides. Arthritis Res Ther 2006;8 4. 
24. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B et al. The American 
College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical 
 20 
 
trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 
1993;36 6: 729-40. 
25. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and 
review. Arthritis Care Res 1992;5 3: 119-29. 
26. Pincus T, Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and 
clinical care. Best Pract Res Clin Rheumatol 2003;17 5: 753-81. 
27. Dougados M, Aletaha D, van Riel P. Disease activity measures for rheumatoid arthritis. Clin Exp 
Rheumatol 2007;25 5 Suppl 46: S22-9. 
28. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J et al. American College of 
Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid 
arthritis for clinical trials. Ann Rheum Dis 2011;70 3: 404-13. 
29. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958 Revision of diagnostic criteria for 
rheumatoid arthritis. Bull Rheum Dis 1958;9 4: 175-6. 
30. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American 
Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 
1988;31 3: 315-24. 
31. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd et al. 2010 rheumatoid 
arthritis classification criteria: an American College of Rheumatology/European League Against 
Rheumatism collaborative initiative. Ann Rheum Dis 2010;69 9: 1580-8. 
32. Hart FD. History of the treatment of rheumatoid arthritis. Br Med J 1976;1 6012: 763-5. 
33. Weisman MH. Natural history and treatment decisions in rheumatoid arthritis revisited. Arthritis 
Care Res 1989;2 3: S75-83. 
34. Whittle SL, Colebatch AN, Buchbinder R, Edwards CJ, Adams K, Englbrecht M et al. Multinational 
evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: 
integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e 
Initiative. Rheumatology (Oxford) 2012;51 8: 1416-25. 
35. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-
counter NSAIDs. Ther Clin Risk Manag 2015;11: 1061-75. 
36. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M. Management of rheumatoid arthritis: 
summary of NICE guidance. BMJ 2009;338: b702. 
37. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al. 2012 update of the 
2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic 
 21 
 
drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64 5: 
625-39. 
38. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M et al. EULAR 
recommendations for the management of rheumatoid arthritis with synthetic and biological disease-
modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73 3: 492-509. 
39. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D et al. Tofacitinib versus 
methotrexate in rheumatoid arthritis. N Engl J Med 2014;370 25: 2377-86. 
40. Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P et al. Efficacy of 
biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update 
of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73 3: 
516-28. 
41. Yoo DH. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Expert 
Rev Clin Immunol 2014;10 8: 981-3. 
42. van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F et al. 
Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials 
and daily practice. Ann Rheum Dis 2010;69 11: 1913-9. 
43. Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F et al. EULAR evidence-
based and consensus-based recommendations on the management of medium to high-dose 
glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72 12: 1905-13. 
44. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic 
diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50 11: 3408-17. 
45. Spies CM, Strehl C, van der Goes MC, Bijlsma JW, Buttgereit F. Glucocorticoids. Best Pract Res 
Clin Rheumatol 2011;25 6: 891-900. 
46. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al. 
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with 
sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350 9074: 309-18. 
47. Calguneri M, Pay S, Caliskaner Z, Apras S, Kiraz S, Ertenli I et al. Combination therapy versus 
monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999;17 6: 699-
704. 
48. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M et al. Combination 
therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of 
 22 
 
sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999;58 4: 220-
5. 
49. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M et al. 
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised 
trial. FIN-RACo trial group. Lancet 1999;353 9164: 1568-73. 
50. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al. Effect of a treatment 
strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled 
trial. Lancet 2004;364 9430: 263-9. 
51. Verschueren P, Westhovens R. Optimal care for early RA patients: the challenge of translating 
scientific data into clinical practice. Rheumatology (Oxford) 2011;50 7: 1194-200. 
52. Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G. Very early rheumatoid 
arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-
progression. Ann Rheum Dis 2011;70 7: 1292-5. 
53. Raza K. The Michael Mason prize: early rheumatoid arthritis--the window narrows. Rheumatology 
(Oxford) 2010;49 3: 406-10. 
54. van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW et al. Long-
term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 2010;62 12: 3537-46. 
55. Raza K, Stack R, Kumar K, Filer A, Detert J, Bastian H et al. Delays in assessment of patients 
with rheumatoid arthritis: variations across Europe. Ann Rheum Dis 2011;70 10: 1822-5. 
56. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J et al. Delay to institution of 
therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug 
therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46 4: 894-8. 
57. Raza K, Gerlag DM. Preclinical inflammatory rheumatic diseases: an overview and relevant 
nomenclature. Rheum Dis Clin North Am 2014;40 4: 569-80. 
58. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM et al. Efficacy of 
methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-
controlled trial. Arthritis Rheum 2007;56 5: 1424-32. 
59. Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, van Oosterhout M, Harbers JB et al. A 
two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the 
IMPROVED study. Ann Rheum Dis 2014;73 7: 1356-61. 
60. Kay J, Westhovens R. Methotrexate: the gold standard without standardisation. Ann Rheum Dis 
2009;68 7: 1081-2. 
 23 
 
61. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ et al. Treatment of 
rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all 
three medications. N Engl J Med 1996;334 20: 1287-91. 
62. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G et al. Combination therapy with 
cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination 
Study Group. N Engl J Med 1995;333 3: 137-41. 
63. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis 
and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333 3: 142-6. 
64. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM 
et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 
2007;146 6: 406-15. 
65. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ et al. 
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer 
Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum 
Dis 2007;66 11: 1443-9. 
66. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ et al. A multicentre, 
double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 
receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann 
Rheum Dis 2004;63 9: 1062-8. 
67. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al. 
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with 
adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, 
aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 
2006;54 1: 26-37. 
68. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P et al. Clinical 
efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor 
prognostic factors. Ann Rheum Dis 2009;68 12: 1870-7. 
69. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z et al. Golimumab, a new human anti-
tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid 
arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-
controlled study. Arthritis Rheum 2010;62 4: 917-28. 
 24 
 
70. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W et al. Inhibition of 
joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid 
arthritis: the IMAGE trial. Ann Rheum Dis 2011;70 1: 39-46. 
71. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B et al. Clinical, 
functional and radiographic consequences of achieving stable low disease activity and remission with 
adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from 
the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72 1: 64-71. 
72. Detert J, Bastian H, Listing J, Weiss A, Wassenberg S, Liebhaber A et al. Induction therapy with 
adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus 
methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an 
investigator-initiated study. Ann Rheum Dis 2013;72 6: 844-50. 
73. Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R et al. Clinical, radiographic 
and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the 
ACT-RAY study. Ann Rheum Dis 2014;73 5: 803-9. 
74. Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR et al. Certolizumab 
pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, 
randomised, placebo-controlled trial. Ann Rheum Dis 2015;74 5: 843-50. 
75. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I. Low-dose 
prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active 
rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized 
trial. Arthritis Rheum 2005;52 11: 3360-70. 
76. Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L et al. Factorial randomised 
controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. 
Ann Rheum Dis 2008;67 5: 656-63. 
77. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E et al. Low-dose 
prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a 
randomized trial. Ann Intern Med 2012;156 5: 329-39. 
78. den Uyl D, ter Wee M, Boers M, Kerstens P, Voskuyl A, Nurmohamed M et al. A non-inferiority 
trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: 
clinical results after 26 weeks. Ann Rheum Dis 2014;73 6: 1071-8. 
 25 
 
79. Meyfroidt S, van Hulst L, De Cock D, Van der Elst K, Joly J, Westhovens R et al. Factors 
influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis. 
Scand J Rheumatol 2014;43 4: 265-72. 
80. Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppanen O et 
al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from 
an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann 
Rheum Dis 2013;72 6: 851-7. 
81. Horslev-Petersen K, Hetland ML, Junker P, Podenphant J, Ellingsen T, Ahlquist P et al. 
Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early 
rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an 
investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 
2014;73 4: 654-61. 
82. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down 
treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 2008;47 
1: 59-64. 
83. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T et al. Inequities in access to biologic 
and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73 1: 198-206. 
84. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment 
predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56 10: 
3226-35. 
85. Verschueren P, Esselens G, Westhovens R. Predictors of remission, normalized physical 
function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: 
an observational study. Scand J Rheumatol 2009;38 3: 166-72. 
86. Raza K, Filer A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? 
Ann Rheum Dis 2015;74 5: 793-4. 
87. van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH. Evaluating 
relationships between symptom duration and persistence of rheumatoid arthritis: does a window of 
opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. Ann Rheum Dis 
2015;74 5: 806-12. 
88. Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA et al. A tight 
control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual 
 26 
 
care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring 
registry. Ann Rheum Dis 2012;71 6: 845-50. 
89. O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL, Jr., Ranganath VK et al. Validation of the 
methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-
year randomized, double-blind trial. Arthritis Rheum 2013;65 8: 1985-94. 
90. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E et al. Addition 
of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients 
with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374 9688: 
459-66. 
91. Ter Wee MM, den Uyl D, Boers M, Kerstens P, Nurmohamed M, van Schaardenburg D et al. 
Intensive combination treatment regimens, including prednisolone, are effective in treating patients with 
early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, 
randomised, non-inferiority trial. Ann Rheum Dis 2014. 
92. de Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA et al. 
Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of 
the tREACH trial. Ann Rheum Dis 2013;72 1: 72-8. 
93. de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA et al. Randomised 
comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose 
glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis 2014;73 7: 1331-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27 
 
 
 
 
 
CHAPTER 1 
 
 
 
 
 
Treatment delay in RA care 
 
 
Page 28  De Cock D, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P. A 
detailed analysis of treatment delay from the onset of symptoms in early 
rheumatoid arthritis patients. Scandinavian journal of rheumatology. 
2014;43(1):1‐8. 
 
 
 
 
 
 
 
 
 28 
 
A detailed analysis of treatment delay from the onset of 
symptoms in patients with early Rheumatoid Arthritis  
 
ABSTRACT 
Objectives: A treatment delay above 12 weeks can negatively affect treatment 
response in Rheumatoid Arthritis (RA). Our aim was to quantify the different 
stages of delay before RA treatment in different rheumatology centers and to 
explore influencing factors. 
Methods: 156 DMARD naive early RA patients were included from eight 
practices: one academic hospital, five general hospitals and two private practices. 
Eight different types of delay were defined from symptom onset till treatment 
initiation. Information on the duration of each stage of delay was collected from 
the patient, their general practitioner (GP) and patient files at the rheumatology 
practice. Patient/GP demographics and disease activity/severity parameters 
were registered.  
Results: The median total delay from symptom onset until treatment initiation 
was 23 weeks whereas patient-, GP- and rheumatologist-related median delay 
was 10, 4 and 7 weeks respectively. Only 21.6% of patients had a total delay 
below 12 weeks. Total median delay in private rheumatology practices was 
shorter compared to academic and general hospitals (p<0,001). Furthermore, RA 
patients treated within less than 12 weeks showed a higher level of disease 
activity. The duration of rheumatologist related delay was inversely correlated 
with disease activity parameters. Patients with morning stiffness were treated 
sooner, on average 3 weeks, than those without morning stiffness (p<0,006). 
Conclusion: In only one out of five early RA patients, treatment was initiated 
within less than 12 weeks as recommended. Patient-related delay contributed 
most to overall delay. Disease activity and type of rheumatology center seem 
pivotal determinants of delay. 
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Introduction 
Rheumatoid Arthritis (RA) is a chronic, systemic inflammatory disorder, which can 
inflict joint destruction and malformation resulting in functional disability (1, 2). A 
delay in initiating therapy could adversely affect treatment outcomes such as 
disease activity, remission, functional capacity, and radiographic progression (3-
12). It has been demonstrated that the best predictor for a beneficial disease 
outcome consists of treating RA patients as early as possible.  A period of 12 
weeks between symptom onset and treatment start is found to be the threshold 
between favorable or adverse disease outcomes (13, 14). Thus, intensive therapy 
should be initiated as early as possible (15), with the first three months after RA 
symptom onset representing a therapeutic window of opportunity (16, 17). 
Likewise, the European League Against Rheumatism (EULAR) 
recommendations and  the National Institute for Health and Clinical Excellence 
(NICE) guidelines state that therapy should be initiated as soon as RA diagnosis 
is made (18, 19). The American College of Rheumatology (ACR) 
recommendations are somewhat less clear in that respect (20). 
 
Current reports documenting time from symptom onset to treatment initiation in 
different countries show a delay ranging from a median of 6 to 42 months (21-
27). These papers also demonstrate that only a minority of the population is 
treated in less than 12 weeks ranging from 8% to 42% of patients. 
 
The total treatment delay is determined by patient-, disease- and physician-
related factors but also by differences in healthcare organization and referral 
pathways across various countries (25). Total treatment delay can be divided in 
two segments.  
The first segment is patient related. This delay is the time elapsed between time 
of onset of RA symptoms and the first appointment with a healthcare professional. 
In some countries this type of delay contributes the most to the total delay (25, 
28). It is influenced by various factors such as RA disease severity and help 
seeking behavior of the patient (29-32).  
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The second segment of total treatment delay is physician related. It consists of 
the time between the first appointment with a health care provider, usually a 
general practitioner (GP), and initiation of therapy. The physician delay is 
primarily associated with the effectiveness of the intervention  by treating 
physicians such as the GP or the rheumatologist: rapidity of the diagnostic 
process, promptness of referral and therapeutic decisiveness. Moreover, various 
other factors influence referral or time to treatment initiation (29, 33-36). For 
example, women are referred later than men (37, 38) and DMARDs are initiated 
earlier in patients without concomitant musculoskeletal conditions (39).  
 
The main aim of this prospective study was to quantify total treatment delay and 
the different stages of delay across different rheumatology centers and to verify 
and elaborate the existing knowledge on delay using a different data collection 
methodology involving patients as well as GP’s. Furthermore, we aimed to 
identify differences between types of rheumatology centers and to investigate 
potential patient-, GP- and disease- related determinants of delay. A better insight 
in determining factors might be beneficial for organizing RA care. 
 
Patient and methods 
Study Design 
This study was performed as a side project of the CareRA study, an ongoing 
multicenter prospective randomized controlled trial comparing different intensive 
initial combination treatment strategies in early RA (EudraCTnumber: 2008-
007225-39). Diagnosis of RA was defined by the 1987 revised RA criteria. Early 
RA was defined as a disease duration less than or equal to one year. A total of 
262 consecutive DMARD naïve early RA patients were included between 
February 2009 and January 2012 by 23 rheumatologists in eight Rheumatology 
Centers across Flanders. 
The Ethics committee of the University Hospitals Leuven approved this study and 
all patients gave their written informed consent.  
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To the GPs of all 262 patients, a letter was sent requesting the following 
information about their patients: date of first RA related GP contact, duration of 
RA related symptoms before seeking help according to the GP and date of 
referral to a rheumatology center. The following GP demographics were also 
registered:  age, gender and experience with RA. Their level of experience was 
assessed by asking for the length of their professional career and the number of 
RA patients, being new patients or subjects in follow-up, they were seeing in their 
practice per year. GPs were contacted through the treating rheumatologists by 
regular mail as of February 2012. A reminder was sent after a month to the GPs 
not responding to the first mailing. 
Ultimately, we received the information of 156 patients from 150 GPs 
corresponding to a GP response rate of 60%. Thus, the data of 156 out of 262 
patients could be studied. These patients were seen in eight different 
rheumatology centers, all participating in the CareRA study. Of these eight 
centers, one was an academic hospital, five were general hospitals and two were 
private rheumatology practices. 
 
At their first visit to the rheumatology center and before treatment initiation, 
patient demographics and disease activity and severity parameters were 
registered. Continuous variables were age, BMI, DAS28(CRP), visual analogue 
scales (0-100) such as the Patient Global Assessment (PGA), Physician Global 
Assessment (PhGA), pain and fatigue, Health Assessment Questionnaire (HAQ; 
0-3), Tender Joint Count (TJC), Swollen Joint Count (SJC) and morning stiffness 
in minutes. Dichotomous variables were gender, smoking and drinking habits, 
employment status until symptom onset and at treatment initiation, presence of 
morning stiffness, presence of nocturnal pain, presence of Rheumatoid Factor 
(RF), presence of Anti-Citrullinated Protein Antibody (ACPA)and erosion status.  
Patients were verbally asked by the rheumatologist or the staff for the date of 
onset of their first  RA symptoms. The rheumatologist registered the date of RA 
diagnosis, date of first visit to the rheumatology center and date of treatment 
initiation in the patient file. 
Outcomes of interest 
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The collected dates were used to construct eight types of delay:  
 Patient delay according to the patient: time elapsed between symptom 
onset as viewed by the patient and 1st visit to a GP regarding RA 
symptoms 
 Patient delay according to the GP: time elapsed between symptom onset 
as observed by the GP  and 1st visit to a GP regarding RA symptoms 
 GP delay: time elapsed between 1st visit to a GP and referral  to a 
rheumatologist  
 Rheumatologist delay 1: time elapsed between referral to and  1st 
screening by rheumatologist 
 Rheumatologist delay 2: time elapsed between 1st screening by 
rheumatologist -start of treatment 
 Total rheumatologist delay: time elapsed between referral  to 
rheumatologist-start of treatment  
 DMARD initiation delay: time elapsed between diagnosis of RA and start 
of treatment 
 Total delay: time elapsed between symptom onset and start of treatment 
Because the information to calculate these different stages of delay came from 
different sources, in some cases a certain delay was found negative. A negative 
patient delay could be caused by a patient reporting the date of symptom onset 
after consulting their GP for their symptoms. Considering that a delay by definition 
could not be lower than zero, such cases were removed. 
Negative values for GP (5) and rheumatologist delay 1 (2) were marginal, but 31 
negative values for patient delay were calculated. 
 
Statistical analysis 
Data are presented as mean values and standard deviations (SD) or as median 
values and interquartile range (IQR) depending on the distribution of the data. 
Comparisons between the same stages of delay across different centers were 
made with the Wilcoxon or Kruskal–Wallis test. The different levels of delay within 
the total population were compared using the Wilcoxon signed rank test. 
Characteristics of patients with early treatment (ETRA: total delay ≤ 12weeks) 
and patients with late treatment (LTRA: delay > 12 weeks) were compared with 
the Chi-square or the Wilcoxon test. Spearman’s test was used to assess the 
correlation between different stages of delay and patient/GP demographics or 
disease activity and severity parameters. A stepwise multiple linear regression 
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model was constructed to test the influence of different correlating variables on 
total delay. Delay was log transformed to resolve the skewed distribution. 
Statistical analysis was performed using Statistical Package for the Social 
Sciences (SPSS) version 17.0. All statistical tests were two-sided and evaluated 
at the 0.01 significance level. This level was chosen to correct for multiple 
comparisons. We choose not to perform a Bonferroni correction because the 
resulting significance level would be too small to detect any statistically significant 
difference resulting in false negative outcomes. 
 
 
 
 
 
Results 
Study population 
Table 1 displays the patients’ characteristics of our study population. This was a 
typical RA population  with a majority being female and ACPA/RF positive. 
 
Data on the referral process of these 156 patients were provided by 150 GP’s 
(65% male) with a mean age (±SD) of 51 (±11) years, with a mean (±SD) 
experience of 25 (±11) years and seeing a mean number of 13 (±12) RA patients 
per year.  
 
To control for selection bias we compared the characteristics of our study 
population of 156 patients with those of all 262 consecutive patients recruited in 
the CareRA study between February 2009 and January 2012. No significant 
differences were found (data not shown).   
 
 
 
Table 1: Patients’ characteristics of the study population  
 Study population (n=156) 
Age (years)  51 (±13) 
Female Gender (%)  68.6% 
BMI (kg/m²)  26.4 (±4.4) 
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Smokers (% )  28.2% 
Alcohol Consumption (%)  58.3% 
Previously Employed (%)  64.7% 
Currently Employed (%)  55.8% 
   
PGA (0‐100)  53.3 (±24.3) 
Pain (0‐100)  53.9 (±24.5) 
Fatigue (0‐100)  46.4 (±25.0) 
PhGA (0‐100)  52.1 (±18.6) 
Noctural Pain (%)  63.5% 
Morning Stiffness (%)  67.1% 
Morning Stiffness (minutes)  122.3 (±93.2) 
   
RF present (%) 73.7 
ACPA present (%) 71.6 
TJC total  13.4 (±8.4) 
SJC total  10.4 (±6.8) 
TJC 28  8.1 (±5.4) 
SJC 28  6.8 (±5.0) 
Erosions present (%) 20.5% 
  
DAS28(CRP) 4.70 (±1.16) 
HAQ  (0-3) 0.98 (±0.64) 
BMI= Body mass index; PGA= Patient global assessment; PhGA= Physician global assessment;  DAS28(CRP)= 28 
joint Disease activity score calculated with C-reactive protein; HAQ= Health assessment questionnaire; TJC= Tender 
joint count; SJC= Swollen joint count; RF= Rheumatoid factor; ACPA= Anti-citrullinated protein antibody; n= 
Number of patients. Previously employed was defined as employment at disease onset. Morning Stiffness as a 
categorical variable was defined as lasting at least 1 hour.  
Values given are percentages for discrete variables or mean and standard deviation(SD) for continue variables 
 
 
 
 
 
 
Different stages of delay 
Table 2 shows the different types of delay for the total population and compares 
these stages of delay between the three different types of rheumatology centers. 
Overall, the median total delay was 23 weeks; whereas patient, GP and 
rheumatologist delay were 10, 4 and 7 weeks respectively. Only 21.6% of the 
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patients had a total delay ≤ 12 weeks. In academic and general hospitals, patient 
delay contributed the most to overall delay. In a private practice setting, patient 
and rheumatologist delay added both equally to total delay. GP delay contributed 
the least to total delay in all settings. 
 
Table 2: Comparison of each level of delay in early RA patients in the three types 
of rheumatology settings. 
All 
settings 
Academic
Hospital 
General  
Hospital 
Private  
Practice 
p-value  
Number of patients 156 55 53 48  
Patient delay in weeks 
(IQR) 
10 (4-22) 11 (3-34) 12 (4-26) 5 (2-13) 0,076 
Patient delay according 
to the GP in weeks 
(IQR) 
10 (4-24) 8 (3-22) 14 (8-26) 5 (2-20) 0,061 
GP delay in weeks 
(IQR) 
4 (0-13) 4 (1-20) 4 (0-14) 2 (0-10) 0,431 
Rheumatologist delay 
type 1 in weeks (IQR) 
6 (3-11) 7 (2-11) 7 (5-12) 5 (3-10) 0,181 
Rheumatologist delay 
type 2 in weeks (IQR) 
0 (0-1) 0 (0-1) 0 (0-1) 0 (0-1) 0,861 
Total Rheumatologist 
delay in weeks  (IQR) 
7 (4-12) 7 (3-14) 8 (5-14) 6 (3-11) 0,077 
DMARD initiation 
delay in weeks (IQR) 
1 (0-3) 1 (0-4) 2 (2-4) 0 (1-3) 0,520 
Total delay in weeks 
(IQR) 
23 (14-43) 32 (18-
51) 
25 (15-
43) 
17 (11-23) <0,001 
GP= General practitioner; IQR= Interquartile ranges. 
P-values represent the result of the statistical comparison between delays in academic hospitals, general hospitals and 
private practices. All tests were conducted at the 0.01 significance level. 
Values given are median and interquartile ranges.  
 
 
 
 
Total delay in private rheumatology practices was shorter compared to academic 
and general hospitals (p<0.001). No statistically significant differences in delay 
were detected between academic and general hospitals. 
Comparisons between the different stages of delay in the total population showed 
that GP delay was statistically significantly shorter than patient delay (p<0.001), 
but not shorter than total rheumatologist delay (p=0.024). GP delay and 
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rheumatologist delay, and patient delay according to the patient and patient delay 
according to the GP did not differ (p=0.492 and p=0.919).  
 
Early versus late treated RA patients 
Table 3 displays the comparison between patients’ characteristics of the early 
treatment group and late treatment group. Patients treated early  showed a 
statistically significantly higher PhGA and pain score at the time of study 
recruitment compared to patients treated after more than 12 weeks. Patients 
treated early also tended to have a higher PGA, DAS28(CRP) and HAQ score, 
to be RF positive and to suffer more from nocturnal pain.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Comparison of the characteristics of two categories of patients with 
different lengths of total delay 
 
 ETRA (n=34) LTRA (n=122) p-value 
Age (years)  49.4 (±13.8)  50.9 (±12.6)  0.609 
Female Gender (%)  70.6%  68.0%  0.776 
BMI (kg/m²)  26.6 (±5.1)  26.4 (±4.1)  0.813 
       
Smokers (% )  38.2%  25.4%  0.277 
Alcohol Consumption (%)  47.1%  61.5%  0.132 
Previously Employed (%)  61.8%  65.6%  0.681 
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Currently Employed (%)  52.9%  56.6%  0.707 
 
PGA (0‐100)  61.1 (±22.3)  51.1 (±24.5)  0.035 
Pain (0‐100)  64.1 (±21.9)  51.1 (±24.5)  0.007 
Fatigue (0‐100)  50.9 (±23.3)  45.2 (±25.4)  0.346 
PhGA (0‐100)  61.4 (±20.6)  49.6 (±17.2)  0.002 
Noctural Pain (%)  71.9%  59.8%  0.075 
Morning Stiffness (%)  67.6%  63.1%  0.626 
Morning Stiffness (minutes)  145.8 (±89.8) 113.5 (±96.0)  0.324 
       
RF present (%) 85.3% 70.5% 0.083 
ACPA present (%) 76.5% 70.2% 0.477 
TJC total  13.4 (±9.5) 13.4 (±8.1)  0.575 
SJC total  11.9 (±8.5) 9.9 (±6.2)  0.404 
TJC 28  8.7 (±6.6) 8.0 (±5.0)  0.931 
SJC 28  7.1 (±6.5) 6.5 (±4.4)  0.432 
Erosions present (%) 17.6% 21.3% 0.640 
    
DAS28(CRP) 5.06 (±1.29) 4.60 (±1.10) 0.060 
HAQ  (0-3) 1.20 (±0.65) 0.93 (±0.63) 0.031 
ETRA= Early treated RA patients= total delay≤12weeks; LTRA= Late treated RA patients= total delay>12 weeks. 
BMI= Body mass index; RF= Reumatoid factor; ACPA= Anti-citrullinated protein antibody; PGA= Patient global 
assessment;  PhGA= Physician global assessment; DAS28(CRP)= 28 joint Disease activity score calculated with C-
reactive protein; HAQ= Health assessment questionnaire; total TJC= Tender joint count 68; total SJC= Swollen joint 
count 66. n= Number of patients. Alcohol consumption is defined as intake of any amount of alcohol. Morning 
Stiffness as a categorical variable was defined as lasting at least 1 hour. All tests were conducted at the 0.01 
significance level. 
Values given are percentages for discrete variables or mean and standard deviation(SD) for continuous variables. 
 
 
 
 
 
 
 
 
 
 
 
Table 4 shows that patient delay is the main determinant of the difference in 
total delay between patients with early and late treatment initiation. 
Table 4: Relative importance of the different stages of delay for each patient 
subgroup defined by the total delay before treatment initiation 
 
 ETRA (n=34) LTRA 
(n=122) 
p-value 
Patient Delay in weeks (IQR) 2 (1-4) 13 (6-27) <0.001 
Patient Delay according to GP in weeks 
(IQR) 
8 (3-31) 12 (4-24) 0.327 
GP Delay in weeks (IQR) 1 (0-7) 4 (0-15) 0.142 
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Rheumatologist delay type 1 in weeks 
(IQR) 
5 (1-8) 7 (3-12) 0.025 
Rheumatologist delay type 2 in weeks 
(IQR) 
0 (0-0) 0 (0-1) 0.013 
Total rheumatologist delay in weeks 
(IQR) 
5 (2-8) 7 (4-14) 0.012 
DMARD initiation delay in weeks 
(IQR) 
1 (0-2) 2 (0-4) 0.003 
Total delay in weeks (IQR) 9 (8-11) 29 (21-48) <0.001 
ETRA= Early treated RA patients= total delay≤12weeks; LTRA= Late treated RA patients= total delay>12 weeks. n= 
Number of patients ; IQR= Interquartile ranges. All tests were conducted at the 0.01 significance level. 
Values given are median and interquartile ranges.  
 
 
 
 
 
 
 
 
 
 
 
Factors influencing the stages of delay 
Table 5 shows the correlation between the different stages of delay and 
patients’ characteristics or disease activity and severity parameters. Patient 
delay was not found to be statistically significantly correlated with any of these 
parameters. Most rheumatologist related stages of delay were inversely related 
to disease activity and severity parameters.  
 
Table 5: Correlations between stages of delay and patients’ characteristics 
measured at the time of recruitment to the study 
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 GP 
delay 
Rheumatologi
st delay type 1 
Rheumatologi
st delay type 2 
Total 
Rheumatologi
st delay 
DMAR
D 
initiatio
n delay 
Total 
delay 
PGA -0.110 -0.071 -0.129 -0.077 -0.259* -0.135 
Pain -0.167 -0.059 -0.153 -0.065 -0.285* -0.183 
PhGA -0.282* -0.213 -0.144 -0.232* -0.227* -0.257* 
TJC -0.105 -0.074 -0.256* -0.116 -0.246* -0.028 
SJC -0.100 -0.120 -0.273* -0.158 -0.261* -0.165 
TJC28 -0.077 -0.174 -0.206 -0.205 -0.303* -0.078 
SJC28 -0.028 -0.136 -0.224* -0.163 -0.303* -0.128 
DAS28(C
RP) 
-0.067 -0.236* -0.273* -0.273* -0.387* -0.179 
HAQ -0.021 0.170 -0.216* -0.142 -0.300* -0.161 
 
PGA= Patient global assessment; PhGA= Physician global assessment; DAS28(CRP)= 28 joint Disease activity score 
calculated with C-reactive protein; HAQ= Health assessment questionnaire; TJC= Tender joint count; SJC= Swollen 
joint count. Results marked with an asterisk are significant at the 0.01 significance level. Patient delay is not 
displayed because no variables correlated with this type of delay. Values given are correlation coefficients. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 displays statistically significant differences in the length of different 
stages of delay depending on certain patients’ characteristics. Patients with 
morning stiffness at recruitment to the study had shorter total rheumatologist 
and DMARD initiation delay compared with subjects without morning stiffness. 
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Figure 1: Differences in the length of different stages of delay depending on 
morning stiffness 
 
 
Morning Stiffness Yes No p-value 
Total Rheumatologist delay in weeks 
(IQR) 
6 (3-11) 9 (5-
17) 
0.006 
DMARD initiation delay in weeks 
(IQR) 
1 (0-3) 2 (1-4) 0.002 
 
IQR= Interquartile ranges. Morning Stiffness as a categorical variable was defined as lasting at least 1 hour. Values 
given are median (IQR) All tests were conducted at the 0.01 significance level. 
 
 
 
 
 
 
 
 
 
Table 6 shows the results of the stepwise multiple linear regression analysis for 
total delay. All parameters (type of hospital, Pain, PGA, PhGA, TJC, SJC, HAQ 
and Morning Stiffness) that were correlated with any stage of delay were included 
at start of analysis, except DAS28(CRP), TJC28 and SJC28. These variables 
were connected to other variables used in the model and could result in a false 
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model.  SJC and type of hospital were related with total delay. These variables 
explained together 15% of the variability in total delay. Type of hospital explained 
8.4% while SJC explained 6.6%. 
 
Table 6: Stepwise multiple regression models for total delay (in weeks) 
 
Variable β – standardized 
coefficient 
B (95% CI) - unstandardized 
coefficient 
p-value 
Constant  55.980  
Types of 
hospital 
-1.384 -1.339 (-1.531; -1.169) <0.001 
SJC -1.278  -1.026 (-1.042; -1.010) 0.002 
CI= confidence intervals; SJC= Swollen joint count. DAS28(CRP) was not selected as a predictor because it is 
calculated with the aid of variables (PGA, SJC and TJC) used in the model. SJC 28 and TCJ28 were also not used 
because these variables are related to the total SJC and TJC. All tests were conducted at the 0.01 significance level. 
Values presented are geometric means. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
In this study, the length of different types of delay before treatment initiation was 
computed. Only approximately one in five of new early RA patients in our large 
population were treated in less than or equal to 12 weeks, which is the critical 
period to have most beneficial effects on disease outcome (14). Furthermore, we 
have shown that differences in delay existed between different types of 
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rheumatology centers: in private practices, total delay was less pronounced than 
in academic or general hospitals. Jamal et al already found indications for this 
trend in their data (40). 
A linear regression model showed that the type of practice was the only 
statistically significant independent determinant of total delay, besides the total 
swollen joint count. SJC at recruitment to the study was already previously found 
to have an influence on delay (41). Age and gender were not found to have an 
influence on total delay in contrast to earlier studies (29, 37). However, despite 
being built with a large number of variables associated with delay, our regression 
model could only explain a very small fraction of the variability of total delay.  To 
explore additional determinants of delay, a need certainly exists for further 
research, including qualitative approaches. 
Patient related delay 
In the total population, patient delay contributed most to overall delay. This type 
of delay can be theoretically further subdivided in two parts: firstly, the time 
between initial onset of symptoms and seeking medical advice and secondly, the 
time to get an appointment with a GP. This second component of patient delay 
was probably proportionally less important in our study, due to the way GP 
appointments are organized in Flanders. Most likely, patient delay was mainly 
determined by how quick the individual became aware of the nature and the 
seriousness of the problems (30). This hypothesis was substantiated in our study 
by two findings. Firstly, patients treated early displayed a relatively shorter patient 
delay compared with patients treated later than 12 weeks.  
Secondly, patients treated early reported more pain and showed a higher level of 
RA disease activity according to their rheumatologist at treatment initiation. 
 
Patients were asked for the date of symptom onset at treatment start. Memory 
bias could thus have influenced patient delay as illustrated by the many negative 
calculations of patient delay leading to exclusion of these patients for further 
analysis. As a fail-safe, GPs were also requested to check their file when their 
patients had mentioned possible rheumatic symptoms for the first time. Patient 
delay according to patient or GP showed similar results in the total population.  
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 GP related delay 
GP delay in our study was the least important contributor to the total delay, in 
contrast to other studies where GP delay contributed the most to overall delay 
(13, 42). This finding could mean that RA symptoms were rapidly recognized by 
the GP and the patient was immediately referred to the rheumatologist. 
Furthermore, the four weeks GP delay found in our study is comparable to GP 
delays registered in Stockholm and Birmingham, although shorter compared to 
other centers in the same study (25). 
Rheumatologist related delay 
The second most important contributor to overall delay was the rheumatologist 
delay. This type of delay was split into two subtypes: rheumatologist delay type 1 
and type 2. 
Clearly, rheumatologist delay type 1 contributed the most to total rheumatologist 
delay. This finding could have two reasons: either the patients waited to make an 
appointment with the rheumatologist after referral by their GP and/or they 
struggled to get an appointment. Arguments can be found for the latter. 
Rheumatologist type 1 delay is shorter in private practices compared with general 
hospitals and, in absolute numbers, academic hospitals. The logistic pathway in 
hospitals is probably longer than in more flexible private practices. For example, 
due to staff hours and limited availability of consultation rooms, appointments in 
a hospital are more difficult to schedule. Furthermore, rheumatologists in 
hospitals can have more additional tasks than only the ambulatory care for their 
patients. Getting the right patient to the right department can also be problematic 
in large hospitals. Additionally, higher numbers of secondary referrals and a 
greater complexity of patients could lead to more difficulties and increased delay 
in academic centers.  
 
Rheumatologist delay type 2 and DMARD initiation delay were both very short, 
meaning that once patients were screened or diagnosed, they were promptly 
treated, as was shown in earlier studies (40). All types of rheumatologist delay 
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are inversely correlated with various disease activity and severity parameters. 
Presence of morning stiffness at treatment initiation was apparently an important 
predictor for shorter rheumatologist-related delays. Possibly, patients who have 
a more active disease, will try to get an appointment more rapidly and 
rheumatologists will probably be more inclined to treat them faster.  
Strengths and limitations 
This study has both strengths and limitations. We were able to study a 
representative sample of the early RA patients participating in the CareRA study. 
In principle, all consecutive patients diagnosed with early RA between February 
2009 and January 2012 were included in this large multicenter RCT, with the 
participation of almost one third of the Flemish rheumatologists from all provinces. 
Therefore we consider our results to be a reflection of the current situation in our 
region, but further data are needed in other health care systems. Another 
important strength of this delay study is that memory bias was limited as much as 
possible: analyzing GP log books and hospitals databases minimized this error. 
To our knowledge, we are the first to use information from the GP concerning the 
important time points from symptom onset to referral, in order to lower risk of 
memory bias. The only date that remained difficult to reconstruct with accuracy 
was the date of symptom onset. The 31 negative values calculated for patient 
delay as discussed in the methods section underscore this difficulty. This bias 
was countered by asking the GP when their patient reported  RA symptoms for 
the first time. In writing specifically and only to the GP to inquire for dates of first 
appointment and referral, we included another possible confounding factor. In 
Flanders, GPs function as gatekeepers to specialists, so the most logical care 
pathway to be followed is that the patient first sees the GP and afterwards the 
rheumatologist. However, patients could also use alternative ways via other 
specialists to get an appointment with a rheumatologist. This study did not take 
these potential heterogenic pathways into account. It could be that these routes 
are a cause of a more prolonged delay. Another limitation of this study is that 
disease activity parameters could only be measured at recruitment to the study 
and not at onset of symptoms or any earlier stage. Data from earlier in the disease 
course could possibly give a more complete picture of the help seeking behavior 
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of patients or the referral behavior of GPs. Unfortunately this is not achievable 
without the help of experienced GPs trained in the evaluation of disease activity 
in early RA.We did no Bonferonni correction for repeated testing in this study 
which could lead to false positive findings. However, a significance level of 0,01 
was chosen to correct for multiple testing while trying to lower the chance of false 
negatives at the same time. 
Conclusion 
In conclusion, delay from symptom onset to treatment initiation is still too long 
with a median of 23 weeks, similar to previous studies (25). Only one out of five 
patients are seen on time. Patient delay contributes the most to this overall delay. 
The type of rheumatology center and certain disease activity parameters 
influence treatment delay and its components. Interventions are needed to lower 
this delay. Increasing people’s awareness of RA, education and development of 
screening tools (43) for GPs and for other healthcare professionals who are 
potentially the first to be consulted by early RA patients to make assessments 
more efficient and to shorten the logistical pathways in rheumatology centers are 
future opportunities. Early Arthritis Recognition Clinics are an excellent example 
of such a measure to decrease delay (44). 
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The performance of matrices in daily clinical practice to 
predict rapid radiologic progression in patients with 
early RA 
ABSTRACT 
Objectives: To compare in daily clinical practice the reliability of matrices which 
forecast rapid radiologic progression (RRP) at year one, at year two and over two 
years in patients with early Rheumatoid Arthritis (RA). 
Methods: 74 early RA patients with X-rays of hands and feet at baseline, year 
one and year two were included. Initial DMARD combination therapy with steroids 
(ICTS) or DMARD monotherapy (IMT) was initiated according to patients’ RA 
severity, based on rheumatologist opinion. The images were scored via the 
modified Sharp/van der Heijde (SvH) method. A total Sharp score progression of 
equal or higher than five per year was considered RRP. 
Six matrices were tested: ASPIRE CRP/ESR matrices, the BEST matrix, two 
SWEFOT matrices and the ESPOIR matrix. Patients were placed in each of them 
yielding a RRP probability. The performance was tested by Area Under the Curve 
analysis reflecting the predictive value.  
Results: Four patients developed RRP in year one, five in year two and four over 
two years. With regards to face validity, the predicted probability did not 
correspond to the risk in reality: the one ICTS patient who developed RRP over 
two years was always found in the lowest RRP categories of all matrices. The 
ASPIRE CRP matrix yielded at least a moderate predicting value for the three 
time points. The other matrices showed moderate to no predicting value. 
Conclusion: The performance of all matrices was disappointing and it is 
impossible to fully rely on the existing matrices in daily clinical practice.  
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INTRODUCTION 
One of the most important targets in the management of Rheumatoid Arthritis 
(RA) is preventing structural damage and disability in the long term. Many 
treatment possibilities exist to avert such excessive radiologic progression (1-5). 
However, a physician must decide for each individual patient separately which 
treatment is optimal. Rapid radiologic progression (RRP) occurs only in a minority 
of patients with early RA and it is of key importance to detect these patients.  
In the last decade many predicting factors for radiographic progression and RRP 
were identified, but  individually these predictors have only a limited prognostic 
value (1, 6-19). Therefore, composite predicting models, arranged in so called 
matrices, were constructed to help the treating physician to detect patients at risk 
for RRP. Six prediction matrices were identified: the ASPIRE CRP/ESR (20), the 
BEST (21), the SWEFOT which has two submodels (22, 23) and the ESPOIR 
(24) matrix. The ESPOIR matrix was the only model developed in an 
observational cohort while the others originated from clinical trials. Durnez et al. 
tested the predictive value of the ASPIRE matrix in a daily practice early RA 
cohort and found that it yielded a strong negative predictive value, but lacked a 
positive predictive value (25). Furthermore, the ASPIRE, the BEST and the 
SWEFOT matrix were tested in a cohort of established RA patient and were found 
to have a limited ability to predict RRP (26). Fautrel et al tested the performance 
of these matrices on the French ESPOIR cohort and concluded that the BEST 
matrix had the greatest validity to detect RRP in their population (27).  
Our aim was to compare the performance of the existing matrices to reliably 
predict RRP in an early RA cohort in daily practice in the first year, in the second 
year and over a period of two years. 
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METHODS 
The patient population for this trial was part of an observational cohort at the 
department of Rheumatology of the University Hospitals of Leuven. This cohort 
consisted of consecutive DMARD naïve early RA patients, enrolled between 2001 
and 2007 (28). Only patients enrolled in parallel randomized clinical trials (RCT) 
were excluded. 74 patients were selected for this study because they had X-rays 
of hands and feet at baseline, year one and year two. Patients received initial 
combination therapy with steroids (ICTS) or DMARD monotherapy (IMT) and 
were evaluated at least every four months. 42 Patients received IMT while 32 
started ICTS . The disease course of this population was previously published in 
part (25, 28-30). This study was approved by the Ethics Committee of the 
University Hospitals Leuven and all patients gave written informed consent before 
inclusion. 
Demographics were registered at baseline and the following clinical 
characteristics were obtained at baseline, year one and year two: swollen/tender 
joint counts (TJC , SJC, TJC28 and SJC28), assessment scores by Visual 
Analogue Scales (VAS patient global-PGA,  VAS physician global-PhGA, VAS 
pain and VAS fatigue), Health assessment questionnaire (HAQ), erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP). Disease activity score 
based on CRP status (DAS 28(CRP)) was calculated from these parameters. 
The X-ray images were scored according to the modified Sharp/van der Heijde 
(SvH) method (31) by three readers separately: two experienced radiologists (LL 
and GVDS) and one clinical researcher (DDC). A joint score was only selected 
when two out of three readers gave this joint a score higher than zero. If joint 
scores were not equal, the lowest score was selected. The highest score was 
only selected if two readers scored the joint equally higher than the other reader. 
This modified method of calculating a general SvH score was used instead of the 
more common mean scores of all readers or consensus score to minimize 
potential bias and overestimation of radiographic damage. 
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A total Sharp score (TSS) progression of equal or higher than five per year was 
considered RRP. This definition meant that a TSS progression equal or higher 
than ten between baseline and year two was considered RRP. The threshold of 
five points matches the destruction of one small joint and the typically reported 
smallest detectable difference (32, 33). 
Six matrices were used in this study: the ASPIRE, the BEST, the SWEFOT and 
the ESPOIR matrices (table 1). The ASPIRE matrix itself has two sub models: 
ASPIRE CRP and ASPIRE ESR. The ASPIRE matrices use SJC28, RF status 
(U/mL) and CRP (mg/dL) or ESR status (mm/h). The BEST matrix consists of 
baseline erosion scores, RF and ACPA presence combined and CRP status 
(mg/L). The SWEFOT matrix has two submodels. The first model (SWEFOT1) 
consists of gender, RF presence, ACPA presence and ESR status (mm/h). This 
matrix was not developed for detecting RRP, but for detecting any radiologic 
progression. However, it was deemed interesting enough to be tested in our 
study. The second model (SWEFOT2) predicts rapid radiologic progression and 
uses smoking status, presence of erosions and CRP status (mg/L). The ESPOIR 
matrix uses presence of erosions, ACPA positivity, CRP status (mg/L) and SJC28 
as predicting variables. The ASPIRE and BEST matrices yield a different risk 
probability for patients on mono- or combination therapies.  
Table 1: Parameters used in the six tested matrices to predict RRP  
Matrix type  SJC28  RF 
(U/L) 
RF 
+/‐ 
ACPA 
+/‐ 
CRP 
status 
(mg/L) 
ESR 
status 
(mm/h) 
Erosions  Gender Smoking 
ASPIRE CRP     X  X  X   
ASPIRE ESR  X  X  X   
BEST  X  X  X  X*   
SWEFOT1  X  X  X  X   
SWEFOT2          X    X**    X 
ESPOIR  X      X  X    X**     
RRP= Rapid radiographic progression; SJC= Swollen joint count RF= Rheumatoid factor; ACPA= Anti‐citrullinated 
protein antibody; CRP= C‐reactive protein; ESR= Erythrocyte sedimentation rate. * according to the Sharp/van der 
Heijde method ** typical RA erosions evaluated by the rheumatologist 
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 One other algorithm was developed from data from an early RA cohort, 
SONORA, in Canada and the United States (34). However, this matrix uses 
ACPA titers(U/L). In our observational cohort, this parameter was not available 
for most of our patients and thus this algorithm could not be tested in this study. 
Patients were systematically placed in each of the matrices yielding a RRP 
probability. The mean RRP probability associated with the expert’s initial 
treatment choice was compared between patients with and without RRP. The 
performance of the matrices to identify RRP patients was tested by Receiver 
Operating Characteristic (ROC) curve analysis in which the Area Under the Curve 
(AUC) reflected the discriminating power. A ROC curve plots the fraction of true 
positives out of the positives (true positive rate) against the fraction of false 
positives out of the negatives (false positive rate). In this performance test, we 
used the probabilities given in the six matrices. A matrix with an AUC of less than 
0.5 was considered as having no predicting value, a matrix with an AUC between 
0.5 and 0.7 was considered to have moderate predicting value and a matrix with 
an AUC higher than 0.7 was regarded as having good predicting value. 
Statistical analysis was performed using Statistical Package for the Social 
Sciences (SPSS) version 17.0. 
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RESULTS 
Table 2 shows the descriptive statistics at baseline of the total population and of 
the rapid progressors in the first year, in the second year and over two years. 
Four patients developed RRP in the first year. Five other patients developed RRP 
in the second year. Four patients in total had a TSS progression of more than ten 
points over two years. Remarkably, three patients out of these four were common 
between groups with RRP in the first year and the one with RRP over the two-
year study period. RRP patients were different in the first and second year. 
Table 2: Baseline descriptive statistics of the total population and RRP patients 
  Total 
population 
RRP first year  RRP second 
year 
RRP over two 
years 
Number of patients  74  4  5  4 
Age (years)   52 ± 16  51 ± 14  43 ± 33  46 ± 18 
Gender (female %)   65%  25%  100%  50% 
Smoker (%)*  28%  25%  33%  0% 
Symptom duration (months)   8 ± 7  8 ± 4  14 ± 13  9 ± 3 
Disease duration (months)   1 ± 1  1 ± 2  1 ± 0  1 ± 2 
RF positive (%)  71%  75%  60%  50% 
RF (U/mL)  224.7 ± 281.1  350.5 ± 296.1  139.6 ± 68.4  200.5 ± 146.6 
ACPA positive (%)  71%  50%  80%  50% 
ESR (mm/h)  36.66 ± 24.06  44.50 ± 34.91  26.40 ± 13.98  38.75 ± 37.48 
CRP (mg/L)  28.80 ±33.78  35.50 ± 46.71  38.40 ± 34.28  51.43 ± 48.92 
PGA (0‐100)  53.56 ± 24.87  56.00 ± 23.58  67.20 ± 20.19  46.00 ± 8.72 
Pain (0‐100)  51.52 ±24.39  47.00 ± 39.05  71.40 ± 16.03  38.67 ± 24.66 
Fatigue (0‐100)  41.70 ±25.42  14.67 ± 12.42  64.20 ± 17.11  40.33 ± 40.22 
PhGA (0‐100)  42.14 ± 19.36  35.25 ± 7.14  45.33 ± 19.50  33.00 ± 8.52 
Total TJC  14.35 ± 10.59  8.25 ± 2.99  14.60 ± 10.02  7.75 ± 2.99 
Total SJC  12.45 ± 8.19  7.75 ± 5.50  16.00 ± 10.51  8.75 ± 4.65 
TJC28  8.28 ± 6.38  4.25 ± 2.75  7.80 ± 7.46  3.75 ± 3.20 
SJC28  8.01 ± 5.35  6.75 ± 5.56  10.00 ± 8.19  6.75 ± 5.56 
HAQ score (0‐3)   1.10 ± 0.76  1.50 ± 0.78  1.66 ± 1.12  1.79 ± 1.04 
DAS28 (CRP) score   4.91 ± 1.22  4.48 ± 0.95  5.21 ± 1.34  4.40 ± 0.98 
RRP= Rapid radiographic progression; RRP first year = Rapid radiographic progression between baseline and the first 
year, defined as a total Sharp score ≥ 5; RRP second year = Rapid radiographic progression between the first and the 
second year, defined as a total Sharp score ≥ 5; RRP over two years = Rapid radiographic progression between 
baseline and the second year, defined as a total Sharp score ≥ 10; RF= Rheumatoid factor; ACPA= Anti‐citrullinated 
protein antibody; ESR= Erythrocyte sedimentation rate; CRP= C‐reactive protein; PGA= Patient global assessment; 
PhGA= Physician global assessment; TJC= Tender joint count; SJC= Swollen joint count;  HAQ= Health assessment 
questionnaire; DAS28(CRP)= 28 joint Disease activity score calculated with C‐reactive protein. Values given are 
percentages or mean േ	SD.*This is calculated on 65 patients. Data about smoking behavior of nine patients is 
missing. 
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For only one patient ACPA status was missing at baseline and data from this 
patient could not be used in matrices using ACPA status as a variable (BEST, 
SWEFOT1 and ESPOIR matrices). For nine patients data about smoking status 
were missing. Likewise, these patients were excluded in the evaluation of the 
SWEFOT2 matrix. 
Table 3 shows radiographic progression in the total population and the groups 
with RRP between baseline and year one, between year one and year two and 
between baseline and year one.  
Table 3: Radiographic evolution of the population and RRP patients over two years 
RRP= Rapid radiographic progression; RRP first year = Rapid radiographic progression between baseline and the first 
year, defined as a total Sharp score ≥ 5; RRP second year = Rapid radiographic progression between the first and the 
second year, defined as a total Sharp score ≥ 5; RRP over two years = Rapid radiographic progression between 
baseline and the second year, defined as a total Sharp score ≥ 10; TSS= Total sharp score; Change in TSS is calculated 
from baseline. Radiographic damage is a TSS larger than 0. Values given are percentages or mean ሺേ	SD). 
  Total 
population 
RRP ‐ first 
year 
RRP ‐ second 
year 
RRP over 
two years 
Number of patients  74  4  5  4 
Baseline  Radiographic 
damage 
46%  75%  80%  75% 
TSS  2.62 (±4.94)  2.50 (±5.00)  1.20 (±2.68)  2.50(±5.00) 
Year 1  Radiographic 
damage 
58%  100%  80%  75% 
TSS  3.69 (±5.78)  13.25 (±5.32)  1.40 (±3.13)  11.00(±8.60) 
Change in TSS  1.07 (±2.59)  10.75 (±2.87)  0.20 (±0.45)  8.50 (±6.25) 
Year 2   Radiographic 
damage 
66%  100%  100%  100% 
TSS  4.66 (±6.30)  13.75 (±4.86)  9.60 (±5.18)  15.75(±3.76) 
Change in TSS  2.04 (±3.43)  11.25 (±2.63)  8.40 (±4.88)  13.25 (±3.30) 
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 Patients with RRP were systematically placed in each of the matrices yielding a 
RRP probability. For illustrative purposes, the prediction matrices with RRP 
patients over two years can be viewed in the supplementary files. With regards 
to face validity, all matrices gave a confusing image in predicting RRP. The ICTS 
patient developing RRP over two years was always found in the lowest risk 
categories except in the SWEFOT2 matrix. Here, the patient was found in the 
third lowest risk category. The three IMT patients with RRP over two years were 
found scattered in all risk categories. Only the ASPIRE CRP and ESR matrices 
put one patient in the highest risk category. Prediction matrices for RRP patients 
at year one or at year two yielded similar findings. 
The predictive capacity of the matrices was measured by calculating the AUC 
with the aid of ROC curves. Data of patients developing RRP in the first year, in 
the second year and over two years was used. In the first year, the BEST and the 
ASPIRE ESR/CRP matrix yielded an AUC between 0.5 and 0.7, which gives them 
moderate predicting value. The SWEFOT matrices lacked any predicting value 
with an AUC below 0.5. In the second year, the ASPIRE CRP and SWEFOT 
matrices displayed an AUC between 0.5 and 0.7, which gives them moderate 
predicting value. The BEST and ASPIRE CRP yielded an AUC equal or lower 
than 0.5, which means they have no predictive value at all. Over two years, the 
ASPIRE CRP matrix displayed an AUC higher than 0,7, which gives it good 
predicting value. The BEST and ASPIRE ESR matrix yielded an AUC between 
0.5 and 0.7, which gives them moderate predicting value. The SWEFOT matrix 
lacks any predicting value. Table 4 gives an overview of the AUCs of all matrices 
tested. 
Table 4: Matrices with their respective AUC  
 Area under the curve to predict RRP 
First year Second year Over two years 
ASPIRE CRP 0.675 0.646 0.704 
ASPIRE ESR 0.675 0.368 0.566 
BEST 0.599 0.500 0.599 
SWEFOT1 0.344 0.535 0.254 
SWEFOT2 0.517 0.435 0.407 
ESPOIR 0.351 0.502 0.351 
RRP= Rapid radiographic progression  
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DISCUSSION 
In this study, the performance of six matrices to predict RRP in daily clinical 
practice was analyzed at three time points. The ASPIRE CRP matrix showed the 
highest discriminating power to predict RRP in our observational cohort of early 
RA patients. This is in contrast to findings in the ESPOIR cohort in which the 
BEST matrix yielded the best predictive value (27).The overall performance of all 
matrices was however disappointing in patients with early RA as already 
demonstrated in patients with established RA by Lillegraven et al (26). First of all, 
the face validity of the matrices was inadequate and yielded a confusing image 
of RRP probabilities for all patients when placed in the matrices. Worrisome, the 
one ICTS patient developing RRP, who was viewed as a high risk patient by his 
treating physician and thus given an intensive therapy, was always found in the 
lowest risk categories of all matrices. The ROC analyses revealed that only 
moderate predicting capacity could be reached by some matrices at some time 
points. The ASPIRE CRP matrix was chosen to be the most promising matrix 
because of consistently having moderate predicting value in our population. All 
matrices use parameters that are commonly used in clinical practice and many 
use similar variables. However, different cut-offs are used for the same 
parameters. The poor results seem to show that the matrices are too much 
tailored on the patient population in which they were conceived and are not 
applicable in clinical practice, a setting in which they were originally intended to 
be used. In daily practice, more diverse patients are treated and more dynamic 
therapeutic strategies are used, which could alter the risk level for radiographic 
progression in comparison to strictly protocol driven trials. This is a problem for 
most matrices because they are based on RCT data. The ESPOIR matrix, 
however,  was developed in a large observational cohort of so called “possible 
RA” patients. Patients treated with methotrexate or leflunomide and with a profile 
likely to be RA were chosen for the construction of this matrix (24). The selection 
of patients could partially explain the poor performance of this matrix in our study. 
In our trial population, no such treatment selection took place: both patients on 
DMARD monotherapy in a step up approach and patients on combination therapy 
following a step down approach were included.  
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The rheumatologists based their therapy choice on an informal evaluation of risk 
factors. These factors were primarily the presence of erosions at baseline, 
RF/ACPA status and DAS28(CRP) score. These variables resemble those from 
the BEST matrix. However, the BEST matrix still lacked predicting power in 
clinical practice while the treating physicians proved to make a good choice in 
therapy intensity depending on the risk profile of their RA patients.  
The low number of patients in our study could be seen as a limitation. However, 
the clinical characteristics of our study population are similar to those of the total 
patient population of our observational cohort, with a less severe profile as 
compared to our population of patients included in RCT’s and compared to the 
ASPIRE population (25, 28-30). Furthermore, the use of biologics, known to be 
particularly effective at halting radiographic progression, could in theory have 
influenced the matrices performance, but only very few patients used these 
agents in our cohort (30). The ICTS group of our population had a more severe 
RA profile and was thus more prone to receive biologicals. This could possibly 
bias our results to a certain extent. 
A second limitation could be the low number of patients with RRP in this study. 
RRP was only present in 5% of patients in the first year, 8% in the second year 
and 5% over  two years. These numbers are low compared to other studies (20). 
This could be due to chance, given the small sample size. Secondly, our 
population had a less severe RA profile as stated above. The occurrence of RRP 
could therefore be reduced.  Another reason could be that therapy was chosen 
by expert opinion. The risk for radiologic progression was apparently estimated 
quite well and a suitable therapy was chosen. The last and probably most 
important reason for the low number of patients with RRP in our study is that the 
tight control principle in this cohort gave the treating physician flexibility to adjust 
therapy if needed, in contrast to a RCT setting. As proof of success of this 
principle, RRP patients in the first year had little radiographic progression in the 
second year. Thus, the few patients with RRP can more be seen as a success of 
the initial treatment choices and the application of the tight control principle.  
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In conclusion the low number of RRP cases in this study and the small sample 
size are no justification for the meager performance of the evaluated matrices. A 
reliable predicting matrix still should be able to identify the scarce patients at risk 
in a real life situation to be of help for physicians having to make the difficult initial 
treatment choice for each individual patient with early RA. 
The different time frames defined in this study should be regarded with caution 
because they partly overlap and the results cannot be interpreted completely 
independently. However, the value of the three chosen timeframes can be found 
in the fact that patient characteristics differ in these three periods. Remarkable in 
our study population are for example the patients developing RRP in the second 
year. These patients were all female, with a mean age clearly lower than the rest 
of our population, with a long symptom duration at baseline and a majority being 
ACPA positive. It could be that in certain subgroups of RA patients, RA severity 
is underestimated which could affect the treatment choice and consequently the 
risk on RRP. 
CONCLUSION 
The predicting performance of the six matrices (ASPIRE CRP/ESR, BEST, 
SWEFOT 1/2 and ESPOIR matrices) to detect risk of RRP was modest at best. 
The ambiguity in results points to the need to improve the existing matrices or 
even to build new predicting matrices for use in daily clinical practice. A 
collaboration to unite several early RA cohorts with various patient profiles would 
be beneficial to create a prediction matrix in which rheumatologists could trust.  
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Supplementary files: Patients with RRP over 2 years systematically placed in each of the 
matrices yielding a RRP probability. 
ASPIRE (ESR) MATRIX – IMT – n=42 
 
 
 
 
28 SJC 
>17  1       
>50 
 
 
 
ESR 
(mm/h) 
10‐17  2/1    1 
<10  1  2  3 
>17         
21‐50 10‐17  5  1  2 
<10  4  3  4/1 
>17  1       
<21 10‐17  1     
<10  5  3/1  3 
  <80  80‐200  >200   
RF titer (U/mg) 
blue: 0–9%: green: 10–19%: yellow: 20–29%: orange: 30–39%: red: 40–100% 
ASPIRE (ESR) Matrix – ICTS – n=32 
 
 
 
 
28 SJC 
>17         
>50 
 
 
 
ESR 
(mm/h) 
10‐17      3 
<10    2  2 
>17  1    2   
21‐50 10‐17  4    2 
<10  2  3  1 
>17         
<21 10‐17  1  1  1/1 
<10  4  1  2 
  <80  80‐200  >200   
RF titer (U/mg) 
blue: 0–9%: green: 10–19%: yellow: 20–29%: orange: 30–39%: red: 40–100% 
ASPIRE (CRP) MATRIX – IMT – n=42 
 
 
 
 
28 SJC 
>17  1       
>3 
 
 
 
CRP 
(mg/dl) 
10‐17  4/1    1 
<10  2  3/1  3 
>17  1       
0.6‐3 10‐17  2  1  2 
<10  3  3  3/1 
>17         
<0.6 10‐17  2     
<10  5  2  4 
  <80  80‐200  >200   
RF titer (U/mg) 
blue: 0–9%: green: 10–19%: yellow: 20–29%: orange: 30–39%: red: 40–100% 
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ASPIRE (CRP) Matrix – ICTS – n=32 
 
 
 
 
28 SJC 
>17      2   
>3 
 
 
 
CRP 
(mg/dl) 
10‐17  1    4 
<10    2  2 
>17  1       
0.6‐3 10‐17  3    1 
<10  6  2  1 
>17         
<0.6 10‐17  1  1  1/1 
<10    2  2 
  <80  80‐200  >200   
RF titer (U/mg) 
blue: 0–9%: green: 10–19%: yellow: 20–29%: orange: 30–39%: red: 40–100% 
BEST Matrix – IMT – n=41 
 
 
 
 
CRP 
(mg/l) 
≥35  1/1  2    ≥4   
 
 
Erosion 
score at 
baseline 
  1  1  1‐4 
2  1/1  3  0 
10‐35  1  1  3  ≥4 
1    2  1‐4 
2  1  6/1  0 
<10    1    ≥4 
    2  1‐4 
2  1  7  0 
  ‐/‐  ‐/+ or +/‐  +/+   
RF and ACPA 
blue: 0–9%: green: 10–19%: yellow: 20–29%: orange: 30–39%: red: 40–100% 
BEST Matrix – ICTS – n=32 
 
 
 
 
CRP 
(mg/l) 
≥35    1    ≥4   
 
 
Erosion 
score at 
baseline 
  1  4  1‐4 
    4  0 
10‐35    2    ≥4 
  1  2  1‐4 
  1  3  0 
<10  1    3  ≥4 
  2  1  1‐4 
1  4/1  1  0 
  ‐/‐  ‐/+ or +/‐  +/+   
RF and ACPA 
blue: 0–9%: green: 10–19%: yellow: 20–29%: orange: 30–39%: red: 40–100% 
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ESPOIR Matrix – n=73 
  Absence of erosions  Presence of erosions 
SJC<14  14≤SJC<20  SJC≥20  SJC<14  14≤SJC<20  SJC≥20 
ACPA +  CRP≥35  5/1**  1  1  5  1   
4≤ CRP<35  13/1**  2  1  15     
CRP<4  6      1  1   
ACPA ‐  CRP≥35  1  1    3/1**  1   
4≤ CRP<35  5      5  1   
CRP<4  3/1*      1     
red >50%: orange 25‐50%: yellow 10‐25%: green <10% 
*ICTS patient 
**IMT patient 
SWEFOT1 Matrix – n=73 
RF +  ESR high  1  4  10/1**  17 
ESR low  1  4/1*  6  9 
RF ‐  ESR high  5/1 **  5  3  5 
ESR low    1    2/1** 
  Male  Female  Male  Female 
ACPA ‐  ACPA + 
red 90%: orange 80%:  yellow 50%: green 20%: blue 10% 
*ICTS patient 
**IMT patient 
SWEFOT2 Matrix – n=65 
  CRP<10  10≤CRP<35  CRP≥35 
Smokers  Erosive  1  2  2 
Non Erosive  1  3  3 
Non‐smokers  Erosive  9  11  9/1** 
Non Erosive  15/1*  11/1**  7/1** 
Red 40% Orange 30%  Yellow 20% Green 10% White no risk factor given. 
*ICTS patient 
**IMT patient 
 
n= total number of patients used in matrix. 
RF= Rheumatoid factor; ACPA= Anti‐citrullinated protein antibody; ESR= Erythrocyte 
sedimentation rate; CRP= C‐reactive protein; SJC= Swollen joint count; ICTS= initial 
combination therapy with steroids; IMT=  DMARD monotherapy 
Numbers in cells of matrix represent the number of patients with a set of clinical 
characteristics yielding the RRP probability corresponding to a particular cell in the matrix. 
Numbers behind a dash show how many of these patients actually developed rapid radiologic 
progression (RRP). For example, ‘X/Y’ means that X patients had a particular set of clinical 
characteristics corresponding to this cell in the matrix and Y of these X  patients developed 
RRP. 
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Two year clinical and radiologic follow-up of early RA 
patients treated with initial step up monotherapy or 
initial step down therapy with glucocorticoids, followed 
by a tight control approach: lessons from a cohort study 
in daily practice. 
 
ABSTRACT 
Objectives: To evaluate the effect of initial DMARD combination therapy with 
steroids (ICTS) and DMARD monotherapy (IMT) on the clinical and radiologic 
evolution of patients with early RA over a two year treatment period, applying tight 
control (TC) in daily practice.  
Methods: 74 DMARD-naïve early RA patients received ICTS or IMT in a TC 
setting. Baseline, year one and year two X-rays of hands and feet were scored 
according to Sharp/van der Heijde. Rapid radiographic progression (RRP) was 
defined as total Sharp score (TSS) of >5 units/year. 
Results: At year one, both treatment groups achieved 50% remission. At year 
two, 37% of IMT and 60% of ICTS patients were in remission, despite ICTS 
patients having initially a more severe RA profile.  
RRP was found in 4/74 patients at year one: 3 IMT and 1 ICTS patient. 
Remarkably, 3 of these 4 patients had no radiographic progression in the second 
year. Five other patients had RRP in the second year: four IMT and one ICTS 
patient. 
Conclusion: In a TC setting, ICTS and IMT can prevent radiographic progression 
in the majority of patients in the daily practice of a Belgian academic hospital over 
two years. ICTS seems to be more effective than IMT in achieving higher 
remission rates and less radiographic progression.  
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Introduction 
Combination therapy with disease-modifying antirheumatic drugs (DMARDs) and 
glucocorticoids (GCs) or biological agents is superior in achieving a clinical 
response and preventing joint damage compared to DMARD monotherapy in 
patients with early rheumatoid arthritis (RA). [1-4] Previously it was demonstrated 
that initial DMARD combination therapy with steroids (ICTS), is feasible in a tight 
control (TC) setting in daily practice. Additionally, ICTS proved clinically more 
effective in treating early RA compared with initial DMARD monotherapy (IMT) in 
daily practice. [5] Furthermore, patients given ICTS had less rapid radiographic 
progression (RRP) after one year than those receiving IMT, despite more severe 
baseline disease characteristics. [6] Moreover, early disease outcome predicts 
normalized physical function, working status and remission later on in the disease 
course. [7] We hypothesized that in patients with early RA treated in daily practice 
ICTS would be more effective than IMT in preventing long-term radiological 
damage and set up this study to test this.  
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Patient and methods 
Patients enrollment 
At the Rheumatology department of the University Hospitals Leuven (UZL), 
consecutive patients with newly diagnosed DMARD-naïve RA were included in 
an observational cohort between 2001 and 2007. Patients included in clinical 
trials were excluded from the cohort. 74 patients from this cohort were selected 
in the current study because X-ray images of hands and feet at baseline, year 
one and year two were available. 
This study was approved by the Ethics Committee of UZL and all patients 
consented to participate. 
Treatment strategy 
Based on expert opinion of two experienced rheumatologists (RW and PV) after 
informal evaluation of prognostic factors (rheumatoid factor (RF), anti-citrullinated 
protein antibodies (ACPA), erosions and/or active disease), patients received 
ICTS or IMT. The ICTS scheme consisted of a modified COBRA (Dutch acronym 
Combinatie therapie Bij Rheumatoide Arthritis) regimen [8] of 2g sulphasalazine 
(SSZ) daily, 15mg methotrexate (MTX) weekly and a step-down dosage of oral 
prednisolone starting at 60mg, which is tapered in six weeks to 7.5 mg/d and 
discontinued after 28 weeks.  
In IMT, initial DMARD choice was freely chosen by the treating physician. 
Tight control 
Patients were evaluated approximately every three months and treatment 
adjustments, if feasible and desirable, were made whenever the target, a 28joint 
disease activity score [DAS28 (CRP) ] below 3.2, was not reached. Therapeutic 
changes were defined as discontinuing, changing or adding DMARDs or 
biologicals and were left to the discretion of the treating physician. Dose changes 
were not counted as therapy changes. 
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Demographics and disease characteristics 
Demographics were registered at baseline and the following clinical 
characteristics were obtained at baseline, year one and year two: swollen/tender 
joint counts (TJC , SJC, TJC 28 and SJC 28), assessment scores by Visual 
Analogue Scales (VAS patient global-PGA, VAS physician global-PhGA, VAS 
pain and VAS fatigue), Health assessment questionnaire (HAQ), erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP). Disease activity score 
based on CRP status [DAS28 (CRP) ], good EULAR DAS response (if the DAS28 
score is below 3.2 and dropped 1.2 points), clinically meaningful HAQ response 
(if the HAQ score dropped 0.22 points), DAS change and HAQ change were 
calculated from DAS28CRP and HAQ at year 1 or year 2 versus baseline. 
Remission was defined as a DAS28(CRP) score below 2.6.  
Radiographic scoring 
X-ray images were scored according to the modified Sharp/van der Heijde (SvdH) 
method[9] by three readers in consensus: two experienced musculoskeletal 
radiologists (LL and GVDS) and one clinical researcher (DDC). Radiographic 
damage was defined as a total Sharp score (TSS) higher than 0. TSS progression 
equal or higher than 5 units per year was considered RRP. Mean change in TSS, 
erosion and joint space narrowing score and the proportion of patients with RRP 
were compared between both groups.  
Statistical analysis 
Repeated measures analyses of variance (ANOVA) were used firstly to 
determine the within subject effect of treatment with a post-hoc Bonferroni 
correction on the whole group, on the ICTS patients and on the IMT patients and 
the interaction effect between time and treatment by Wilks’Lambda. Secondly, a 
repeated measures analyses of variance (ANOVA) was chosen to explore the 
effect of treatment on clinical and radiographic outcome variables with treatment 
strategy as a between subjects factor. Eta squared, a measure of the amount of 
the variation explained by the model, was used as a degree of effect size of ICTS 
over IMT. Variables were log transformed to correct for normality. Remission 
scores, DAS changes, proportion of good EULAR responders, HAQ change, 
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proportion of clinically meaningful HAQ responders, cumulative GCs dose, 
proportion of GC users were compared between IMT and ICTS at year 1 or year 
2 with Chi square or Mann-Whitney U-tests.  
All statistical tests were evaluated at the 0.01 significance level to control for 
multiple comparison. Statistical analysis was performed using the Statistical 
Package for the Social Sciences (SPSS) version 17.0. 
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Results 
Treatment Strategy 
42 Patients received IMT while 32 started ICTS. At baseline, 26 patients in the 
IMT group received MTX monotherapy, 14 followed SSZ treatment, one got a 
combination of MTX with hydroxychloroquine (HCQ) and one started treatment 
with azathioprine. The patient who received a combination of MTX with HCQ was 
considered to be on monotherapy: HCQ was started before screening in our 
hospital, but stopped immediately after treatment initiation. The patient was then 
put on MTX monotherapy. After two years of treatment in the IMT arm, 37 patients 
received monotherapy, four a combination of DMARDs and one no DMARDs. At 
baseline, all ICTS subjects except one started the modified Cobra scheme. One 
patient received an adapted regime without MTX because of a pregnancy wish. 
After two years, 22 ICTS patients received monotherapy, four a combination of 
DMARDs, four a biological (Infliximab+MTX, Humira, Etanercept and Rituximab) 
and two no DMARDs. 
The IMT group required 40 therapeutic changes (0.95 therapy changes/IMT 
patient) compared to 18 changes in the ICTS group (0.47 therapy changes/ICTS 
patient). 
 
Glucocorticoid use 
After one year, the mean ± SD cumulative GCs dose (in prednisolone 
equivalents) reached 2501 ± 306 mg in ICTS patients and 1041 ± 1198 mg in IMT 
patients (p<0.001). In the second year, the mean ± SD cumulative GCs dose was 
333 ± 702 mg in the ICTS group and 355 ± 684mg in the IMT group (p=0.895). 
At any moment in the first year, 100% of the ICTS group used GCs compared to 
62% in the IMT group (p<0.001). In the second year 19% of the ICTS group used 
GCs at any moment compared with 36% in the IMT group (p=0.089). Over the 
two year study period, the ICTS patients took a mean ± SD daily GCs dose of 3.3 
± 1.2 mg, while the IMT patients took 1.7 ± 2.0 mg (p<0.001). 
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Demographics 
In the ICTS group, mean ± SD patient age was 50 ± 15 years at inclusion with a 
mean ± SD symptom duration of 8 ± 6 months and a mean disease duration of 
less than 1 ± 1 month. 69% of patients was female, 75% RF positive, 75% ACPA 
positive and 56% erosive. In the IMT group, mean ± SD patient age was 53 ± 17 
years at inclusion with a mean ± SD symptom duration of 9 ± 8 months and a 
mean disease duration of less than 1 ± 1 month. 62% of patients was female, 
69% RF positive, 68% ACPA positive and 38% erosive. Demographics did not 
differ between IMT and ICTS patients (data not shown).  
 
Clinical evolution 
At baseline, SJC and PhGA were significantly higher in the ICTS patients 
compared to the IMT patients. In absolute numbers, all other variables were also 
higher in the ICTS group. Thus ICTS patients were initially perceived to have a 
higher level of RA severity compared with IMT patients. 
In both groups and in the total population, treatment had a statistically significant 
beneficial effect on all clinical characteristics except fatigue. Interaction between 
time and treatment was significant in PhGA and DAS28(CRP) (data not shown). 
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Table 1: Comparison of the clinical characteristics between the IMT and ICTS group 
Clinical 
characteristics 
Treatment 
group 
n  Baseline  n  Year 1  n  Year 2  p‐
value
Effect 
size 
Total TJC  IMT  42  11.71 ± 10.34  42  3.19 ± 4.62  42 4.88 ± 6.57  0.890 0,089ICTS  32  17.81 ± 10.05  32  4.47 ± 5.01  32 3.79 ± 4.88 
Total SJC  IMT  42  10.17 ± 7.15  42  2.26 ± 3.20  42 1.79 ± 2.60  0.002 0,278ICTS  32  15.44 ± 8.61  32  2.84 ± 4.05  32 3.28 ± 5.38 
TJC28  IMT  42  6.95 ± 6.08  42  1.50 ± 2.39  42 2.12 ± 3.09  0.270 0,048ICTS  32  10.03 ± 6.43  32  2.28 ± 3.03  32 3.09 ± 4.66 
SJC28  IMT  42  7.12 ± 5.13  42  1.67 ± 2.38  42 1.45 ± 2.02  0.019 0,195ICTS  32  9.19 ± 5.47  32  1.94 ± 2.56  32 2.41 ± 4.15 
ESR  IMT  42  35.76 ± 25.05  42  16.31 ± 17.78  41 16.83 ± 14.89  0.299 0,015ICTS  32  37.84 ± 23.03  32  12.47 ± 12.64  32 13.94 ± 14.89 
CRP  IMT  42  28.67 ± 34.81  42  6.49 ± 8.08  40 8.07 ± 10.02  0.516 0,066ICTS  32  28.97 ± 32.93  32  4.81 ± 6.89  32 5.60 ± 6.81 
PhGA (0‐100)  IMT  37  32.84 ± 16.91  42  12.10 ± 10.57  41 12.05 ± 13.05  0.318 0,015ICTS  29  54.00 ± 15.57  32  15.75 ± 12.60  30 12.40 ± 13.05 
PGA  (0‐100)  IMT  39  50.31 ± 25.09  42  33.62 ± 21.66  42 37.71 ± 24.39  0.151 0,042ICTS  31  57.65 ± 24.36  32  31.25 ± 25.08  31 32.10 ± 26.04 
Pain (0‐100)  IMT  38  49.92 ± 25.15  42  34.69 ± 22.07  42 34.69 ± 22.79  0.565 0,005ICTS  31  53.48 ± 23.67  32  33.19 ± 25.74  31 33.13 ± 29.50 
Fatigue (0‐100)  IMT  38  41.08 ± 25.47  42  35.05 ± 24.92  42 33.60 ± 22.41  0.578 0,005ICTS  31  42.45 ± 25.76  32  34.91 ± 25.42  31 32.39 ± 26.12 
HAQ (0‐3)  IMT  36  1.09 ± 0.81  42  0.54 ± 0.65  41 0.66 ± 0.72  0.727 0,004ICTS  30  1.11 ± 0.71  32  0.55 ± 0.68  32 0.76 ± 0.75 
DAS28 CRP  IMT  39  4.67 ± 1.14  42  2.70 ± 0.98  38 2.90 ± 1.09  0.605 0,004ICTS  31  5.23 ± 1.27  32  2.80 ± 1.11  30 2.64 ± 1.14 
 
IMT=Disease modifying anti rheumatic drug (DMARD) monotherapy; ICTS= initial combination therapy with 
steroids; TJC= tender Joint count; SJC= Swollen joint count; ESR = Erythrocyte sedimentation rate; CRP= C‐reactive 
protein; PhGA = Physician global assessment; PGA = Patient global assessment; HAQ=Health assessment 
questionnaire; DAS28 = 28 joint Disease activity score. n = number of patients with available data at evaluation 
time. P‐values represent the result of the statistical between subject comparison with repeated measures ANOVA 
between the IMT and ICTS group. Eta squared, a measure of the amount of the variation explained by the model, 
was used as a degree for effect size of ICTS over IMT. 
Values given are mean േ	SD. All tests were conducted at the 0.01 significant level. 
 
Table 1 shows that this baseline difference between the two groups was rendered 
equal in the following two years with the exception of the swollen joint count, 
which remained slightly higher in the ICTS group. 
At year one, both treatment groups achieved 50% remission. After two years of 
treatment, 37% of IMT patients and 60% of ICTS patients were in remission. The 
absolute DAS change was significantly higher in ICTS patients after two years of 
treatment. Table 2 describes these disease outcome parameters in more detail.  
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 Table 2: Remission, change in DAS28 score, Good EULAR DAS response, change in HAQ score 
and clinically meaningful HAQ response in the total population, IMT and ICTS group 
IMT=Disease modifying anti rheumatic drug (DMARD) monotherapy; ICTS= initial combination therapy with 
steroids; HAQ=Health assessment questionnaire; DAS28 = 28 joint Disease activity score. 
Remission was defined as a DAS28 CRP score of lower than 2.6. Changes in HAQ and DAS28 score were calculated 
between year 1 or year 2 and baseline. A Good EULAR DAS response was defined as a DAS28 ≤ 3.2 with a DAS28 
change >1.2. A clinically meaningful HAQ response was defined as a HAQ change >0.22. n = number of patients with 
available data at evaluation time. P‐values represent the result of the statistical comparison with Chi‐square tests or 
Mann‐Whitney‐U tests between the IMT and ICTS group. 
Values given are percentages or mean േ	SD. All tests were conducted at the 0.01 significant level. 
 
 
 
 
 
 
 
 Period   Disease outcome  Total  n  IMT  n  ICTS  n  p‐value
Year 1 
  
  
Remission  50%  74  50%  42  50%  32  0.593 
Change in DAS28 
(CRP) 
2.14 ± 1.43  70  1.93 ± 1.03  39  2.40 ± 1.80  31  0.176 
Good EULAR DAS 
response 
71%  71  68%  40  77%  31  0.257 
Change in HAQ score  0.55 ± 1.10  66  0.53 ± 1.14  36  0.58 ± 1.04  30  0.883 
Clinically meaningful 
HAQ response 
66%  65  71%  35  60%  30  0.239 
Year 2 
  
  
Remission  47%  68  37%  38  60%  30  0.049 
Change in DAS28 
(CRP) 
2.22 ± 1.50  64  1.76 ± 1.33  35  2.77 ± 1.53  29  0.007 
Good EULAR DAS 
response 
67%  64  60%  35  76%  29  0.140 
Change in HAQ score  0.37 ± 1.16  65  0.40 ± 1.17  35  0.34 ± 1.17  30  0.840 
Clinically meaningful 
HAQ response 
59%  65  63%  35  53%  30  0.300 
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Radiographic evolution 
In the total population, 54% of the patients at baseline, 42% at year 1 and 34% 
at year 2 had no radiographic damage, defined as a TSS equal to 0. In the IMT 
group, 62% of the patients at baseline, 43% at year 1 and 33% at year 2 had no 
radiographic damage. In the ICTS group, 44% of the patients at baseline, 41% at 
year 1 and 34% at year 2 had no radiographic damage. Progression is thus well 
controlled in the majority of patients. 
Figure 1 displays the erosive evolution and radiologic scores over two years of 
the IMT and ICTS patients. Both groups showed similar progression. However, a 
trend for less structural damage in the long term in favor of ICTS was observed.  
 
Figure 1: Comparison of the radiologic evolution between the IMT and ICTS group over two 
years 
IMT=Disease modifying anti rheumatic drug (DMARD) monotherapy; ICTS= initial combination therapy with 
steroids. Values given are mean േ	SD. P‐values represent the result of the statistical between subject comparison 
with repeated measures ANOVA between the IMT and ICTS group. Eta squared, a measure of the amount of the 
variation explained by the model, was used as a degree for effect size of ICTS over IMT. All tests were conducted at 
the 0.01 significant level. 
 
 
 
 
 
   
 
Period 
Total Sharp Score  Joint Space Narrowing Score  Erosion Score 
IMT  ICTS  IMT  ICTS  IMT  ICTS 
Baseline  2.60 ± 5.26        2.66 ± 4.57  1.98 ± 4.26  1.81 ± 3.48  0.62 ± 2.26      1.03 ± 2.18 
Year 1  3.90 ± 6.40  3.41 ± 4.93  2.67 ± 5.02  1.91 ± 3.12  1.29 ± 3.00  1.50 ± 3.04 
Year 2  5.05 ± 6.96  4.16 ± 5.37  3.31 ± 5.22  2.25 ± 3.27  1.79 ± 3.45  1.91 ± 3.47 
p‐value  0.732  0.486  0.697 
Effect size  0,002  0,006  0,002 
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Rapid radiographic progression 
 RRP at year 1 
RRP was found in four patients between baseline and year one: three IMT 
patients and one ICTS patient. All three IMT patients started initially MTX 
monotherapy. In the first year, all three received GCs and the dose was increased 
for two patients. In the second year two IMT patients switched to another classic 
DMARD and all received further GCs. The ICTS patient with RRP was given SSZ 
without dosage changes or GC use after the initial Cobra scheme. 
From these four patients with RRP in year one, none developed RRP between 
year one and year two.  
 
 RRP between year 1 and year 2 
RRP between year one and year two was found in four additional IMT patients, 
all on SSZ initial monotherapy and in one other ICTS patient. Four out of five 
were erosive at baseline. These IMT patients all switched to MTX during the 
second year. They were young females with a mean ± SD age of 31 ± 9 years. 
Two displayed a pregnancy wish. The three youngest were ACPA positive. 
However, these four patients displayed no high scores at baseline for the joint 
counts, DAS28(CRP) score, ESR/CRP status and PhGA, and were thus 
perceived as low risk. 
 
 RRP over 2 years 
Four patients had a change of ≥10 TSS units over two years. Three of these 
patients belonged to the IMT group and one to the ICTS group. Remarkably, three 
out of these four patients had already developed RRP during the first year but 
made no further radiographic progression in the second year. 
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Discussion 
The aim of this study was to evaluate the clinical and radiologic evolution of 
patients with early RA treated with ICTS and IMT in a tight control setting in daily 
practice over a two year follow-up period.  
 
Treatment Strategy 
In daily practice, experts will logically choose a more intensive therapy for more 
severe RA patients. [10] Our observational study showed that this choice was not 
always ideal in all cases. More IMT patients developed RRP despite lower RA 
severity and radiographic damage at baseline. Besides, ICTS patients achieved 
higher remission rates and DAS change over two years, although disease 
characteristics and clinical outcomes were equal after one year. 
Additionally, this study shows that a less intensive initial approach leads to more 
therapy changes reflecting the treating physician’s difficult and time consuming 
search for an optimal treatment schedule. 
 
Tight Control 
Our study highlights the potential of tight control to achieve remission and to 
prevent structural progression over two years. This confirms previous findings 
where tight control in daily practice was shown more effective in achieving 
remission after one year. [11] Radiologic progression is effectively halted by a 
DAS driven approach in a TC setting in clinical practice. The majority of patients 
didn’t have any or minimal radiological progress and both IMT and ICTS patients 
with RRP after one year showed minimal radiographic progression in the second 
year.The TC setting, without a strict treatment protocol, gives the rheumatologist 
more flexibility in tailoring the right medication for a patient in a timely fashion. 
This approach could diminish differences in effect between ICTS and IMT 
strategies in contrast to what can be observed in trials. [2-4, 8] The impact of 
adapting a treatment more frequently deserves additional attention from a patient 
perspective. Dealing with extra-therapeutic stressors, e.g. disappointments in 
therapy outcome or fear for novel drugs, should not be neglected. 
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Clinical evolution 
The higher proportion of patients with an ICTS regimen in remission after two 
years is remarkable. Firstly, because IMT patients were perceived as having a 
less severe RA profile at baseline. Secondly, because ICTS and IMT patients had 
equal rates of remission at year 1. Finally because a similar tight control approach 
was applied in both groups after the induction phase. 
 
Radiographic evolution 
A trend towards less radiographic progression in the ICTS patients compared 
with the IMT patients was detected. This effect can partially be explained because 
no IMT patients versus 4 ICTS patients received any biological treatment. 
Physicians were possibly more strict in applying the TC principle in ICTS patients 
whom they considered to have a more severe disease profile. Furthermore, the 
initial intensive use of GCs in the first year by ICTS patient could protect against 
radiographic progression. [12] 
In general, radiographic progression in our total population over two years was 
lower than what is considered to be clinically relevant. [13, 14] 
 
Rapid radiographic progression 
In this study, only one ICTS patient per year developed RRP out of 32 patients 
versus three IMT patients in the first year and four in the second year out of 42 
patients. 
Four notably young female IMT patients, considered to be at low risk despite a 
majority being ACPA positive [15], were initially treated with SSZ monotherapy 
but developed RRP in the second year. The two youngest patients had an active 
pregnancy wish. Therefore, physicians were possibly inclined to choose a more 
conservative treatment. It could be that this approach influenced RRP 
development. Thus, the risk of RRP is underestimated in certain patient groups, 
which is translated in conservative therapy choices. 
 
 
Limitations 
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This study is a small sized observational cohort study and not a randomized 
clinical trial. No strong causality can be shown in this setting because of the less 
controlled environment and patient diversity. For example, the lack of medication 
protocol biases therapy comparison. The fact that four ICTS patients and no IMT 
patients received biologicals, illustrates this problem. Furthermore, the more 
severe RA profile of the ICTS patients, caused by leaving the treatment choice to 
an expert, gave the ICTS group the possibility to clinically improve more than the 
IMT group. Moreover, the small size of our population plus the occurrence of 
missing data, although only in a minority of cases, limits the ability to demonstrate 
true differences. Missing variables occurred randomly and were infrequent. 
Conclusions should be regarded with caution. 
An important advantage of our approach is the lack of selection bias in the 
absence of in- and exclusion criteria and the possibility to extrapolate the results 
to clinical practice.  
 
Conclusion 
Both initial combination therapy with steroids and initial monotherapy prevent 
radiologic progression over two years, when applying the tight control principle in 
the daily practice of a Belgian academic hospital. ICTS appears to be more 
effective than IMT because of higher sustained remission rates with less therapy 
changes. In specific cases such as a pregnancy wish, physicians underestimate 
or ignore disease severity, which puts patients at risk for RRP. 
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CHAPTER 3 
 
 
 
 
 
Optimal intensive treatment 
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Methotrexate in Combination with Other DMARDs is not superior 
to Methotrexate alone for Remission Induction with moderate to 
high dose Glucocorticoid Bridging in early Rheumatoid Arthritis 
after 16 weeks of treatment: the CareRA trial.  
Abstract 
Objectives: To compare the efficacy and safety of intensive combination 
strategies with glucocorticoids (GCs) in the first 16 weeks (W) of early RA (eRA) 
treatment, focusing on high-risk patients, in the CareRA trial. 
Methods: 400 DMARD naïve eRA patients were recruited and stratified into high 
or low-risk according to classical prognostic markers. High-risk patients (n=290) 
were randomized to 1/3 treatment strategies: COBRA Classic (MTX+ 
Sulphasalazine + 60mg prednisone tapered to 7.5mg daily from W7), COBRA 
Slim (MTX + 30mg prednisone tapered to 5 mg from W6), and COBRA Avant-
Garde (MTX + Leflunomide + 30mg prednisone tapered to 5 mg from W6). 
Treatment modifications to target low disease activity were mandatory from W8, 
if desirable and feasible according to the rheumatologist. The primary outcome 
was remission (DAS28(CRP) <2.6) at W16 (ITT analysis). Secondary endpoints 
were good EULAR response, clinically meaningful HAQ response and HAQ equal 
to zero. Adverse events (AEs) were registered. 
Results: Data from 98 Classic, 98 Slim and 94 Avant-Garde patients were 
analyzed. At W16, remission was reached in 70.4% Classic, 73.6% Slim and 
68.1% Avant-Garde patients (p=0.713). Likewise, no significant differences were 
shown in other secondary endpoints. However, therapy-related AEs were 
reported in 61.2% of Classic, in 46.9% of Slim and in 69.1% of Avant-Garde 
patients (p=0.006). 
Conclusion: For high-risk eRA, MTX associated with a moderate step-down dose 
of GCs was as effective in inducing remission at W16 as DMARD combination 
therapies with moderate or high step-down GC doses and it showed a more 
favorable short-term safety profile. 
 
 87 
 
Introduction 
While in the past patients with early Rheumatoid Arthritis (eRA) were treated 
conservatively, current guidelines recommend treating high-risk patients 
intensively, early and to target (1-3). A lot of interesting and important pioneering 
work has already been done but  many questions regarding the optimal dosage 
and combination of medication in the management of eRA patients remain 
unaddressed (4). 
Trials using early intensive combination strategies with classical Disease 
Modifying Anti Rheumatic Drugs (DMARDs) and glucocorticoids (GCs) gave rise 
to the ‘’early window of opportunity” theory (5-10). This implies that if intensive 
treatment is initiated early in the disease process and disease activity is rapidly 
controlled, more patients will go into long-term remission with better functional 
and radiographic outcomes later on (11-16). Discussion still exists about the 
optimal way to rapidly induce remission at the individual patient level. Some 
patients might do equally well on Methotrexate (MTX) monotherapy and even in 
case of insufficient response, intensifying to triple DMARD therapy or a 
combination with a biological can rescue patients later on (17). A delay in optimal 
disease control might indeed not necessarily result in worse outcomes at 
standard evaluation time points, but unfortunately doesn’t take into account the 
cumulative disease activity patients have to suffer before arriving at these 
endpoints. This illustrates that the patient perspective is still understudied in 
traditional eRA trials. 
Guidelines suggest adapting treatment according to prognostic factors (1-3). 
Unfortunately, this doesn’t guarantee a favorable outcome in daily practice (18). 
Until better prediction models become available, the most effective approach to 
utilize the window of opportunity is to combine classical DMARDs with rapid 
remission inducing agents like GCs or biologicals.  
GCs are commonly used to bridge the onset of the therapeutic effect of DMARDs, 
to rapidly control inflammation and to prevent radiographic damage (19-21). 
During the difficult initial treatment weeks, GCs can relieve pain, stiffness and 
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disability, allowing patients to take up again their role in society more rapidly, and 
potentially preventing chronic disease behavior. The perception on GCs remains 
however ambiguous, in both the patient’s and the physician’s mind. Thus many 
rheumatologists hesitate to prescribe GCs due to fear for side effects (22, 23). 
Little is yet known about the optimal initial dose, treatment duration and 
administration route (24).  
Ample evidence exists that compared to MTX monotherapy, biologicals 
combined with MTX are more efficacious in eRA. Unfortunately, insufficient clarity 
exists if these agents can be used as remission induction agents in bridging 
strategies just as well as GCs, since most trial protocols led to persistent 
biological use after the induction phase (8, 9, 25-27). Moreover, TNF blocking 
agents didn’t demonstrate superior efficacy compared to induction regimes with 
GCs (28). Thus, administering GCs could avoid or postpone starting expensive 
long-term biological therapy (29).  
The debate on the ideal DMARD content of initial RA treatment strategies is still 
ongoing (30, 31). Triple therapy (MTX, Sulphasalazine (SSZ) and 
Hydroxychloroquine (HCQ)), COBRA (Combination therapy for early Rheumatoid 
Arthritis)-like schemes (MTX±SSZ+GCs) or other DMARD combination therapies 
show excellent clinical efficacy compared to monotherapy (5-8, 17, 32-37). 
However, studies comparing different intensive treat-to-target regimens of 
classical DMARDs associated with a remission-inducing agent are scarce. 
The aim of the current study was to compare in high-risk eRA patients the efficacy 
and safety of different initial DMARD combinations and GC bridging schemes, 16 
weeks after initiation. 
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Patients and Methods 
The CareRA study 
CareRA (Care in early RA - EudraCTnumber: 2008-007225-39) is a prospective 
2 year investigator-initiated multicenter Randomized Controlled Trial (RCT) 
rooted in daily practice. The trial is conducted in 13 Flemish rheumatology 
centers: 2 academic centers, 7 general hospitals and 4 private practices. 
This study was approved by the Ethics Committee (EC) of the University 
Hospitals Leuven after consultation of the local ECs. All patients gave written 
informed consent before inclusion. 
Patients 
Patients with RA, as defined by the American College of Rheumatology (ACR) 
1987 revised criteria, were recruited between January 2009 and May 2013. The 
main inclusion criteria were having a disease duration ≤1 year and being DMARD 
and GCs treatment naïve. Disease duration was defined as time elapsed between 
RA diagnosis and treatment initiation. Patients having contra indications for 
intensive treatment combinations with GCs as judged by the treating 
rheumatologist were excluded. See supplement 1 for a full list of exclusion 
criteria. 
Patients were allocated to a high-risk group based on an algorithm constructed 
with classical RA prognostic factors: erosions, Rheumatoid Factor (RF) and/or 
anti-citrullinated protein antibody (ACPA) and disease activity score based on C-
reactive protein (CRP) status [DAS28 (CRP)] at screening. (figure 1) 
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Design 
After risk allocation, high-risk patients were randomized into 1/3 treatment arms: 
 COBRA CLASSIC: 15mg MTX weekly, 2g SSZ daily and a weekly step-down 
scheme of oral GCs (60-40-25-20-15-10-7.5mg prednisone) This scheme has a 
higher dose of MTX than the original cobra schedule, based on experience in 
daily clinical practice. (5, 35) 
 COBRA SLIM: 15mg MTX weekly with a weekly step-down scheme of oral GCs 
(30-20-12.5-10-7.5-5mg prednisone).  
 COBRA AVANT-GARDE: 15mg MTX weekly, 10mg Leflunomide (LEF) daily and 
a weekly step-down scheme of oral GCs (30-20-12.5-10-7.5-5mg prednisone).  
The GC dose was tapered down weekly except for the lowest dose (7.5mg in 
COBRA CLASSIC and 5mg in the other arms), which was maintained until week 
(W) 28. Then, GCs were tapered on a weekly basis by leaving out 1 daily dose 
each week over a period of 6 weeks, until complete discontinuation. Prophylactic 
treatment including oral folic acid, calcium and vitamin-D supplements was 
prescribed to all patients. Furthermore, all patients received face-to-face 
education and info-material (leaflet, DVD and website) about the disease as well 
as on the proposed treatment at screening. Additional information was given on 
demand.  
A treat-to-target approach was used in a tight control setting (38), aiming for a 
DAS28(CRP) ≤3.2 (39). If patients failed to reach this target, treatment 
adjustments were made according to protocol from week 8 onwards. Treating 
rheumatologists had the option not to adapt treatment, but in that case had to 
motivate their decision based on a predefined list of specific clinical conditions. 
Other treatment adjustments not stated in the protocol could not be implemented 
by the treating physician. The first adjustment in all treatment arms was a weekly 
increase in MTX dose to 20mg. If necessary a second adjustment could be made 
from 8 weeks after the first adjustment. The second adjustment depended on the 
treatment arm: a SSZ dose increase to 3g daily in COBRA CLASSIC, a LEF 
addition of 10mg daily in COBRA SLIM or a LEF dose increase to 20mg daily in 
COBRA AVANT-GARDE. If patients did not reach the target after 2 predefined 
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treatment adjustments during the first year , this was considered a strategy failure 
for efficacy reasons. 
Intramuscular and intra-articular GC injections were allowed maximally every 8 
weeks, but not within 4 weeks preceding W16. Concomitant therapy with NSAIDS 
and analgesics was allowed and registered.  
Assessment 
Patients were assessed at screening, baseline, W4, W8 and W16. Maximally four 
weeks were allowed between screening and baseline. In case a treatment 
adjustment was required according to the protocol at W8, an optional visit was 
performed at W12. Demographics were registered at screening and clinical 
parameters, DAS28(CRP) and HAQ at every visit. (table 1) 
Safety and toxicity 
At each visit, patients were asked about any adverse events (AE) and medication 
changes. Each reported AE was registered and evaluated in relation to therapy, 
seriousness and severity by the treating rheumatologist. In case of toxicity, the 
protocol predefined schemes for tapering/interrupting the assigned treatment 
strategy. If toxicity was persistent, this was considered a strategy failure for safety 
reasons. 
Outcomes 
The primary outcome of this study was the proportion of patients in remission 
(DAS28(CRP)<2.6) at W16. Secondary outcomes were the proportion of good 
EULAR responders (DAS28(CRP) change>1.2 and DAS28(CRP)≤3.2 ), the 
proportion of patients having a clinically meaningful improvement of the HAQ 
(HAQ change>0.22) and the proportion of patients having a HAQ equal to zero 
at W16. 
Statistical analysis 
The study was designed as a superiority analysis of CLASSIC versus SLIM and 
AVANT-GARDE versus SLIM. Sample-size calculation was based upon the 
proportion of patients in remission at W16. Eighty-five patients per treatment arm 
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were required for a power of 80% and significance level of 0.05, starting from an 
estimated clinically relevant difference in effect size of 20%. All patients starting 
treatment were analyzed. 
Missing data were handled as follows. Screening variables were used to impute 
missing baseline variables and vice versa. A maximum likelihood model ( by the 
Expectation-Maximization algorithm) was applied to impute missing data needed 
to calculate the DAS28(CRP) at W4, W8 and W16.  
An intention-to-treat (ITT) analysis was performed by χ² or Kruskal-Wallis test, 
when appropriate. Area Under the Curve (AUC) analysis was used to evaluate 
the DAS28(CRP) over time. All statistical analyses were carried out using the 
Statistical Package for the Social Sciences (SPSS) version 20. A p-value <0.05 
was considered statistically significant. 
Results 
A total of 400 patients were screened and 380 patients were included in CareRA. 
75% of these patients were included in non-university centers. No differences in 
demographic and clinical characteristics were observed between screened and 
included patients. 290 patients were allocated to the high-risk group and 
randomly assigned to treatment in the COBRA CLASSIC (98), COBRA SLIM (98) 
and COBRA AVANT-GARDE (94) arm. Randomization resulted in similar 
baseline characteristics between groups. (table 1) 
Figure 2 describes the patient disposition from screening until week 16. 
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Table 1: Patients’ characteristics at baseline per treatment arm 
BMI= Body mass index; Symptom duration = time elapsed between onset of symptoms and start of treatment; 
Disease duration= time elapsed between diagnosis of RA and start of treatment; Morning stiffness = being stiff in 
the morning for at least 45 minutes; RF= Rheumatoid factor; ACPA= Anti‐citrullinated protein antibody; PGA= 
Patient global assessment; PhGA= Physician global assessment;  TJC= Tender joint count; SJC= Swollen joint count; 
ESR = Erythrocyte sedimentation rate; CRP = C‐reactive protein; DAS28= 28 joint Disease activity score; HAQ= Health 
assessment questionnaire. Data is presented as mean ± standard deviation or as percentages. 
 
Cobra Classic  Cobra Slim  Cobra Avant‐Garde 
Number of patients  98  98  94 
Age (years)  53.2 ± 11.9  51.8 ± 13.1  51.2 ± 12.8 
BMI (kg/m²)  26.0.99 ± 4.3  26.8 ± 4.2  26.5 ± 4.2 
Gender (female)  65.3%  64.3%  69.1% 
Smoking Status (ever)  57.1%  59.2%  60.6% 
Alcohol Intake (yes)  55.1%  56.1%  54.3% 
Symptom Duration (weeks)  33.8 ± 35.5  33.2 ± 38.2  44.2 ± 65.6 
Comorbidities at screening (yes)  72.4%  74.5%  64.9% 
Morning Stiffness (yes)  74.5%  68.4%  58.4% 
RF (yes)  79.6%  83.7%  75.5% 
ACPA (yes)  77.6%  79.6%  77.7% 
Erosions (yes)  32.7%  32.7%  34.0% 
Total TJC  14.7 ± 9.5  13.7 ± 8.2  14.0 ± 9.0 
Total SJC  11.9 ± 8.9  10.8 ± 6.5  10.5 ± 6.8 
PGA (0‐100)  59.5 ± 21.7  56.2 ± 21.7  54.5 ± 24.3 
Pain (0‐100)  59.5 ± 23.6  56.5 ± 21.9  56.9 ± 23.88 
Fatigue (0‐100)  50.6 ± 26.0  49.0 ± 21.3  48.68 ± 23.78 
PhGA (0‐100)  54.7 ± 18.5  53.1 ± 18.1  51.8 ± 18.2 
ESR  33.59 ± 25.2  32.1 ± 23.3  25.18 ± 17.7 
CRP  19.7 ± 28.9  21.5 ± 33.3  15.1 ± 20.0 
DAS28(ESR)  5.4 ± 1.3  5.2 ± 1.2  5.0 ± 1.3 
DAS28(CRP)  5.0. ± 1.2  4.9 ± 1.1  4.7 ± 1.2 
HAQ (0‐3)  1.2 ± 0.7  0.98 ± 0.69  0.99 ± 0.64 
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Efficacy 
Primary outcome 
Remission was achieved in 70.4% (68/98) COBRA CLASSIC patients, 73.5% 
(72/98) COBRA SLIM patients and 68.1% (64/94) COBRA AVANT-GARDE 
patients (p =0.713) at W16. (figure 3a)  
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Secondary outcomes 
At W16, a good EULAR response was reached in 79.6% of CLASSIC patients, 
79.6% of SLIM patients and 76.6% of AVANT-GARDE patients (p =0.844). A 
clinically meaningful HAQ response was reached in 84.7% of CLASSIC patients, 
86.7% of SLIM patients and 76.6% of AVANT-GARDE patients (p =0.271). HAQ 
was equal to zero in 45.9% of CLASSIC patients, 42.9% of SLIM patients and 
48.9% of AVANT-GARDE patients (p =0.700). (table 2) 
Table 2: Clinical outcomes at week 16 per treatment arm 
Cobra Classic  Cobra Slim  Cobra  
Avant‐Garde 
p‐value ∆ between Classic vs 
Slim (95% C.I.) 
∆ between Avant‐Garde 
vs Slim (95% C.I.) 
Number of patients  98  98  94       
DAS28 (CRP) Change  2.8 ± 1.2  2.6 ± 1.2  2.4 ± 1.3  0.140  0.2 (‐0.13 to 0.52)  ‐0.2 (‐0.49 to 0.21) 
Remission  70.4%  73.5%  68.1%  0.713  ‐3.1% (‐15.4% to 9.5%) ‐5.4% (‐18.0% to 7.4%) 
Low Disease Activity  84.7%  86.7%  87.2%  0.863  ‐2.0% (‐12.0% to 7.9%)  0.5% (‐9.3% to 10.2%) 
Good Eular Response  79.6%  79.6%  76.6%  0.844  0.0% (‐11.3% to 11.3%)  ‐3.0% (‐14.7% to 8.7%) 
Moderate Eular 
Response 
98.0%  95.9%  93.6%  0.320  2.1% (‐3.6% to 8.2%)  ‐2.3% (‐9.6% to 4.6%) 
HAQ Change  0.8 ± 0.6  0.6 ± 0.6  0.7 ± 0.6   0.081  0.2 (0.02 to 0.37)  0.1 (‐0.17 to 0.19) 
Clinically Meaningful 
HAQ Change 
84.7%  76.5%  76.6%  0.271  8.2% (‐ 3.0% to 19,1%) 0.1% (‐11.9% to 12.0%) 
HAQ = 0  45.9%  42.9%  48.9%  0.700  3.0% (‐10.7% to 16.6%)  6.0% (‐7.9% to 19.7%) 
DAS28(CRP) = 28 Joint disease activity score calculated with C‐reactive protein; DAS28(CRP) change = DAS score on 
baseline minus DAS score on week 16; Remission was defined as DAS28(CRP) <2.6; Low Disease Activity was defined 
as DAS(CRP) ≤3.2; Good Eular Response was defined as low disease activity with a DAS28(CRP) change >1.2. 
Moderate Eular Response was defined as DAS28(CRP) change >1.2 or a DAS28(CRP) ≤5.1 and a DAS28(CRP) change 
between 0.6 and 1.2; HAQ = Health Assessment Questionnaire; HAQ change = Baseline HAQ minus week 16 HAQ; 
clinically meaningful HAQ change was defined as a HAQ change >0.22. Data is presented as mean ± standard 
deviation or as percentages. Statistical analysis was performed by χ² or Kruskal‐Wallis test. A p‐value <0.05 was 
considered statistically significant. ∆ = difference; C.I. = Confidence Intervals (calculated by the Newcombe method 
for differences between proportions). DAS28(CRP) was imputed in 7 out of 98 Classic, 2 out of 96 Slim and 4 out of 
94 Avant‐Garde patients. HAQ was imputed in 7 out of 98 Classic, 2 out of 96 Slim and 5 out of 94 Avant‐Garde 
patients. 
Likewise, complete case analysis (without missing data imputation) of the primary 
and secondary outcomes revealed no significant differences between the 3 
treatment arms (data not shown). 
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Area Under the Curve 
The mean ± SD AUC for DAS28(CRP) from baseline to W16 was 10.66 ± 3.41, 
11.05 ± 3.39 and 10.72 ± 2.96 for the CLASSIC, SLIM and AVANT-GARDE 
respectively (p=0.521). (figure 3b) 
Treatment adaptations according to protocol 
During the first 16 weeks of therapy, treatment adaptations were performed in 
19.4%, 22.4% and 14.9% in the CLASSIC, SLIM and AVANT-GARDE arm 
respectively (p=0.407). Of these patients requiring treatment adaptations at W8, 
50,0%, 87,5% and 60,0% in the CLASSIC, SLIM and AVANT-GARDE arm 
respectively reached the low disease activity target at W16 (p=0.086). Of 61 
patients requiring per protocol treatment adaptation at week 8, 39% (24/61) had 
no change in therapy because of contraindications or because the treating 
physician judged the disease sufficiently controlled. These 24 patients received 
no other medication and stayed on the initial strategy without treatment 
adaptation. Intra-articular GC injections were given in 3.1% of CLASSIC patients, 
5.1% of SLIM patients and 5.1% of AVANT-GARDE patients (p=0.703). 
Safety 
Therapy related AEs were registered in 171 out of the 290 patients (59%) during 
the first 16 weeks of treatment. These were reported in 61.2% of CLASSIC, in 
46.9% of SLIM and in 69.1% of AVANT-GARDE patients (p=0.006). The total 
number of AEs related to CLASSIC, SLIM and AVANT-GARDE treatment was 
148, 70 and 130 respectively, with a similar distribution for discomfort and toxicity. 
(table 3) 
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Table 3: Number of adverse events per treatment arm during 16 weeks of treatment 
AE = Adverse event 
 
Discussion 
In eRA patients with unfavorable classical prognostic factors such as RF, ACPA, 
erosions and/or high disease activity, MTX associated with a moderate step-down 
dose of GCs was as effective as DMARD combination therapies with moderate 
or high step-down GC doses, for remission induction at 16 weeks. Furthermore, 
the short-term safety profile of MTX associated with a moderate step-down dose 
of GCs was more favorable. 
This finding has 2 implications. Firstly, in association with a moderate or high GC 
dose, the combination of MTX with other DMARDs does not seem to be more 
effective compared to MTX alone, at least in the early treatment stage. Until now 
only few studies have addressed the question if DMARD combinations are 
superior to MTX monotherapy independent from additional GC bridging in eRA 
(7, 32-34). The tREACH trial showed that DMARD combination was better than 
  Cobra Classic  Cobra Slim  Cobra Avant‐Garde 
Number of patients  91  96  91 
AE related to therapy  148  70  130 
Type related AE  Discomfort  111  50  96 
  Toxicity  27  10  23 
  Infection  5  3  5 
  Others  4  7  6 
  Surgery  1  0  0 
Severity of related AE  Mild   121  64  103 
  Moderate  23  5  21 
  Severe  4  1  6 
Serious AE  2  1  3 
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MTX monotherapy, both in association with low dose GC bridging. In our trial, the 
COBRA-like moderate or high dose GC scheme bridged the time lag before full 
DMARD efficacy, probably erasing any difference between the different DMARD 
schedules. As a consequence, less medication is needed over time, which might 
impact adverse events and possibly also  patients’ adherence to treatment. The 
tight control setting could also correct swiftly for any suboptimal treatment 
regimen, explaining some of the good efficacy of COBRA SLIM. However, only 
MTX dose adjustment and no step up to combination therapy could be 
implemented before W16. Furthermore, the proportion of treatment adjustments 
between the three arms wasn’t significantly different.  
Secondly, a high-dose GC scheme starting at 60mg prednisone does not seem 
to improve early clinical outcomes compared with a moderate-dose scheme 
starting at 30mg prednisone, regardless of the DMARD strategy used. Thus, a 
lower cumulative GC dose is still equally effective, perhaps avoiding long-term 
AEs. Furthermore, the possibility to use a lower dose of GCs, while having the 
same efficacy could benefit the implementation of COBRA-like strategies. 
Rheumatologists appear more reluctant to administer complex therapies with 
high dosages of GCs (22, 23, 40-42), although we showed that this approach is 
feasible in daily practice (35). Den Uyl et al reported similar results comparing an 
attenuated COBRA regimen with the original one in a moderately active eRA 
population (36). However, this study lacked decisive evidence, the MTX dose in 
the classical scheme was suboptimal, and the glucocorticoid scheme in the 
attenuated COBRA version was cumulatively comparable to the classical one. 
Many rheumatologist use low dose GCs in association with DMARDS for eRA in 
daily practice, much to their own and their patients’ satisfaction. They have 
however doubts about the need for higher GC dosages and prolonged use. The 
potential advantage of a COBRA-like schedule over low-dose GCs is two-sided . 
Firstly, a high or moderate dose could have a more radical biological effect on the 
disease process favoring “real” remission induction (43). Low-dose GCs show 
only a slow genomic effect, while higher dosages show both slow genomic and 
faster non-genomic effects (44, 45). Secondly, compared to using GCs only short 
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term and discontinuously, it can be more effective to bridge systematically the 
entire time window before maximum DMARD efficacy, taking up to six months 
(46-48).  DMARD combinations could therefore have a short-lived advantage 
over DMARD monotherapy in trials using GCs not systematically, at a too low 
dose or for a too short period of time (32, 33, 37, 46). 
The analysis of the area under the curve of disease activity reinforced the study 
findings at every visit, illustrating that the disease burden was the same during 
the first 16 weeks of treatment over the three treatment arms. A delayed targeted 
therapy as proposed by others (17) would result in a much higher cumulative 
disease activity. This study only presents the first 16 weeks of the CareRA trial, 
but this initial treatment period, the so-called ‘window of opportunity’ is crucial for 
longer-term outcome at the biological and probably also at a psychosocial level 
(15, 49). Long-term disease control and patient reported outcomes after one and 
two years are awaited in CareRA. 
The safety analysis strengthened the efficacy outcomes further. The proportion 
and number of related AEs was comparable in CLASSIC and AVANT-GARDE, 
while SLIM patients had half the related AEs. GC dosage doesn’t make any 
difference in the frequency or type of related AEs at this stage. Remarkable are 
the comparable number of AEs of the combination therapies with different GC 
dose, underscoring again the prejudice against GC dosage and lack of 
knowledge of GC side effects. 
The first two limitations are related to the design of this study, although 
unavoidable in a pragmatic trial aiming to reflect daily clinical practice. Firstly, 
medication adherence wasn’t measured. However, if adherence was lower in a 
certain trial arm, the same could be expected from this treatment regimen in daily 
clinical practice. Secondly, no blinding was implemented. Rheumatologists could 
have been biased towards a certain therapy and therefore report less therapy 
related AEs. Certain patients could also be more motivated for certain treatment 
regimens than for others. 
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Another limitation was the superiority design of this study. We opted for this 
design because in a non-inferiority trial the number of patients needed would be 
doubled. Hence, we can only state that Cobra Classic and Cobra Avant-Garde 
are non-superior to Cobra Slim, which is not the same as claiming non-inferiority. 
In conclusion, the data presented are positioning classical MTX therapy with 
bridging GCs at a lower dose than in the original COBRA study as a highly 
effective and safe remission induction therapy in more than 70% of high-risk eRA 
patients and this in a close to daily practice setting applying a treat-to-target 
strategy 
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Patients lacking classical poor prognostic markers might also 
benefit from a step-down glucocorticoid bridging scheme in 
early Rheumatoid Arthritis: week 16 results from the randomized 
multicenter CareRA trial 
 
Abstract 
Introduction: Considering a lack of efficacy data in patients with early 
Rheumatoid Arthritis (eRA) presenting without classical poor prognosis 
markers, we compared methotrexate (MTX) with or without step-down 
glucocorticoids in the Care in early RA (CareRA) trial.  
Methods: Disease Modifying Anti-Rheumatic Drugs (DMARDs) naïve eRA 
patients were stratified into a low-risk group based on prognostic markers 
including non-erosiveness, Anti-Citrullinated-Protein Antibodies (ACPA) and 
Rheumatoid Factor (RF) negativity and low disease activity (DAS28(CRP)≤3.2).  
Patients were randomized to 15mg MTX weekly (MTX-TSU) or 15mg MTX 
weekly with prednisone bridging, starting at 30mg and tapered to 5mg daily 
from week 6 (Cobra Slim). A tight step-up (TSU) approach was applied. 
Outcomes were DAS28(CRP) remission, cumulative disease activity, Health 
Assessment Questionnaire (HAQ) and adverse events (AEs) after 16 treatment 
weeks.  
Results: 43 Cobra Slim and 47 MTX-TSU patients were analyzed: 65.1% in the 
Cobra Slim group and 46.8% in the MTX-TSU group reached  remission 
(p=0.081). Mean ± SD AUC-DAS28(CRP) was 13.84 ± 4.58 and 11.18 ± 4.25 
for the MTX-TSU and Cobra Slim patients respectively (p=0.006). More Cobra 
Slim patients had a HAQ=0 (51.2% vs 23.4%, p=0.006) at week 16. Therapy 
related AEs did not differ.  
Conclusion: In patients with low-risk eRA, MTX with step-down glucocorticoid 
bridging seems more efficacious than MTX step-up monotherapy with a 
comparable number of AEs over the first 16 treatment weeks. 
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Introduction: 
Current guidelines recommend treating patients with early Rheumatoid Arthritis 
(eRA) immediately, intensively and to target [1-3]. Early intensive treatment 
strategies combining classical Disease Modifying Anti-Rheumatic Drugs 
(DMARDs) with rapid remission inducing agents like glucocorticoids (GCs) or 
biologicals are  the most effective approach for eRA [4-6]. In daily practice, 
however, the initial treatment choice is based on physician’s preference, patient 
and disease characteristics as well as cost issues [7]. Traditionally, the absence 
of bone erosions, Rheumatoid Factor (RF) or Anti-Citrullinated-Protein 
Antibodies (ACPA) and low disease activity are considered markers of a good 
prognosis, but the bad performance of these markers and derived matrices 
might lead to under treatment of so-called low-risk patients [8]. 
New very sensitive classification criteria for RA were developed in light of the 
early treatment paradigm [9], but patients with eRA still form a heterogeneous 
group [10]. Current treatment recommendations are mostly based on evidence 
from Randomized Controlled Trials (RCT) in preselected populations with a 
poor prognosis based on classical markers and high disease activity. Few 
studies examine how to treat patients not reflecting this classic RCT image of 
eRA.  
Early intensive treatment appears successful also in undifferentiated arthritis, 
including patients with so-called pre-RA, but confirmation is needed in studies 
with a longer follow-up [11]. On the other hand some authors suggest that too 
stringent treatment targets might not outweigh potential side effects in eRA 
patients lacking poor prognosis markers [12]. 
This paper evaluates the efficacy and safety of step-up Methotrexate (MTX) 
with or without a step-down glucocorticoid bridging scheme after 16 weeks of 
treatment, in patients with eRA presenting without classical markers of poor 
prognosis. 
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Patients and methods: 
This study is part of the Care in early RA (CareRA) trial, a Flemish prospective 
2 year investigator-initiated multicenter RCT rooted in daily practice 
(EudraCTnumber: 2008-007225-39). The trial is conducted in 2 academic 
centers, 7 general hospitals and 4 private practices. 
The ethics committee (EC) of the University Hospitals Leuven approved this 
study after consultation of the local ECs. All patients gave written informed 
consent. The full names of all approving ethical committees can be located 
within the Acknowledgements section 
Patients 
DMARD naïve patients with eRA, as defined by the American College of 
Rheumatology 1987 criteria, with a disease duration ≤1 year and aged ≥18 
years, were recruited between January 2009 and May 2013. Patients having 
contra indications for MTX and/or GCs were excluded.  
Eligible patients were stratified into a low or high-risk group. This allocation was 
based on classic RA prognostic factors: presence of erosions, presence of RF 
or ACPA and baseline disease activity score based on C-reactive protein 
[DAS28 (CRP)].  
 
Patients were considered low-risk if: 
•No erosions + ACPA and RF negative 
•Erosions + ACPA and RF negative + DAS28 (CRP) ≤3.2 
•No erosions + ACPA/RF positive + DAS28 (CRP) ≤3.2  
See figure 1 for more detail about the risk stratification. 
Patients were assessed at screening, baseline, Week (W) 4, W8 and W16. If a 
treatment adjustment was required at W8, an optional visit was performed at 
W12. The analysis of the first 16 weeks in the high-risk arm of the CareRA trial 
was already reported in a separate paper [13]. 
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Design 
Low-risk patients were randomized in 1 of 2 treatment arms: 
 MTX Tight Step-Up (MTX-TSU): 15mg MTX weekly, no oral steroids 
allowed 
 Cobra Slim: 15mg MTX weekly with a step-down scheme of daily oral 
GCs (30-20-12,5-10-7,5-5mg prednisone). From W28, GCs were tapered 
on a weekly basis by leaving out 1 daily dose each week over a period of 
6 weeks, until complete discontinuation. 
A treat-to-target approach was used in a tight-control setting [14], aiming for a 
DAS28 (CRP) ≤3.2 . If patients failed to reach this goal, treatment adjustments 
were made in both groups from W8: firstly a MTX dose-increase to 20mg 
weekly and secondly the addition of 10mg Leflunomide daily. Not reaching the 
target after these treatment adjustments was considered an efficacy failure. 
Intramuscular and intra-articular GC injections were allowed maximally every 8 
weeks, except within 4 weeks preceding W16.  
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Outcome 
The primary outcome was the proportion of patients in remission at W16, 
defined as a DAS28(CRP)<2.6. Secondary outcomes were the proportion of 
good EULAR responders, patients having a clinically meaningful Health 
Assessment Questionnaire (HAQ) response, patients having a HAQ=0 at W16 
and cumulative disease activity. 
Safety and toxicity 
Patients were asked about experienced adverse events (AE) at each visit. Each 
reported AE was subtyped (toxicity, discomfort, infection, surgery or other) and 
evaluated for relation to the therapy, seriousness and severity by the treating 
rheumatologist. In case of toxicity, medication was adjusted according to a 
predefined scheme. Persistent toxicity was considered a safety failure.  
Statistical analysis 
No power calculation was done in view of the low-risk sub-analysis of the 
CareRA trial. 
We performed an intention-to-treat (ITT) analysis by χ²-test, Mann-Whitney-U 
test, Area-Under-the-Curve (AUC) and General-Estimated-Equations (GEE) 
analysis. Screening data were used to impute missing baseline data and vice 
versa. A maximum likelihood model was applied to impute missing data at W4, 
W8 and W16. Missing data at the optional visit W12 were imputed by taking the 
mean of W8 and W16. SPSS version 20.0 was used. A p-value < 0.05 was 
considered statistically significant. 
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Results 
Ninety of the 380 patients in the CareRA trial were stratified as low-risk patients: 
47 MTX-TSU and 43 Cobra Slim patients. Both groups had similar baseline 
characteristics, which reflect a mild eRA, with a moderate mean disease activity 
and low numbers of erosions, RF and ACPA positivity (table 1). One MTX-TSU 
and three Cobra Slim patients withdrew their consent before W16. 
 
Table 1: Patients’ characteristics at baseline per treatment group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMI= Body mass index; Alcohol Intake = consumption of any form of alcohol; Symptom duration = time elapsed 
between onset of symptoms and start of treatment; Disease duration = time elapsed between diagnosis of RA and start 
of treatment; Morning stiffness = being stiff in the morning for at least 45 minutes; RF= Rheumatoid factor; Anti 
CCP= Anti cyclic citrullinated protein; PGA= Patient global assessment; PhGA= Physician global assessment;  TJC= 
Tender joint count; SJC= Swollen joint count; ESR = Erythrocyte sedimentation rate; CRP = C-reactive protein; 
DAS28= 28 joint Disease activity score; HAQ= Health assessment questionnaire. Values reported are proportions or 
mean ± standard deviation. 
 
Tight Step Up Cobra Slim 
n=47 n=43 
Age (years) 51.02 ± 14.00 51.42 ± 14.42 
BMI (kg/m²) 26.98 ± 4.22 25.40 ± 4.27 
Gender (female) 80.9% 76.7% 
Smoking Status (ever) 38.3% 48.2% 
Alcohol Intake (yes) 61.7% 55.8% 
Symptom Duration (weeks) 33.11 ± 62.21 34.42 ± 68.16 
Comorbidities present (yes) 66.0% 60.5% 
Morning Stiffness (yes) 68.1% 53.5% 
RF (yes) 23.4% 25.6% 
Anti-CCP (yes) 23.4% 27.9% 
Erosions (yes) 0.0% 2.3% 
Total TJC 14.06 ± 8.61 13.14 ± 10.70 
Total SJC 10.00 ± 6.98 10.93 ± 7.55 
PGA (0-100) 49.89 ± 22.99 48.60 ± 30.68 
Pain (0-100) 52.09 ± 23.23 48.23 ± 31.19 
Fatigue (0-100) 45.91 ± 22.07 39.40 ± 27.66 
PhGA (0-100) 48.34 ± 23.37 48.63 ± 20.80 
ESR  (mm/h) 23.04 ± 16.90 30.00 ± 29.40 
CRP (mg/l) 13.53 ± 18.62 20.14 ± 39.25 
DAS28(ESR) 4.83 ± 1.68 4.88 ± 1.64 
DAS28(CRP) 4.55 ± 1.63 4.50 ± 1.63 
HAQ (0-3) 0.99 ± 0.67 0.92 ± 0.85 
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Efficacy (table 2) 
Primary and secondary outcomes 
Remission was accomplished in 46.8% MTX-TSU and 65.1 % Cobra Slim 
patients (p =0.081). A good EULAR response was achieved in 44.7% of MTX-
TSU and 58.1% Cobra Slim patients (p = 0.202). A clinically meaningful HAQ 
response was reached in 53.2% MTX-TSU and 62.8% Cobra Slim patients (p 
=0.357). Less patients had a HAQ=0 in the MTX-TSU (23.4%) compared to the 
Cobra Slim (51.2%) group (p=0.006). 
 
Table 2: Clinical outcomes at week 16 per treatment group 
Tight Step-Up Cobra Slim p-value 
 n=47 n=43  
DAS28 (CRP) Change 1.76 ± 1.68 2.12 ± 1.41 0.192 
Remission 46.8% 65.1% 0.081 
Low Disease Activity 72.3% 79.1% 0.458 
Good Eular Response 44.7% 58.1% 0.202 
Moderate Eular Response 72.3% 86.0% 0.111 
HAQ Change 0.40 ± 0.62 0.58 ± 0.64 0.267 
Clinically Meaningful HAQ 
Change 
53.2% 62.8% 0.357 
HAQ is Zero 23.4% 51.2% 0.006 
DAS28(CRP) = 28 Joint disease activity score calculated with C-reactive protein; DAS28(CRP) change = DAS score 
on baseline minus DAS score on week 16; Remission is defined as DAS28(CRP) <2.6; Low Disease Activity is 
defined as DAS(CRP) ≤3.2; Good Eular Response is defined as low disease activity with a DAS28(CRP) change 
>1.2. Moderate Eular Response is defined as DAS28(CRP) change >1.2 or a DAS28(CRP) ≤5.1 and a DAS28(CRP) 
change between 0.6 and 1.2; HAQ = Health Assessment Questionnaire; HAQ change = Baseline HAQ minus week 
16 HAQ; clinically meaningful HAQ change is defined as a HAQ change >0.22. Values reported are proportions or 
mean ± standard deviation. χ²-tests and Mann-Whitney-U tests were applied when appropriate. The significance level 
was 0.05. 
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Longitudinal analyses 
The mean ± SD AUC DAS28(CRP) was 13.84 ± 4.58 and 11.18 ± 4.25 for the 
MTX-TSU and Cobra Slim patients respectively (p=0.006)(Figure 2). GEE 
analysis showed a better treatment effect of Cobra Slim over MTX-TSU on 
longitudinal disease activity (p=0.005). 
 
 
 
Treatment adaptations 
At W8, treatment adjustments were performed in 34.0% of MTX-TSU patients 
and 23.3% of Cobra Slim patients (p=0.259).  At W16, treatment adjustments 
were performed in 21.3% of MTX-TSU patients and 16.3% of Cobra Slim 
patients (p=0.545). One Cobra Slim patient was considered an efficacy failure at 
W16.  
Intra-articular GC injections were given in 21.3% of MTX-TSU and 7.0% of 
Cobra Slim patients (p=0.054). Only one MTX-TSU patient received two GC 
injections. 
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Safety 
Until W16, therapy related AEs were reported in 44.7% of MTX-TSU and in 
39.5% of Cobra Slim patients (p=0.622). MTX-TSU was related to 32 and Cobra 
Slim to 30 AEs, with a similar distribution for discomfort and toxicity (table 3). In 
the MTX-TSU group 11/23 AEs related to discomfort were intestinal problems 
(nausea and diarrhea), while 10/23 discomfort problems in the Cobra Slim 
group were intestinal issues (nausea and constipation). In the Cobra Slim 
group, there were 2 cases of increased appetite. Furthermore, 8/23 discomfort 
problems in the MTX-TSU and 8/23 AEs related to discomfort in the Slim group 
were general malaise problems (dizziness, agitation, headache, fatigue). There 
were 7 toxicity problems related to therapy in the MTX-TSU group: 4 cases of 
abnormal liver values, 1 case of abnormal kidney values, 1 oral ulcer and 1 
pyrosis. In the Cobra Slim group there were 4 toxicity problems related to 
therapy: 2 cases of alopecia, 1 tendinitis and 1 stomatitis. The only infection in 
our study was an upper respiratory tract infection in a MTX-TSU patient. No 
serious adverse events were registered. Mean ± SD Weight gain was 0.00 ± 
2.44 kg in the MTX-TSU group and 0.70 ± 3.16 kg in the Cobra Slim group 
(p=0.287). Mean ± SD BMI gain was 0.01 ± 0.90 kg/m² in the MTX-TSU group 
and 0.23 ± 1.12 kg/m² in the Cobra Slim group (p=0.286). 
 
Table 3: Number of adverse events per treatment group 
 Tight Step Up Cobra Slim 
 n=47 n=43 
AE related to therapy 32 30 
Type related AE Discomfort 23 23 
 Toxicity 7 4 
 Infection 1 0 
 Others 1 3 
 Surgery 0 0 
Severity of related AE Mild  29 28 
 Moderate 3 2 
 Severe 0 0 
Serious AE 0 0 
AE = Adverse event.  
Protocol determines the severity rating of the adverse event:  
-Mild (does not interfere with daily living)  
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-Moderate (somewhat interferes with daily living or medications needed to relieve event)  
-Severe (incapacitating) 
 
Discussion 
We demonstrated that, although the primary outcome was not met at week 16, 
low-risk eRA patients treated with MTX and a step-down glucocorticoid bridging 
scheme showed a better cumulative control of disease activity over time and 
better functionality than patients treated with step-up MTX only, while having a 
similar safety profile during the first 16 treatment weeks.  
In both groups favorable remission and low disease activity scores were 
achieved after 16 weeks. Efficacy scores didn’t differ at W16, probably due to 
the limited number of patients included in this substudy, but also due to a trend 
for more treatment modifications and GC injections in the MTX-TSU group. The 
lower cumulative disease activity with Cobra slim during the first 16 weeks of 
treatment might have important consequences for the future disease course 
[15, 16]. Moreover, the speed of disease control and frequency in treatment 
adaptations could also have differential effects on the evolution of patient 
centered outcomes.  
In this study, we applied a step-down bridge GC scheme which has two 
advantages over more traditional short-term low dosage GC use[17]. Firstly, 
high or moderately-dosed GCs demonstrate, apart from slow genomic effects, 
also faster non-genomic effects with a more profound impact on the disease 
process [18, 19]. Secondly, systematic and prolonged use of GCs is more 
efficacious than on demand use in the therapeutic time window before 
maximum DMARD efficacy [6, 20]. Intensive remission induction regimens 
appear to be equally advantageous in so-called low-risk as in high-risk eRA 
patients, but the appropriateness and performance of the currently used 
prognostic parameters need further evaluation in the long-term [8]. 
A significant finding is the safety profile of both groups. Patients in the MTX-
TSU and Cobra slim group showed comparable numbers and types of adverse 
events related to therapy in the period their treatment schedules differed the 
most. Not much is known about the safety of short term glucocorticoid use. Our 
study adds to the much needed evidence about glucocorticoid use in the 
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management of early RA [21, 22] and shows that glucocorticoids are relatively 
safe to use in a remission induction scheme in patients with early RA, also in 
so-called mild RA. This result is in contrast to some rheumatologists’ negative 
perception of glucocorticoid use in intensive treatment strategies in early RA 
[23], while patients themselves are rapidly convinced after glucocorticoid 
administration [24]. 
 
This explorative study has some limitations. Firstly, the total population in the 
low-risk arm is relatively small. Power calculation for the CareRA study was 
done in view of the high-risk subpopulation. Because 25% of patients were 
stratified as low risk patients, we did not achieve the same power as in the high 
risk arm. Therefore, results of our explorative study in the low risk arm should 
be interpreted with caution.  Furthermore, the low number of low-risk patients is 
possibly responsible for the lack of statistical difference in the primary outcome 
at week 16. Secondly, we did not measure medication adherence and there 
was no blinding procedure, but this is unavoidable in a pragmatic trial reflecting 
daily clinical practice. 
Thirdly, we report the results after 16 weeks of treatment, which is a relatively 
short time span to evaluate the full impact of a treatment strategy. This timing 
was chosen because there is increasing evidence that long term RA outcomes 
are mostly influenced by the initial success of treatment. Of course, the ultimate 
effect of treat to target adaptations according to the protocol cannot be 
evaluated in this time window. 
 
Our exploratory data are of importance in the ongoing debate about the optimal 
initial treatment strategy for early RA in daily practice [25]. Patients with RA who 
are negative for biomarkers such as RF and especially ACPA are traditionally 
seen as having a better prognosis. Barra et al. have shown very clearly that this 
assumption is not always true [26]. The absence of serum markers for RA 
cannot be claimed to predict in general a milder disease course. This means 
that patients conventionally perceived as having a lower risk on a severe 
disease course should be treated according to the same standards as high-risk 
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patients. In this study we show that just like high-risk patients, so called low-risk 
patients can be more successfully treated with an intensive treatment strategy, 
while having a similar safety outcome as patients treated more conservatively. 
Until such time that prognostic factors can reliably stratify patients by prognosis 
to specific treatment approaches, our data suggest every RA patient could 
benefit from an upfront intensive treatment approach. 
 
Conclusion 
In conclusion, eRA patients, perceived to be at low-risk of a severe disease 
course, seem to improve more, at least in terms of cumulative disease activity 
and functionality, if treated intensively with MTX and a step-down bridge 
moderate-dose glucocorticoid scheme compared to with MTX alone over 16 
weeks. 
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Efficacy and safety of different remission induction strategies 
combining synthetic DMARDS with or without glucocorticoid 
bridging for early rheumatoid arthritis (CareRA): 1 year results 
of a randomized pragmatic superiority trial 
Abstract 
Background: Combining Disease Modifying Anti-Rheumatic Drugs (DMARDs) 
with glucocorticoids (GCs) is an effective treatment strategy for Early Rheumatoid 
Arthritis (ERA), yet the ideal schedule in daily practice is still a matter of 
discussion. Moreover, it remains unclear if treatment allocation has to differ 
depending on prognostic markers. In this study we aim to compare different 
DMARD combinations and GC remission induction schemes in poor prognosis 
patients and to evaluate Methotrexate (MTX) with or without GC remission 
induction in good prognosis patients, over a one year treatment period. 
Methods: The Care in ERA (CareRA) trial is a 2-year investigator-initiated 
randomized pragmatic superiority trial, ran in 13 Flemish rheumatology practices. 
DMARD naïve ERA patients were stratified into a high- or low-risk group based 
upon presence of erosions, disease activity and serummarkers. High-risk patients 
were randomized to a Cobra-CLASSIC (MTX+Sulphasalazine+prednisone step-
down  from 60mg), Cobra-SLIM (MTX+prednisone step-down  from 30mg) or 
Cobra-AVANT-GARDE (MTX+Leflunomide+prednisone step-down  from 30mg) 
scheme. Low-risk patients were randomized to MTX with tight step-up (MTX-
TSU) or Cobra-SLIM. The primary outcome was the proportion of patients in 
remission in both risk groups after 52 weeks in an intention-to-treat analysis. 
Findings: 98 CLASSIC, 98 SLIM (high-risk), 93 AVANT-GARDE, 47 MTX-TSU 
and 43 SLIM (low-risk) were included. Remission was achieved in 64.3% (63/98) 
CLASSIC, 60.2% (59/98) SLIM (high-risk) and 62.4% (58/93) AVANT-GARDE 
patients at W52 (p=0.840); and in 57.4% (27/47) MTX-TSU and 67.4 % (29/43) 
SLIM (low-risk) patients (p=0.329). Less adverse events related to therapy 
occurred per patient in the SLIM (high-risk) compared to the CLASSIC or the 
AVANT-GARDE group (p=0.038). Adverse events were similar in MTX-TSU and 
SLIM (low-risk) patients (p=0.871). 
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Interpretation: GC remission induction with MTX shows similar efficacy as with 
DMARD combinations in poor prognosis ERA patients, regardless of the initial 
GC dose. In good prognosis patients, MTX with GC remission induction displays 
similar safety but an earlier disease control than without remission induction. 
Hence, MTX with a moderate GC dose remission induction scheme seems 
effective and safe for all ERA patients after 52 weeks. 
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Introduction 
Rheumatoid Arthritis (RA) is a chronic inflammatory condition, traditionally seen 
as a severe destructive joint disease associated with many comorbidities, putting 
a huge burden on both the affected individual as well as society. In the last two 
decades, the clinical prospects for RA patients have improved drastically thanks 
to extensive research identifying new treatment strategies and potent new drugs. 
Current international guidelines recommend to treat a patient with Early RA (ERA) 
early, intensively and to target (1-3). 
These recommendations were prompted by trials using early intensive treatment 
strategies based on combinations of classical Disease Modifying Anti Rheumatic 
Drugs (DMARDs) and glucocorticoids (GCs) (4-10). These studies advocate the 
‘’window of opportunity” principle which states that if patients are treated 
intensively and early in the disease process and disease activity is rapidly 
controlled, they have definite benefit with better radiographic outcomes and 
preserved functionality later on. However, these strategies are not always 
implemented in daily clinical practice because of open questions regarding the 
optimal dosage and combination of drugs used. Indeed, Methotrexate (MTX) 
monotherapy might be sufficient to control ERA in many patients, and even in 
case of insufficient response, stepping-up to triple DMARD therapy or biological 
therapy could rescue them later on (11, 12). However, delaying optimal disease 
control unfortunately leaves some of these patients with unnecessary further 
suffering and loss of participation before arriving at endpoints targeted. 
Guidelines also advise adapting treatment to the patient’s prognostic profile 
based on disease activity; and on the presence of erosions and/or autoantibodies 
(1-3). Such recommendations are mostly based on results from clinical trials in 
preselected populations and with a fixed treatment schedule without treating to 
target. The use of classical prognostic algorithms predicting structural damage 
proved to be unreliable in daily practice and scarce data suggest that patients 
with a better prognosis might be under-treated applying such principles (8, 13). 
To utilize the window of opportunity optimally, we hypothesize that a combination 
of classical DMARDs with rapid remission inducing agents like GCs or biologicals 
is the most effective approach for all patients with ERA emphasizing also the 
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need for further definition of the most feasible combination of drugs for daily 
practice.  
GCs are commonly used to bridge the slow onset of classical synthetic DMARD 
effect. During the demanding early treatment period, GCs can relieve pain, 
stiffness and disability, allowing patients to promptly retake their place in society, 
and potentially preventing disease chronicity. Yet, the optimal initial dosage, 
treatment duration and administration route of GCs are up for discussion (14, 15). 
The role of GCs is still perceived as ambiguous, in both the patient’s and the 
physician’s mind (16, 17). Thus many rheumatologists hesitate to prescribe GCs 
due to fear for side effects and/or the confrontation with hesitation of their 
patients.  
Biologicals combined with MTX are more efficacious than MTX monotherapy in 
ERA trials (18), but their temporary use as remission induction agents in bridging 
strategies just as GCs is less well studied. Most trial protocols led to persistent 
biological use after the early induction phase and only recently the feasibility of 
dose tapering has been shown. So far, TNF blocking agents didn’t demonstrate 
superior efficacy compared to induction regimes with GCs (7, 19) and their cost-
effectivity has not been demonstrated in ERA (20). The optimal and most feasible 
drug combination for ERA treatment is still up for debate. COBRA (Combination 
therapy for early Rheumatoid Arthritis)-like schemes (MTX± Sulphasalazine 
(SSZ) + GCs) Triple therapy (MTX, SSZ and Hydroxychloroquine (HCQ)), or 
other DMARD combinations demonstrate excellent clinical efficacy compared to 
monotherapy. However, studies comparing different combination regimens while 
following a treat to target approach are still scarce. Such studies are needed to 
inform the practicing physician. 
 
The aim of the current study is to contribute in defining an optimal yet feasible 
therapy for every ERA patient. Therefore, we compare in patients with ERA the 
efficacy, effectiveness and safety of different initial DMARD combinations with or 
without GC bridging schemes, depending on the prognostic profile, 52 weeks 
after treatment initiation. 
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Methods 
Study design 
The CareRA trial (Care in early RA) is a 2 year prospective investigator-initiated 
multicenter pragmatic open-label randomized superiority trial. Thirteen Flemish 
rheumatology centers actively recruited: 2 academic centers, 7 general hospitals 
and 4 private practices.This study was approved by the central Ethics Committee 
(EC) of the University Hospitals Leuven and the local ECs. Detailed results of the 
first 16 treatment weeks, the crucial very early disease phase, were published 
elsewhere (21, 22). 
 
Patients 
Patients with RA, as defined by the American College of Rheumatology (ACR) 
1987 revised criteria, were recruited between January 2009 and May 2013. Main 
inclusion criteria were having a disease duration ≤1 year and being DMARD and 
GCs treatment naïve. Disease duration was time elapsed between RA diagnosis 
and treatment initiation. Patients having contra indications for intensive treatment 
combinations with GCs as judged by the treating rheumatologist were excluded. 
Supplement 1 gives a full list of exclusion criteria. Patients with specific co-
morbidities such as controlled diabetes, osteoporosis and previous malignity 
were not excluded, reinforcing study generalizability. All patients gave written 
informed consent before inclusion.  
 
Randomisation and Procedures  
Patients were stratified to a high or low-risk group based on an algorithm 
constructed with classical RA prognostic factors: erosions, Rheumatoid Factor 
(RF) and/or anti-citrullinated protein antibody (ACPA) and disease activity score 
based on C-reactive protein (CRP) status [DAS28 (CRP)] at screening. (figure 1). 
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Figure 1: Classification of patients in high or low-risk according to classic 
prognostic factors 
 
 
 
 
 
 
 
 
 
RF= Rheumatoid Factor, ACPA= Anti-citrullinated protein antibody, DAS28 (CRP) = 28 joint disease activity 
score calculated with C-reactive protein. 
 
After risk allocation, high-risk patients were randomised via a computer sequence 
into 1/3 treatment arms: 
• COBRA CLASSIC: 15mg MTX weekly, 2g SSZ daily and a weekly step-down 
scheme of oral GCs (60-40-25-20-15-10-7.5mg prednisone) 
• COBRA SLIM: 15mg MTX weekly with a weekly step-down scheme of oral GCs 
(30-20-12.5-10-7.5-5mg prednisone).  
• COBRA AVANT-GARDE: 15mg MTX weekly, 10mg Leflunomide (LEF) daily and 
a weekly step-down scheme of oral GCs (30-20-12.5-10-7.5-5mg prednisone). 
Low-risk patients were randomised via a computer sequence into 1/2 treatment 
arms: 
• COBRA SLIM 
• MTX Tight Step-Up (MTX-TSU): 15mg MTX weekly, no oral steroids allowed. 
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No blinding procedures were undertaken in this pragmatic trial. Prophylactic 
treatment including oral folic acid, calcium and vitamin-D supplements was 
prescribed to all patients. Moreover, face-to-face education and standardized 
info-material (leaflet, DVD and website) was provided about the disease and the 
proposed treatment at screening. Additional information was given on demand. 
 
The GC dose was tapered down weekly except for the lowest dose (7.5mg in 
COBRA CLASSIC and 5mg in the other arms), which was maintained until week 
(W)28. Then, GCs were further tapered on a weekly basis by leaving out 1 daily 
dose each week over a period of 6 weeks, until complete discontinuation at W34. 
MTX monotherapy at W40 was aimed for in all treatment arms, except in COBRA 
AVANT-GARDE. In this arm, patients were re-randomized at W40 to MTX or LEF 
monotherapy, if the disease activity was below 3.2 and in the absence of 
contraindications either for MTX or for Leflunomide.. 
 
Patients were treated to the target of DAS28(CRP) ≤3.2 in a tight control setting. 
If patients failed to reach this target, treatment adjustments were made according 
to protocol from week 8 onwards. The first adjustment in all treatment arms was 
an increase in the weekly MTX dose to 20mg. If necessary a second adjustment 
could be made from 8 weeks after the first adjustment. The second adjustment 
depended on the treatment arm: a SSZ dose increase to 3g daily in COBRA 
CLASSIC, the addition of 10mg LEF daily in COBRA SLIM and MTX-TSU or a 
LEF dose increase to 20mg daily in COBRA AVANT-GARDE. If patients did not 
reach the target after 2 predefined treatment adjustments, this was considered a 
strategy failure for efficacy reasons (efficacy failure). In case of toxicity, the 
protocol predefined schemes for tapering/interrupting the assigned treatment. If 
toxicity was persistent, this was considered a strategy failure for safety reasons 
(safety failure). 
Intra-muscular/articular GC injections were allowed maximally every 8 weeks, but 
not within 4 weeks preceding W16 or W52. Concomitant therapy with NSAIDS 
and analgesics was allowed and registered. 
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Patients were assessed at screening, baseline, W4, W8, W16, W28, W40 and 
W52. Maximally four weeks were allowed between screening and baseline. In 
case treatment adjustment were required according to the protocol, optional visits 
could be performed at W12, W20, W24, W32, W36, W44 and/or W48. 
Demographics and clinical parameters (see table 1) were registered at screening 
and clinical evaluations, DAS28(CRP) and HAQ at every visit. X-Rays of hands 
and feet were obtained at baseline, W28 and W52. Patients experiencing efficacy 
or safety failures of the predefined treatment schedules were followed further and 
evaluated at W28 and W52. 
 
Outcomes 
The centrally assessed co-primary study endpoints were the proportion of 
patients in remission (DAS28(CRP)<2.6) at W52 –the subject of the present 
report-, at W16 already reported earlier (22) and at W104. Secondary efficacy 
outcomes were radiographic evolution by the Sharp Van der Heijde (SvdH) score, 
the proportion of good EULAR responders (DAS28(CRP) change>1.2 and 
DAS28(CRP)≤3.2 ), the proportion of patients having a clinically meaningful 
improvement of the HAQ (HAQ change>0.22) and the proportion of patients 
having a HAQ=0 at W52. 
 
At each visit, patients were questioned about any adverse events (AE). Each 
reported AE was registered and evaluated in terms of relation to therapy, 
seriousness and severity by the treating rheumatologist. AEs were also divided 
in different subtypes: discomfort, toxicity, infection, surgery and a miscellaneous 
category. The categorization of all AEs was evaluated by the data monitoring 
team after 52 weeks and redefined where necessary to harmonize the safety data 
after approval of the individual investigators.  
 
Statistical analysis 
This study was designed as a superiority comparison of COBRA CLASSIC versus 
COBRA SLIM and COBRA AVANT-GARDE versus COBRA SLIM in the high-risk 
arm. Sample-size calculation was based upon the expected proportion of patients 
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in remission at W16 (22). Eighty-five patients per treatment arm were required for 
a power of 80% and significance level of 0.05, starting from an estimated clinically 
relevant difference in effect size of 20%. Analysis of the low-risk population was 
not powered, but was exploratory. 
 
All patients were considered for analysis. Only patients who were incorrectly 
randomized or not fulfilling the in/exclusion criteria were omitted. Three 
databases were constructed to analyse this trial. The safety database registered 
the complete clinical data of all participants, even if patients were considered 
treatment or safety failures and were receiving medication deviating from the 
predefined protocol. This database was used for safety analysis. The per protocol 
(PP) database included only those patients who had followed the protocol strictly 
until the W52 endpoint. Hence, this database did not consider patients with 
efficacy or safety failures. This database was used for efficacy analysis. An 
intention-to-treat (ITT) database was constructed by imputing data when missing 
or from the moment they had to be disregarded because patients were 
considered efficacy or safety failures. This database was used for efficacy 
evaluation. The imputation of missing data was handled as follows. Screening 
variables were used to impute missing baseline variables and vice versa. To 
impute other data, the last observation carried forward method was applied. 
Primary and secondary outcomes were examined by χ² or Kruskal-Wallis test, 
when appropriate. An ITT analysis was used to determine the primary outcomes. 
Radiographic images were scored via the SvdH method chronologically by 5 
readers: one experienced reader (DDC) and 4 medicine students. An overlapping 
scoring scheme was constructed so that all images were scored by 2 students at 
least. The experienced reader scored all images. The mean score was retained 
in case of differences between readers. All statistical analyses were carried out 
using SPSS 22.0. A p-value <0.05 was considered statistically significant. 
 
 
 
 
 132 
 
Results 
 
In total, 400 patients were included in the CareRA trial between 1 January 2009 
and 31 May 2013. The stratification resulted in 289 high-risk and 90 low-risk 
patients, 21 patients were excluded from analysis because of randomization 
errors or the discovery of exclusion criteria after randomization. Randomization 
was successful, resulting in similar characteristics in both risk groups (Table 1). 
Of the 289 high-risk patients, 98, 98 and 93 were randomized in the COBRA 
CLASSIC, SLIM and AVANT-GARDE arm respectively. Of the 90 low-risk 
patients, 47 and 43 were randomized in the MTX-TSU and COBRA SLIM group 
respectively. 
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Table 1: Patients’ characteristics at baseline per treatment arm 
BMI= Body mass index; Alcohol Intake = consumption of any form of alcohol; Symptom duration = time 
elapsed between onset of symptoms and start of treatment; Disease duration = time elapsed between 
diagnosis of RA and start of treatment; RF= Rheumatoid factor; Anti CCP= Anti cyclic citrullinated protein; 
PGA= Patient global assessment; PhGA= Physician global assessment;  TJC= Tender joint count; SJC= 
Swollen joint count; ESR = Erythrocyte sedimentation rate; CRP = C-reactive protein; DAS28= 28 joint 
Disease activity score; HAQ= Health assessment questionnaire. Values reported are proportions or mean ± 
standard deviation.  
 
 
 
 
COBRA 
CLASSIC 
COBRA SLIM 
(High-Risk) 
COBRA 
AVANT-GARDE 
MTX-TSU COBRA SLIM 
(Low-Risk) 
Number of patients 98 98 93 47 43 
Age (years) 53.2 ± 11.9 51.8 ± 13.1 51.1 ± 12.8 51.0 ± 14.0 51.4 ± 14.4 
BMI (kg/m²) 26.0 ± 4.3 26.8 ± 4.2 26.5 ± 4.2 27.0 ± 4.2 25.4 ± 4.3 
Gender (female) 65.3% 64.3% 68.8% 80.9% 76.7% 
Smoking Status (ever) 57.1% 59.2% 60.2% 38.3% 48.2% 
Alcohol Intake (yes) 55.1% 56.1% 54.8% 61.7% 55.8% 
Symptom Duration (weeks) 33.8 ± 35.5 33.2 ± 38.2 44.3 ± 65.9 33.1 ± 62.2 34.4 ± 68.2 
Disease Duration (weeks) 1.8 ± 3.1 2.6 ± 3.3 3.1 ± 6.4 3.2 ± 6.6 1.9 ± 2.7 
Employed before symptom onset (yes) 52.0% 65.3% 62.4% 66.0% 55.8% 
Employed at screening(yes) 44.9% 53.1% 51.6% 57.4% 51.2% 
Comorbidities at screening (yes) 72.4% 74.5% 65.6% 66.0% 60.5% 
RF (yes) 79.6% 83.7% 75.3% 23.4% 25.6% 
ACPA (yes) 77.6% 79.6% 77.4% 23.4% 27.9% 
Erosions (yes) 32.7% 32.7% 34.4% 0.0% 2.3% 
Total TJC 14.7 ± 9.5 13.7 ± 8.2 14.1 ± 9.0 14.1 ± 8.6 13.14 ± 10.70 
Total SJC 11.9 ± 8.9 10.8 ± 6.5 10.6 ± 6.7 10.0 ± 7.0 10.9 ± 7.6 
PGA (0-100) 59.5 ± 21.7 56.2 ± 21.7 54.8 ± 24.2 49.9 ± 23.0 48.6 ± 30.7 
Pain (0-100) 59.5 ± 23.6 56.5 ± 21.9 57.5 ± 23.8 52.1 ± 23.2 48.2 ± 31.2 
Fatigue (0-100) 50.6 ± 26.0 49.0 ± 21.3 48.9 ± 23.7 45.9 ± 22.1 39.4 ± 27.7 
PhGA (0-100) 54.7 ± 18.5 53.1 ± 18.1 51.7 ± 17.9 48.3 ± 23.4 48.6 ± 20.8 
ESR (mm/h) 33.5 ± 25.2 32.1 ± 23.4 25.0 ± 17.6 23.0 ± 16.9 30.0 ± 29.4 
CRP (mg/l) 19.7 ± 28.9 21.5 ± 33.2 14.5 ± 19.2 13.5 ± 18.6 20.1 ± 39.3 
DAS28(ESR) 5.4 ± 1.3 5.2 ± 1.2 5.0 ± 1.3 4.8 ± 1.7 4.9 ± 1.6 
DAS28(CRP) 5.0. ± 1.2 4.8 ± 1.1 4.7 ± 1.2 4.6 ± 1.6 4.5 ± 1.6 
HAQ (0-3) 1.2 ± 0.7 1.0 ± 0.7 1.0 ± 0.6 1.0 ± 0.7 0.9 ± 0.9 
 134 
 
Efficacy analysis 
In the ITT analysis of the high-risk group, the primary outcome did not differ 
between groups. Remission was achieved in 64.3% (63/98) COBRA CLASSIC 
patients, 60.2% (59/98) COBRA SLIM patients and 62.4% (58/93) COBRA 
AVANT-GARDE patients (p=0.840) at W52. A good EULAR response was 
reached in 67.3% of CLASSIC patients, 68.4% of SLIM patients and 67.7% of 
AVANT-GARDE patients (p=0.995). A clinically meaningful HAQ response was 
reached in 68.4% of CLASSIC patients, 70.4% of SLIM patients and 71.7% of 
AVANT-GARDE patients (p=0.877). HAQ=0 was achieved in 37.8% of CLASSIC 
patients, 36.7% of SLIM patients and 44.1% of AVANT-GARDE patients (p 
=0.533).  
In the ITT analysis of the low-risk group, remission was accomplished in 57.4% 
(27/47) MTX-TSU and 67.4 % (29/43) COBRA SLIM patients (p=0.329). A good 
EULAR response was achieved in 57.4% of MTX-TSU and 60.5% SLIM patients 
(p=0.771). A clinically meaningful HAQ response was reached in 57.4% MTX-
TSU and 55.8% SLIM patients (p=0.876). HAQ=0 was accomplished in 29.8% of 
MTX-TSU and in 48.8% of SLIM patients (p=0.064).  
PP analysis showed similar results (data not shown). 
 
Table 2a: Clinical outcomes at week 52 per treatment arm in the high-risk group 
 
 
 
 
 
 
 
 
 
 
  
 
 
Cobra Classic Cobra Slim 
(High-risk) 
Cobra  
Avant-Garde 
p-value 
Number of patients 98 98 93  
DAS28 (CRP) Change 2.5 ± 1.5 2.3 ± 1.4 2.3 ± 1.5 0.329 
Remission 64.3% 60.2% 62.4% 0.840 
Low Disease Activity 74.5% 75.5% 79.6% 0.684 
Good Eular Response 67.3% 68.4% 67.7% 0.995 
Moderate Eular 
Response 
84.7% 88.8% 88.2% 0.654 
HAQ Change 0.7 ± 0.7 0.5 ± 0.7 0.6 ± 0.7 0.368 
Clinically Meaningful 
HAQ Change 
68.4% 70.4% 71.7% 0.877 
HAQ = 0 37.8% 36.7% 44.1% 0.533 
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Table 2b: Clinical outcomes at week 52 per treatment arm in the low-risk group 
 
MTX-TSU Cobra Slim 
(Low-risk) 
p-value 
Number of patients 47 43  
DAS28 (CRP) Change 2.1 ± 1.7 2.1 ± 1.9 0.990 
Remission 57.4% 67.4% 0.329 
Low Disease Activity 76.6% 81.4% 0.577 
Good Eular Response 57.4% 60.5% 0.771 
Moderate Eular 
Response 
78.7% 76.7% 0.822 
HAQ Change 0.5 ± 0.6 0.6 ± 0.7 0.832 
Clinically Meaningful 
HAQ Change 
57.4% 55.8% 0.876 
HAQ = 0 29.8% 48.8% 0.064 
 
DAS28(CRP) = 28 Joint disease activity score calculated with C-reactive protein; DAS28(CRP) change = 
DAS score on baseline minus DAS score on week 52; Remission was defined as DAS28(CRP) <2.6; Low 
Disease Activity was defined as DAS(CRP) ≤3.2; Good Eular Response was defined as low disease activity 
with a DAS28(CRP) change >1.2. Moderate Eular Response was defined as DAS28(CRP) change >1.2 or 
a DAS28(CRP) ≤5.1 and a DAS28(CRP) change between 0.6 and 1.2; HAQ = Health Assessment 
Questionnaire; HAQ change = Baseline HAQ minus week 52 HAQ; clinically meaningful HAQ change was 
defined as a HAQ change >0.22. Data are presented as mean ± standard deviation or as percentages. 
Statistical analysis was performed by χ² or Kruskal-Wallis test. A p-value <0.05 was considered statistically 
significant.  
 
The mean ±SD AUC for DAS28(CRP) from baseline to W52 was 35.0 ±11.6, 35.3 
±10.6 and 33.9 ±8.6 for the CLASSIC, SLIM and AVANT-GARDE respectively 
(p=0.685). MTX-TSU patients had a higher AUC for DAS28(CRP) than Cobra 
Slim patients over 52 weeks of treatment in the low-risk group (42.0 ± 13.1 vs 
35.8 ± 14.1, p=0.017). Figure 3a and 3b display the disease evolution from 
baseline until week 52 in the high and low-risk group. 
 
 
 
 
 136 
 
Figure 3a. The disease evolution from baseline until week 52 in the high-risk 
group 
 
DAS28(CRP) = 28 Joint disease activity score calculated with C-reactive protein; HAQ = Health Assessment 
Questionnaire; CRP= C-reactive protein expressed in mg/l; ESR= Erythrocyte sedimentation rate in 
mm/hour. PGA = Patient Global Assessment on a visual analogue scale from 0-100; Total TJC= Total Tender 
Joint Counts; Total SJC= Total Swollen Joint Counts. Values reported are proportions or mean ± standard 
deviation. 
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Figure 3b. The disease evolution from baseline until week 52 in the low-risk group 
DAS28(CRP) = 28 Joint disease activity score calculated with C-reactive protein; HAQ = Health Assessment 
Questionnaire; CRP= C-reactive protein expressed in mg/l; ESR= Erythrocyte sedimentation rate in 
mm/hour. PGA = Patient Global Assessment on a visual analogue scale from 0-100; Total TJC= Total Tender 
Joint Counts; Total SJC= Total Swollen Joint Counts. Values reported are proportions or mean ± standard 
deviation. 
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80% of baseline X-ray images of hands and feet were available. Overall, baseline 
structural damage and radiographic progression were minimal in all groups. Table 
3 gives more insight in the radiographic evolution. 
 
Table 3: Radiographic evolution per treatment arm from baseline until W52 
 Total 
population 
High-Risk Low-Risk 
 
 
COBRA 
CLASSIC 
COBRA SLIM 
(High-Risk) 
COBRA 
AVANT-GARDE 
p-
value 
MTX-TSU COBRA SLIM 
(Low-Risk) 
p-
value 
Number of patients N=379 N=98 N=98 N=93  N=47 N=43  
N 303 82 75 78 34 34  
SvdH score Baseline 1.1 ±1.9 1.3 ±2.1 1.3 ±2.5 1.0 ±1.5 0.895 0.7 ±1.1 0.9 ±1.5 0.536 
N 306 80 76 79 37 34  
SvdH score W28 1.3 ±2.2 1.5 ±2.5 1.5 ±2.9 1.2 ±1.6 0.853 0.8 ±1.2 1.0 ±1.6 0.579 
N 303 81 77 76 37 32  
SvdH score W52 1.4 ±2.4 1.7 ±2.7 1.7 ±3.3 1.3 ±1.8 0.901 0.9 ±1.3 1.2 ±1.8 0.228 
N 272 73 67 71  31 30  
Change BL-W28 0.2 ±0.5 0.1 ±0.3 0.3 ±0.8 0.2 ±0.4 0.581 0.1 ±0.2 0.1 ±0.2 0.586 
N 269 74 68 68  31 28  
Change Bl-W52 0.3 ±0.67 0.3 ±0.5 0.4 ±1.1 0.3 ±0.6 0.819 0.2 ±0.3 0.3 ±0.5 0.257 
N 291 76 74 74  35 32  
Change W28-W52 0.1 ±0.4 0.1 ±0.3 0.2 ±0.5 0.2 ±0.4 0.856 0.1 ±0.2 0.2 ±0.5 0.376 
N = number of available X rays. SvdH = Sharp van der Heijde score. Radiographic images were scored via 
the Sharp Van der Heijde (SvdH) score method. No imputation of missing data was done. Data is presented 
as mean ±standard deviation. 
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Figure 4: Cumulative Probability Plots of the radiographic progression of the High 
and Low-risk group 
Each dot represents a patient. 
Safety analysis 
Safety analysis in the high-risk group showed that AEs were reported in 67.3%, 
66.3% and 76.3% of CLASSIC, SLIM and AVANT-GARDE patients respectively 
(p=0.255). Per patient 1.8±2.0, 1.3±1.4 and 1.9±1.6 AEs occurred in the 
CLASSIC, SLIM and AVANT-GARDE group respectively (p=0.038).  Two serious 
AEs were reported in each treatment arm. Most adverse events related to gastro-
intestinal problems and a general unwell feeling. To be noted were the higher 
number of AES with intestinal troubles and diarrhea in the AVANT-GARDE group 
and the higher number of AEs with general malaise symptoms and appetite 
changes in CLASSIC patients. 
In the low-risk group, the numbers of AEs were 48 in 27 MTX-TSU patients and 
49 in 20 Cobra Slim patients (p=0.871). AEs were reported in 63.8%, and 51.2% 
of MTX-TSU and SLIM patients respectively (p=0.224). Per patient 1.2±1.2 and 
1.2±1.4 AEs occurred in the MTX-TSU and SLIM group respectively (p=0.737). 
Remarkably, gastro-intestinal problems and a general unwell feeling, the two 
most frequent groups of AEs, were similar between groups. Only higher number 
of AEs related to increased appetite was noted in the SLIM group. Two serious 
AEs (pulmonary infection and anemia) were registered in the SLIM group and 
none in the MTX-TSU group. 
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Discussion 
Overall in the CareRA study, the COBRA SLIM combination yielded excellent 
results in all ERA patients regardless of classical prognostic markers at least in a 
treat to target approach, with high remission rates. Regardless of the prednisone 
dose in the remission induction scheme, in patients with markers of poor 
prognosis, DMARD combinations were not seen superior to MTX only with a 
moderate dose prednisone remission induction scheme, the so-called Cobra 
SLIM regimen, after a treatment period of 52 weeks. Furthermore, the safety 
profile of the latter treatment strategy was more favorable. In patients lacking 
markers of poor prognosis, MTX with or without a moderate dose prednisone 
remission induction scheme yielded similar efficacy and remarkably also similar 
safety results. However, the speed of treatment response and the lower 
cumulative disease activity over 52 weeks were more favorable in the treatment 
strategy with a GC remission induction scheme. 
 
In patients perceived as having a more severe ERA, our findings have two 
implications. Firstly, combinations of DMARDs seem not more effective on the 
group level than MTX alone, when used with a moderate or high-dose remission 
induction scheme. A subgroup of patients could benefit from initial combination 
therapy. This subgroup can unfortunately not yet be predefined. Therefore, Cobra 
SLIM seems the most pragmatic initial approach for all patients, avoiding 
unnecessary “collateral damage” in terms of toxicity and intolerance. Moreover, 
our results show that patients in need of a more intensive therapy can catch up 
very rapidly if a treat to target approach is strictly followed. Contrary to our 
findings, the tREACH trial demonstrated that triple DMARD combination therapy 
was more effective than MTX monotherapy in association with GCs, but in that 
study a rather low-dose short term GC bridging strategy was used (23). In our 
trial, the time lag before full DMARD efficacy was bridged with more highly dosed 
GCs, probably removing any variance between the effects of different DMARD 
schedules. Hence, less DMARDs were required over time, which could impact 
adverse events and patients’ treatment adherence. Secondly, a high GC dose 
was not more advantageous compared with a moderate dose, regardless of the 
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DMARD strategy used. This could benefit the implementation of COBRA SLIM 
strategies in daily clinical practice. Den Uyl et al described comparable findings 
comparing an attenuated version with the original COBRA regimen in patients 
with moderately active ERA (24). Unfortunately, this study lacked decisive 
evidence; MTX was suboptimally dosed in the classical COBRA scheme and 
cumulative glucocorticoid dosages were comparable in the two schemes.  
 
In patients without poor prognosis markers, MTX with and MTX without a 
moderate GC remission induction scheme displayed a similar efficacy at the one 
year endpoint. As shown in other studies, treatment strategies applying tight 
control with a treat-to-target approach seem to have converging efficacy in time, 
although in our data a clear trend for a higher efficacy was notable in MTX with 
GC remission induction, certainly in terms of cumulative disease activity over the 
first year (25). Moreover, treatment response is almost immediate in MTX with 
GCs, which seems more in accordance with patients preferences (26). The most 
outstanding finding in this low-risk population was however the safety profile. Both 
arms showed comparable numbers and types of adverse events related to 
therapy. Our study adds to the much needed evidence about glucocorticoid use 
in the management of early RA and showed that, apart from being efficacious, 
glucocorticoids are relatively safe to use in a remission induction scheme also in 
patients with so-called mild RA. 
 
A limitation is that medication adherence was not measured. However, if 
adherence was lower in a certain treatment arm, the same could be expected in 
daily clinical practice. Secondly, no blinding was implemented. These two 
limitations related to the trial design are unavoidable in a pragmatic trial aiming 
to reflect daily clinical practice. 
For the interpretation of the results in the high-risk patients, representing 75% of 
our study population, a limitation is the superiority design of this study. Therefore, 
we were only capable to demonstrate non-superiority of Cobra Classic and Cobra 
Avant-Garde versus Cobra Slim and not equivalence. The remaining 25% of our 
population were stratified as low-risk patients. Hence, we could not achieve the 
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same power in this arm as in the high-risk arm. Therefore, these results should 
be interpreted as explorative and in need of confirmation. 
Finally, remission based on the DAS28(CRP) criteria was chosen as endpoint by 
protocol. This remission criterion is less stringent than the recently developed 
criteria (27).  
 
The major strength of our study is that it was designed to provide an optimal 
treatment solution for all patients with RA which is of relevance for decision 
making by rheumatologists facing ERA patients in daily practice. Most classical 
trials preselect or try to find subpopulations which are most responsive to the 
treatment strategy under investigation. However, correct and unbiased predicting  
of the treatment response is still impossible in most patients with RA, using 
classical markers of disease prognosis (13, 28, 29). Hence, patients 
conventionally perceived as having a lower risk of a severe disease course can 
now be treated according to the same standards as high-risk patients.  
 
Despite the very high efficacy numbers in our trial, 20% of patients with ERA do 
not reach these target criteria as proposed by international guidelines. Future 
research should investigate reliable markers for optimal treatment steering and 
for timely identification of patient groups, susceptible to failure of standard 
treatment. 
 
In conclusion, we propose an efficacious standardized treatment for all patients 
with RA: COBRA SLIM, methotrexate combined with a moderate dose GC 
remission induction scheme. This scheme seems as effective as DMARD 
combinations with GC remission induction, and shows excellent clinical efficacy 
results in a setting reflecting clinical practice. Furthermore, the safety profile of 
COBRA SLIM seems comparable with MTX monotherapy while the treatment 
response is more rapid, immediately relieving patients from pain and 
dysfunctionality. 
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In the previous chapters, we dealt with three crucial aspects of early Rheumatoid 
Arthritis (RA) management. Firstly, we investigated if patients were treated in time 
after symptom onset. Subsequently, we explored the value of classical prognostic 
biomarkers in daily clinical practice. Finally, we studied the optimal intensive 
treatment strategy in newly diagnosed patients with RA.  In this general 
discussion we will address the same themes. Although a partial overlap is hard 
to avoid, we believe all three aims of this doctoral thesis warrant their own critical 
evaluation. The discussion of each of the three thematic parts of this thesis will 
always follow the same structure. Firstly, we discuss the importance and the 
novelty of our studies. Secondly, we debate the methodological considerations. 
Thirdly, we give suggestions for future research and clinical practice. To 
conclude, we discuss the overarching message of this thesis and the practical 
consequences for the treatment of a patient with RA in daily practice. 
Timely treatment (Chapter 1) 
What have we learned? 
Our research quantified the time elapsed between symptom onset and treatment 
initiation in Flanders for the first time (1) enlarging the current efforts of other 
groups in the field (2-4).  Herein, We demonstrated that only a minority of newly 
diagnosed RA patients is seen in time, within the apparently elusive 12 weeks 
after symptom onset. Patients with more severe disease characteristics at 
baseline seemed to present earlier to the rheumatologist. Moreover, we 
demonstrated a difference in treatment delay between the different types of 
rheumatology practices: patients treated in academic and general hospitals 
showed longer treatment delays than those treated in private practices. A reason 
for this difference could not be found in variations in the patient characteristics at 
baseline. Furthermore, according to our findings patient-related delay 
contributed the most to overall treatment delay in Flanders. 
This research was extended in two subsequent studies from our group, enriching 
the obtained data. Firstly, we explored the influence of psychosocial variables on 
treatment delay (5). We hypothesized that demographic and clinical 
characteristics could never fully explain the individual differences in treatment 
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delay. A person’s individual help-seeking behavior is unlikely to be only 
determined by these ‘easy to measure’ factors, but probably also by a complex 
system of cognitive and emotional pathways (6). We used the illness perceptions 
questionnaire and the Utrecht Coping List to give us an idea of an individual’s 
motivation to seek help. Intuitively, these psychosocial instruments both seem 
strong predictors of health behavior in general (7). Although these instruments 
are both validated (8, 9), measuring such a multifaceted attitude towards a 
disease remains challenging (10, 11). Nevertheless, we demonstrated that 
coping and illness perceptions did indeed have an influence on timely 
treatment, and even in the same magnitude as clinical variables. 
Secondly, we have investigated in more detail the patient-related delay and the 
help-seeking behavior before referral to a rheumatologist (12, 13). This 
quantitative assessment was evoked by our primary delay study showing that 
patient-related delay contributed the most to the overall treatment delay. 
Therefore we constructed a rudimentary assessment form assessing the first 
symptoms and the initial help-seeking trajectory; the reasons why persons were 
seeking help, which Healthcare Professional (HCP) they initially contacted, if this 
HCP recognized RA and how long it took to suspect RA, which steps the HCP 
undertook and to whom the persons were referred. Patients followed in the 
CareRA trial were guided through this assessment form by one of two study team 
members to increase reliability. The investigators recorded any relevant 
additional information provided by the patient as sketches and notes. The main 
findings of this side study were that pain was the most prominent initial 
symptom and the primary reason to visit the HCP. Furthermore, a quarter of 
patients indicated that five visits or more were needed before RA was 
suspected by a HCP. Another qualitative study by our research group revealed 
that many general practitioners (GP) had doubts in their detection skill for RA 
(14). They indicated the lack of specificity of the initial symptoms, the absence of 
effective detection tests and the low incidence of RA in general practice as main 
confounders. As initial symptoms apart from joint pain, patients indicated joint 
swelling, joint rigidity, fatigue, morning stiffness and loss of strength as reasons 
to seek help in our study. Hence, GPs confronted with such general and 
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unspecific vague symptoms, suspected broad disease categories such as other 
musculoskeletal disorders but also unspecified local inflammation and overuse of 
joints. A majority of patients indicated also that blood tests were performed rather 
than a full clinical examination when they presented themselves to the initial HCP. 
Blood tests to detect autoantibodies and inflammation markers such as elevated 
CRP or ESR levels probably are meant to reassure the professional in the 
detection of RA, although these tests are never conclusive. Moreover, a part of 
the patients indicated that they had to return more than five times to the HCP 
before RA was detected, underlining the idea that uncertainty of the GPs was a 
barrier in the detection of RA in Flanders. 
Methodological considerations 
An important remark  is that most of the influencing factors for delay were only 
measured at the moment of inclusion in CareRA, when patients presented 
themselves at the rheumatology practice or even later when treatment was 
already initiated, and not at the moment when the delay occurred. Yet, little is 
known about the evolution of rheumatic symptoms from symptom onset. The 
reliability of those predictors can thus be questioned. Other researchers have 
studied delay retrospectively, asking patients to recapitulate the initial symptoms 
or at least the ‘earlier’ symptoms from the moment of first visit to a rheumatology 
practice (3, 15). However, such investigations introduce probably the most 
common limitation to delay research: recall bias. Patients are asked several 
months after symptom onset when and how the first symptoms arose. We have 
tried to counter this almost unavoidable bias in our research by asking the GP the 
same information, as a kind of double-check.  
A second consideration about our research is that not only individuals like the 
person with early symptoms of RA, the GP or the rheumatologist influence the 
treatment delay, but also the overarching healthcare system. A study by Raza 
et al has shown differences in total treatment delay between countries, but also 
differences in the types of delay influenced by the specific role the various 
stakeholders are playing in patients’ help-seeking behavior (3). These results 
could indicate differences in healthcare pathways between countries. For 
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example, in some countries it could be hard to get an appointment with a GP 
while in other countries the access to a rheumatologist is more problematic than 
in others. In our research, the role of the healthcare system could not be 
determined, because we lacked a comparator population with a different 
healthcare organization. 
Directions for future research and clinical practice 
How can we shorten treatment delay? 
From these studies exploring treatment delay in Flanders, it is clear that timely 
treatment should be further investigated and stimulated. Different targets for 
improvement can be identified (16). 
First of all, public awareness of RA should be improved. Rheumatism is still 
seen in the community as a disease affecting primarily old people. However, 
many rheumatic conditions affect also the younger population. The question is if 
major public campaigns will address the right target audience. The FAST (Face-
Arms-Speech-Time) approach for strokes or the breast lump for breast cancer 
are hallmarks for successful campaigns to raise awareness in public (17, 18). 
However, the indistinct and very individual symptom patterns of persons with RA 
make it more challenging. Furthermore, campaigns could have the opposite 
effect. Patients having other disorders could flood the general or rheumatologist 
practice, making time to get an appointment longer and thus increasing treatment 
delay instead of bringing it down (19). Therefore, a careful approach is needed 
when trying to increase public awareness towards RA by mass campaigns. 
A key role in the Belgian healthcare system seems to be played by the GP who 
probably sees the persons with developing RA symptoms more frequently than 
any other HCP. Reliable tools such as detection checklists should be 
constructed and distributed so that the GP can develop self confidence in his or 
her RA detection skills (20-22). 
Moreover, the patient stories in our study made clear that a multitude of HCPs 
are involved in the detection and diagnosis of RA. Hence, a swift and reliable 
triage by different HCPs could be an opportunity (23, 24). Aside of GPs and 
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rheumatologists, orthopedic surgeons, physical therapist, nurses and 
pharmacists were frequently consulted. Hence, it is key that also other HCPs are 
properly educated in RA symptom detection. In the training curriculum of 
physicians in Flanders, education about RA is already improved by multiple 
courses in musculoskeletal disorders but also by expert patients, teaching 
students and doctors how to recognize the symptoms of early RA during an 
anamnesis and how to examine the joints of patients with early RA; and sharing 
their own stories. A possibility is to further standardize and update these courses 
to educate all physicians up to the same level and to give such courses to a more 
broad audience of HCPs. As a result, the knowledge and the skill to detect RA 
could be extended to a larger group of individuals that could all be consulted, 
formally and informally, by persons with developing rheumatic symptoms.   
Furthermore, the connection between primary care and the rheumatology 
practice should be improved. Initiatives are already undertaken in different 
countries (20, 25-27). Early RA clinics are a prime example of such an initiative. 
The general principle of such organization structures is to give patients with 
inflammatory arthritis swift access to the rheumatologist or specialist nurses. 
Many variations of such clinics exist. Some GPs and rheumatologist collaborate 
closely, sometimes in the same building, on a target population, to improve triage. 
In other clinics, all patients can come in with rheumatic symptoms and a triage 
system is set up to quickly find susceptible patients. Moreover, other methods are 
used such as keeping dedicated consultation slots for patients with early 
rheumatic symptoms at the rheumatology practice or a system of standard 
referral pathways. 
 
How early is (too) early? 
A second important question to address is when to treat. Nowadays, it is clear 
that individuals with a new diagnosis of RA should be treated as soon as possible. 
Hypothetically, treating patients with rheumatic complaints from the time of 
symptom onset would even be better. Possibly, RA as a disease could be 
prevented this way (4). However, the risk of overtreatment and stimulating the 
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development of unnecessary disease behavior is of course huge. The majority of 
patients with undifferentiated arthritis, possibly a precursor of RA, will not develop 
RA, although these patients often show the same initial indistinct symptom 
patterns as patients developing RA. The challenge for the future will be to find 
new and reliable markers for RA detection and testing these in cohorts of patients 
with RA-like complaints (28, 29), hence pushing the boundaries for optimal 
treatment initiation backward while not over treating the majority of patients. 
Capturing the patient perspective 
Our research has shown some indications that delay is not only driven by clinical 
symptoms but also by how persons cope when being confronted with the first 
signals of a rheumatic disease (5). HCPs should take such personal traits into 
account when giving medical advice to individuals with joint complaints or 
other more subtle signs and symptoms potentially related to developing RA. 
Unfortunately, research into this subject is lacking (4).  
Classical Biomarkers of disease progression (chapter 2) 
What have we learned? 
We evaluated the predictive capacity of composite algorithms using classical 
prognostic markers to predict structural damage in patients with early RA 
(Chapter 4). We concluded that none of these predictive matrices could be 
reliably used in daily clinical RA practice (30). The results were unsatisfactory, 
although these matrices were constructed with widely used classical prognostic 
markers of RA, all of which were shown to have some association with structural 
damage individually. Yet, none of the patients developing rapid radiological 
progression in our cohort could be correctly identified. Moreover, these patients 
were even considered to be at low risk of structural progression according to the 
evaluated matrices. These findings were confirmed in a similar trial (31). 
The 2010 EULAR guidelines for RA management suggested that patients without 
poor prognosis markers (absence of erosions, autoantibodies or high disease 
activity) at treatment initiation were not in need for a more intensive therapy 
approach (32). This category of patients was considered to respond equally well 
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to initial monotherapy as to intensive therapies. On the contrary, patients with a 
poor prognosis would benefit more from initial combination therapy. However, the 
new 2013 EULAR guidelines revoked these recommendations: every patient 
should receive the same treatment regardless of his/her risk profile (33). 
Paradoxically, the updated guidelines still recommend risk evaluation as an 
important aspect in the therapeutic approach of RA. Moreover, it is stated that the 
follow-up treatment of patients without poor prognosis markers should be different 
to patients with a poor prognosis after failure of initial MTX monotherapy. A post-
hoc analysis of the BeSt study indicated that the rationale behind this statement 
should be reevaluated (34). Herein, it is suggested that tailored treatment is not 
yet feasible despite the current guidelines. Rapid relief of symptoms should be 
more the focus of treatment than prognostic factors. We explored the value of 
prognostic factors further in chapter 2. Herein we demonstrated that an intensive 
approach with classical DMARD combinations and a GC bridging scheme 
seemed to be more effective than DMARD monotherapy in achieving higher 
remission rates and less radiographic progression in a Belgian monocentric 
cohort after two years of treatment in daily clinical practice, although patients 
were selected by the treating physician to receive a more conservative 
therapy if the RA profile of the patient seemed less severe at baseline (35). 
In a tight control setting, rapid radiological progression (RRP) was inhibited in the 
majority of patients. Numerically, RRP occurred more in patients treated 
conservatively, although these patients had less severe RA characteristics.   
Methodological considerations 
These two studies made use of the same small monocentric observational cohort. 
No trustworthy causality could be shown because of the less controlled cohort 
setting and patient heterogeneity. For instance, the absence of a medication 
protocol and different baseline characteristics between the two group biases 
therapy comparison. Moreover, given the low numbers of RRP, chances that 
matrices would detect patients prone for structural damage are probably lower. 
Furthermore, RRP seems to be largely prevented by a treat to target strategy in 
a tight control setting. Therefore, from our point of view, the importance of X-ray 
damage as disease outcome parameter has become less important (31). 
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Directions for future research and clinical practice 
The everlasting quest for a better RA biomarker 
Many attempts have been made in RA research over the last decades to discover 
biomarkers capable of tailoring the right treatment to the right patient, especially 
on the genetic front (36). This thesis will not go to deep into this topic, but 
researchers should continue investigating biomarkers, because better markers 
will of course improve algorithms to predict RA outcomes such as structural 
damage or persistent inflammation. And although this might seem challenging, 
they should be tested in daily practice, in RA populations treated to target as 
required by the guidelines, and not in classical RCTs. 
Initial treatment response as prognosis marker 
Our studies have shown that the (combination of) current classical prognostic 
markers are not reliable enough to allocate patients to certain less or more 
intensive treatments in clinical daily practice. Recently, an interesting debate was 
initiated on ACPA status as predictive marker (37-40). ACPA negative patients 
seem to present with a more severe disease, but ultimately seem to evolve more 
beneficially (41). Such evidence is of course important to take into account when 
trying to find prognostic markers. It is not because a patient has a certain disease 
characteristic that make the disease look more or less severe at baseline, that 
the disease evolution should be neglected as a prognostic parameter. Treatment 
response is a powerful predictive treatment marker in itself, as demonstrated 
by different studies (42, 43). Unfortunately, treatment response is not something 
that can quickly be incorporated in predictive matrices at baseline. Perhaps a 
standardized treatment strategy with a swift treatment response can tackle such 
treatment allocation problems by quickly selecting patients with a good response, 
while not leaving the bad responders struggle for a long time. Hence, a predictive 
algorithm for bad responders after just a few weeks would be an ideal 
replacement for the matrices based exclusively on baseline parameters, which 
are at this point not reliable enough in daily practice. 
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Treating to target in daily clinical practice 
Steering intensive therapy according to predefined targets, such as the DAS 
score, has been shown to yield better outcomes than routine care leaving 
treatment to the discretion of the physician (44). Furthermore, treating to target 
seems feasible in daily practice (45). However, we must realize that patient 
characteristics and preferences are considered by treating physicians to tailor 
treatment in real life (46, 47). Although clinical decisions based on gut feeling and 
experience are not always backed up by clinical evidence, they should not be 
pushed lightly aside as not being part of good clinical practice (48, 49). Future 
studies should investigate the consequences of such a flexible treat to target 
in which rheumatologists sometimes override the treat to target procedure 
because of -perceived - issues with safety, efficacy and patient preferences.   
Optimal treatment strategy for a patient with early RA (chapter 3) 
What have we learned? 
The most effective current treatment options for the management of early RA are 
(combinations of) synthetic classic DMARDs with remission inducing agents such 
as GCs or biologicals in a tightly controlled treat to target setting (50).  Chapter 3 
firstly demonstrated that DMARD combinations with a high or moderate dose 
GC remission induction scheme are not superior to MTX only with a 
moderate dose GC remission induction scheme in patients with poor 
prognosis markers after 16 weeks of treatment in the CareRA trial (51). Efficacy 
of the three compared treatment strategies was similar. Yet, the safety profile was 
more advantageous for MTX only with a moderate GC scheme. Furthermore, 
chapter 3 showed that MTX monotherapy with a moderate dose GC remission 
induction scheme seems more efficacious than MTX monotherapy without 
GCs in patients presenting without poor prognosis markers after 16 weeks 
of treatment in the CareRA trial (52). Longitudinal analysis showed that disease 
activity and functional problems were lower in patients with a GC remission 
induction scheme. Most remarkable was the comparable safety profile between 
both treatments. 
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Lastly, chapter 3 investigated the efficacy and safety in the CareRA trial after 1 
year of treatment for patients both with,  and without poor prognosis. The results 
confirmed the findings at week 16. Hence, the general conclusion is that MTX 
with a moderate dose glucocorticoid remission induction scheme - ‘’Cobra 
Slim’’ - fits all patients with RA, with a high efficacy and acceptable safety 
profile. This conclusion reinforces the idea that current prognostic markers 
intended to facilitate individual treatment decisions are overpowered by these 
intensive treatment strategies. 
Methodological considerations 
In the CareRA trial, medication adherence was not measured and no blinding 
procedures were implemented. This trial was set up to reflect daily clinical 
practice. If adherence was lower in a certain trial arm, the same could be 
expected from this treatment regimen in daily clinical practice. However, we 
cannot exclude that rheumatologists would still favor a particular strategy or 
patients would be more motivated for a specific regimen, influencing the results.  
This trial was conceived as a superiority trial in patients with poor prognosis 
markers. Hence, we demonstrated non-superiority of DMARD combinations 
with GC remission induction schemes over MTX only with a GC remission 
induction scheme, which is not the same as claiming non-inferiority. Additionally, 
the sample of patients presenting without poor prognosis markers was 
relatively small. Hence, these results are explorative and in need for 
confirmation. 
The primary study endpoint was the proportion of patients in DAS28 (CRP) 
remission defined by a cutoff of 2,6. Nowadays, remission criteria based on 
CDAI/SDAI and the more stringent ACR Boolean criteria have been proposed 
(53). The use of stricter remission criteria as targets for treatment is supposed to 
lead to a more long-standing disease control. Hence, theoretically, it could be 
advocated to investigate if a trial with a similar design as CareRA, but steered by 
other more stringent treat to target criteria, would show different results. 
Directions for future research and clinical practice 
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The puzzle of glucocorticoids use 
The role of GCs in RA therapy is disputed since their ‘discovery’ in the fifties. 
There are ardent supporters but also fierce opponents. However, the use of GCs 
is widespread in the rheumatologic community. 
First of all, the starting dose of glucocorticoids is a matter of debate. GCs have 
their effects in a dose dependent manner (54). Higher GC dosages by higher 
saturation rates of the GC receptor seem to induce more genomic 
transcription and fast non-genomic effects leading to more rapid inhibition 
of inflammation compared to low GC dosages (typically lower than 7,5mg 
prednisone equivalents). Hypothetically, these added effects could explain the 
high efficacy of COBRA like schedules as demonstrated in the CareRA trial. 
However, higher dosages hold also the risk of more side effects (55). The ideal 
glucocorticoid dose in terms of risk/benefit ratio is not yet clear. In the 
CareRA trial we demonstrated that induction regimens with an initial prednisone 
dose of 30 mg daily were not less effective than the original COBRA schedule 
starting from 60 mg. However, It is questionable if a quest for a further dose 
reduction is worth the effort since moderate GC dosages (>10 mg of prednisone) 
are only used for a 3 weeks in these induction regimens. Moreover, we also 
showed in this trial that MTX with 30mg of prednisone initially versus MTX with 
no GCs yielded a similar safety profile, after 16 and 52 weeks of treatment. It 
could be debated that patients on GC therapy report less side effects because 
they experience less disease activity and feel thus more comfortable, but this 
could of course rather be seen as an advantage of therapy with GCs. 
A second factor with more importance than the exact dosage per day is the 
cumulative exposure to glucocorticoids over time. In the CareRA trial, GCs 
are quickly tapered to a low dose and stopped after 6 months of treatment. Other 
trials use GCs, starting from low dosages, but use them much longer, for a year 
or two years. Hence, the cumulative dosage in these studies is much higher than 
in our trial. Therefore, we argue that not the starting dose, but the total cumulative 
dose should be the main focus in future trials. A very interesting trial design to 
prove our point in terms of GC dosing would be to compare MTX with a moderate 
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GC dose bridging scheme versus MTX with a low GC dose without tapering in 
the first year. Another issue is the lack of a systematic standardized approach 
towards GCs. Cobra like schedules are not frequently encountered in common 
practice, yet many different kinds of bridging schemes seem to be used by 
rheumatologists (56). Moreover, a majority of patients seem to be on some sort 
of GC therapy at most times in their treatment, although probably on low dosages 
(57, 58). This ‘ad libitum’ use seems perhaps innocent, but can lead to high 
exposure in the long term for many patients, explaining partly the perception of 
GCs as a medical product with many safety issues. This problem could explain 
possibly the reluctance by rheumatologists and other HCPs to implement Cobra 
like schedules with high starting dosages (47, 56). However, it seems that 
patients alter their perception on temporal GCs use when they experience the 
potent effect on pain and inflammation, regardless of the dose administered(59, 
60). Hence, efforts should be made to standardize the use of GCs to increase its 
efficacy but at the same time diminish safety issues in the long run. 
To combine or not to combine DMARDs? 
Although we cannot predict individual response to treatment as shown in previous 
parts of the discussion, some patients will probably benefit from initial 
DMARD combination (39, 61, 62). Hence, physicians can still opt for DMARD 
combinations, possibly with a slightly higher efficacy rate, but probably in 
exchange for more adverse events (61). Furthermore, it is possible that 
DMARD combinations give better long term outcomes which should be evaluated 
in the longer run of the CareRA trial or possibly other similar trials. 
Another interesting trial design would be a comparison between a COBRA like 
strategy and the popular triple therapy using MTX, SSZ and HCQ. The tReach 
trial already used a similar design comparing triple therapy with MTX only, both 
with a low dose GC bridging scheme for 10 weeks. Triple DMARDs was shown 
to be more efficacious than MTX only (62). The question is however if the GC 
bridging scheme in this trial was powerful enough to bridge the delay until 
maximum MTX efficacy. Ten weeks could be too short considering the fact that 
MTX maximum efficacy is often only reached after 3-4 months. However, the 
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results of this trial still indicate that some patients will probably benefit more from 
DMARD combination compared to MTX only. 
Present and Future 
This doctoral thesis gives indications as to how a patient with newly diagnosed 
Rheumatoid Arthritis can achieve an excellent chance on a good disease 
outcome. First of all, the patient must be detected, referred and treated as soon 
as possible. This initial treatment must be an intensive treatment that should be 
based on MTX with a remission induction scheme of glucocorticoids regardless 
of the patient profile, as determined by current classical prognostic markers. 
Furthermore, the patient should be followed in a tightly controlled setting, with 
swift treatment adaptations if the disease is not controlled sufficiently. 
However, this thesis also shows there is still much to explore in future 
rheumatologic research. The greatest challenges lays in defining RA as a 
disease entity and in predicting the course of this disease. Both issues are 
reflected in the concept of tailored treatment. This concept is the grail of modern 
medicine, whereby any patient with a specific set of characteristics receives the 
ideal treatment for his or her disorder (63). Although much progress is made, 
tailored treatment in RA is still in its infancy. The first challenge is what RA as a 
formal disease entity really encloses. In many aspects we can see differences 
between patients with the same disease called RA: in terms of disease onset 
being it slowly or acute; periodically or gradually, in terms of clinical presentation 
and clinical response, but also not in the least in terms of in genetic background. 
Still, RA is regarded as a unique syndrome and consequently all RA patients are 
managed the same way. Hopefully, enough progress will be made in the future 
to increase the sensitivity and specificity of disease markers and clinical pattern 
recognition, making differentiation between RA subtypes possible. 
The second challenge is the lack of standardization in treatment, initially, but 
especially during follow up. Physicians treat patients with different characteristics 
in various ways, based on clinical experience and scientific evidence. This 
differentiation based on gut feeling seems to work rather well, but strong evidence 
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for optimal treatment prediction is lacking. Most standardization is found in the 
early RA course. The guidelines now propose to use MTX as standard DMARD, 
sometimes associated with GCs (33, 64). Many studies propose schedules based 
on these recommendations (51, 52, 62, 65-71). These trials attain high 
proportions of patients in remission and low disease activity. However, an 
important proportion of patients still escape.  
A third challenge is to explore why certain patients do not respond the same way 
on treatment as their counterparts. A different genetic background or specific 
clinical and serological characteristics are classic culprits, but atypical 
causes such as treatment adherence or even the psychosocial profile of 
patients also deserve attention in future investigations (72). Of course, 
combinations of these aspects are possibly more explanatory.  
A fourth challenge is to standardize treatment after treatment failure. Patients 
initially doing fine on treatment, can fail later on in their disease course. This 
refractory RA is probably the main playfield for biological therapy. However, it is 
not yet clear what type of biologicals should be selected for which patients. In 
contrast, evidence exists that classical DMARD combination therapy can rescue 
many patients even in established disease (73). Additionally, new treatment 
targets and drugs are still being developed and refined. A new drug concept, the 
JAK inhibitors, can possibly add to a tailored treatment, but the role of these 
agents in RA management is still to be determined (74). Algorithms defining 
treatment strategies later on in the disease course are lacking despite being 
important for the future of RA management.  
A fifth challenge is the potential of tapering or even stopping therapies in 
patients with controlled disease (75-77). Such strategies are very important 
also from the patient perspective (78). Drug free remission is an underexplored 
theme in RA, but will get more and more important when treatments become 
more efficacious at repressing the disease for long times. 
To conclude, the treatment of RA changed drastically in the last decades. New 
treatment options, but especially improved treatment strategies changed the 
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classical image of RA patients from crippled invalids with joint deformities to self-
confident individuals without external traits of their disease. This thesis explored 
further the optimal initial treatment strategies for patients with RA. Firstly, time is 
key in treatment of RA and the delay was found to be still too long in a majority 
of patients. Secondly, current classical biomarkers are not reliable in daily 
practice to tailor treatment to an individual patient. Thirdly, MTX only combined 
remission induction with a moderate dose of GC is a powerful and feasible option 
for all patients with RA. Future research should focus on improving the prediction 
of the disease course while not forgetting treatment feasibility in daily clinical 
practice and the patient perspective. The future looks bright for patients with RA! 
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PROTOCOL SYNOPSIS CareRA  
Title of the protocol A two year prospective, multicentre, randomized, controlled trial comparing effectiveness 
in daily practice of different treatment strategies for early RA.  
Study Population and 
enrolment period 
A total of 400 patients are planned to be included in this study. This study has a duration of 
maximally 108 weeks (104 weeks of treatment and a maximal interval of 4 weeks between 
screening and baseline (w0)). 
The enrolment period is open from 2008 – 06/2013.  
Patients with severe RA will be randomly assigned to 1 of 3 treatment groups of 100 patients 
each according to a 1:1:1 ratio.  
Patients with less severe RA will be randomly assigned to 1 of 2 treatment groups of 50 
patients each according to a 1:1 ratio. 
Inclusion criteria  
- Age ≥ 18 years 
- Diagnosis of RA as defined by the 1987-revised ACR classification criteria or the 
new ACR/Eular 2010 criteria for early RA 
- Early RA defined by a disease duration of ≤ 1 year 
- Use of a reliable method of contraception for women of childbearing potential 
- Able and willing to give written informed consent and participate in the study 
Exclusion criteria 
- Previous treatment with: 
o MTX or leflunomide 
o Cyclophosfamide, azathioprine or cyclosporine 
o SSZ for more than 3 weeks 
o Hydroxychloroquine for more than 6 weeks 
o Oral corticosteroids at a daily dosage of more than 10 mg prednisone 
equivalent within 4 weeks before baseline  
o Oral corticosteroids at a daily dosage equal to or less than 10 mg 
prednisone equivalent within 2 weeks before baseline 
o Oral corticosteroids for more than 4 weeks within 4 months before 
screening 
o Intra-articular corticosteroids within 4 weeks before baseline 
o An investigational drug for the treatment/prevention of RA.  
- Contra indications for corticosteroids 
- Contra indications for MTX, SSZ or Leflunomide 
o Known chronic hepatic disease (alcoholic, fibrosis, …) 
o Known pulmonary interstitial disease or fibrosis  
o Known chronic renal failure 
o History of malignant neoplasm within 5 years 
o Hematologic problems at the discretion of the investigator.  
- Psoriatic arthritis 
- Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions, 
chronic or latent infectious diseases or immune deficiency which in the opinion of 
the investigator places the patient at an unacceptable risk for participation in the 
study. 
- Pregnancy, breastfeeding or no use of a reliable method of contraception 
- Alcohol or drug abuse.  
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Study design 
In this prospective, multicentre, randomized, controlled trial of 2-year duration, 400 
patients with early active RA (≤ 1 year), previously untreated with DMARDs; will 
be stratified according to their disease severity and subsequently randomly assigned 
to different treatment strategies (see flow chart). Disease severity will be determined 
according to a scheme based on the presence of Rheumatoid Factor, anti-CCP 
antibody, erosions and disease activity. 
 
Treatment regimens in the induction phase (Year 1) 
- Tight Step Up: MTX 15 mg and no additional oral steroids allowed 
- COBRA classic: MTX 15 mg with SSZ 2g and a step down scheme of 
steroids (60-40-25-20-15-10-7,5 mg prednisone, each for 7 days except for 
the lowest dose, this will be maintained until w28 and than tapered over 6 
weeks). At week 40, patients will continue MTX (min. 15 mg/week) in 
mono therapy if disease activity is acceptable low (DAS 28 CRP ≤ 3,2) 
- COBRA slim: MTX 15 mg with a step down scheme of steroids (30-20-
12,5-10-7,5-5 mg prednisone, each for 7 days except for the lowest dose, 
this will be maintained until w28 and than tapered over 6 weeks). 
- COBRA avant-garde: MTX 15 mg with Leflunomide 10 mg and a step 
down scheme of steroids (30-20-12,5-10-7,5-5 mg prednisone, each for 7 
days except for the lowest dose, this will be maintained until w28 and than 
tapered over 6 weeks). At week 40, patients will be randomly assigned to 
maintenance therapy with either MTX (≥15 mg/week) or leflunomide (20 
mg daily) if disease activity is acceptable low (DAS 28 CRP ≤ 3,2). 
Treatment regimen in the maintenance phase (Year 2) 
Study design
All patients
Low risk High Risk
INDUCTION 
COBRA
INDUCTION
COBRA SLIM
RANDOMIZATION  PROCEDURE
Tight step up INDUCTIONCOBRA SLIM
RANDOMIZATION   PROCEDURE
STRATIFICATION   PROCEDURE
INDUCTION 
COBRA
AVANTGARDE
25% 75%
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Treatment adjustments during the maintenance phase from w52 onwards will be 
at the discretion of the local physician according to good clinical practice. 
Treatment 
adjustments during 
study 
If patients fail to respond (DAS 28 CRP > 3,2), treatment adjustments will be made 
from 8 weeks of treatment onwards, if desirable and feasible.  
- First step: MTX dose increase to 20 mg per week in all groups 
- Second step: 
o COBRA classic: SSZ dose increase to 3 g 
o COBRA slim and Tight Step Up: add Leflunomide 10 mg 
o COBRA avant-garde: Leflunomide dose increase to 20 mg 
- An intramuscular depot-corticoid injection is allowed together with these 
treatment adjustments, but not within 4 weeks preceding week 16, 28, 40 
and week 52 visits. As an alternative an oral bridging scheme could be 
considered, after discussion with the principal investigator.  
- Intra-articular corticosteroids are allowed  maximally once every 8 weeks 
but not within 4 weeks preceding week 16, 28, 40 and week 52 visits 
- Further DMARD treatment adjustments are only allowed from 8 weeks after 
prior treatment adjustments onwards.  
If patients fail to respond (DAS 28 CRP > 3,2) after 2 treatment adjustments, 
from week 24 onwards = treatment failures  treatment of choice = anti-
TNF + MTX 
Primary objectives 
- To study in patients with severe RA, the daily practice efficacy and 
effectiveness of a modified COBRA slim (without SSZ and with half dose 
steroids) scheme vs. a COBRA classic scheme (15 mg MTX) and a modified 
COBRA avant-garde scheme (Leflunomide instead of SSZ and half dose 
steroids). 
- To study in patients with less severe RA, the daily practice efficacy and 
effectiveness of a Tight Step Up regimen (with 15 mg MTX) vs. a modified 
Cobra slim scheme (without SSZ and with half dose steroids). 
- A superiority analysis will be performed: in the high risk arm, COBRA 
classic and COBRA avant-garde vs. COBRA slim and in the low risk arm, 
COBRA slim vs. Tight Step Up.  
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Outcome measures 
- Primary outcome measures: proportion in remission at week 16, 52 and 104 
- Secondary outcome measures:  
o efficacy at week 16, 52 and 104 using: 
 Disease activity: proportion EULAR responders 
 Proportion of patients in remission according to the SDAI 
(score ≤ 3,3). 
 Proportion of patients in remission according to the CDAI 
(score ≤ 2,8). 
 Proportion of patients in remission according to the 
preliminary Boolean ACR/EULAR criteria. 
 Proportion of patients in remission according to 
DAS28CRP <2.4 
 Functionality: proportion CM HAQ responders and 
proportion HAQ = 0 
 X-ray (Sharp Vanderheijde score) (w28, 52 and 104) 
o Effectiveness at week16, 52 and 104 using: 
 Proportion treatment failures due to efficacy/effectiveness 
problems (only failure due to toxicity at week 16)  
 Proportion with unplanned treatment changes 
 Proportion lost of follow up 
 Total cumulative steroid dose/mean steroid dose per day 
 Proportion started on biologics (not at week 16) 
o Safety: number and type of (serious) adverse events.  
o Other outcome measures: Additional questionnaires as described in 
the flow chart. 
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List of Abbreviations 
 
ACR    American College of Rheumatology 
AE    Adverse Event 
ALT    ALanine aminoTransferase 
Anti CCP antibody  anti-Cyclic Citrullinated Peptide antibody 
AST    ASpartaat-aminoTransferase 
CM HAQ difference  Clinically Meaningful HAQ difference 
CME    Centrum Menselijke Erfelijkheid 
CNS    Central Nerveous System 
COBRA   COmbinatie therapie Bij Reumatoïde Artritis 
CRA    Clinical Research Associate 
CRF    Case Report Form 
CRP    C-Reactive Protein 
DAS28   Disease Activity Score based on the 28 joint count 
DMARD   Disease Modifying Anti Rheumatic Drug 
EC    European Commission 
eCRF    electronic Case Report Form 
ESR    Erythrocyte Sedimentation Rate 
ET    Early Termination 
EULAR   European League Against Rheumatism 
GCP    Good Clinical Practice 
GH    General Health 
GI    Gastro Intestinal 
GOT    Glutamate Oxaloacetate Transaminase 
GPT    Glutamate Pyruvate Transaminase 
HAQ    Health Assessment Questionnaire 
ICH    International Conference on Harmonization 
IEC    Independent Ethical Committee 
IM    Intra Muscular 
IPQ    Illness Perception Questionnaire 
IRB    Institutional Review Board 
MACTAR questionnaire McMaster Toronto Arthritis patient preference  
MFI20 questions  Multidimensional Fatigue Inventory based on 20  
mg    Milligrams 
MTX    Methotrexate 
NSAID   Non Steroidal Anti Inflammatory Drug 
QOL    Quality Of Life 
RA    Rheumatoid Arthritis 
RF    Rheumatoid Factor 
SAE    Serious Adverse Event 
SC    Sub Cutaneous 
SF36    Short Form 36 
SJC    Swollen Joint Count 
SPSS    Statistical Package for the Social Sciences 
SSL    Social Support List 
SSZ    Sulfasalazine 
TEN    Toxic Epidermal Necrolysis 
TJC    Tender Joint Count 
TNF    Tumor Necrosis Factor 
UCL    Utrecht Coping List 
ULN    Upper Limit of Normal 
UZ    University Hospital 
VAS    Visual Analog Scale 
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1. Study title  
 
CareRA: a 2 year prospective multicentre randomised controlled trial comparing 
effectiveness in daily practice of different treatment strategies for early RA. 
 
2. Rationale and introduction 
 
The COBRA trial was a milestone in the development of the present treatment paradigm 
for Rheumatoid Arthritis (RA)[1]. This study introduced the principle of fast remission 
induction by means of a combination of standard disease modifying antirheumatic drugs 
(DMARD: methotrexate (MTX) plus sulphasalazine) and a step down bridge therapy 
with high dose steroids in early Rheumatoid Arthritis (RA). A step down strategy 
proved more effective than a more conservative step up approach with a single 
DMARD, without increased side effects or costs. Although meanwhile the importance 
of early intensive treatment has been confirmed and emphasized in numerous 
publications[2;3;4] there seems to be a discrepancy between theoretical acceptance and 
practical implementation of this strategy in the rheumatologic community[5]. The most 
important reason why rheumatologists do not prescribe the COBRA scheme in daily 
practice seems to be concern about their patient’s opinion on the complexity of the 
scheme and the large amount of drugs they have to take. In addition, patients  dislike 
corticosteroids and prefer newer drugs such as anti-TNF agents, but this unfavorable 
perception seems to improve after steroid use[6]. Rheumatologists have also doubts 
about the initial high dosage of steroids, the relatively low dose of MTX (7.5 mg per 
week) and the use of sulphasalazine as maintenance therapy in the original COBRA 
scheme[5]. In a previous study we showed the feasibility of using a step down strategy 
based on the original COBRA scheme for early RA treatment in daily practice[7]. In our 
study with an adapted COBRA regimen we increased the MTX dose to 15 mg per week 
and randomized patients to maintenance therapy with either sulphasalazine (SSZ) or 
MTX[7]. The higher MTX dosage did not cause more side effects and MTX proved to 
be the most effective maintenance therapy.  
 
In the present randomized controlled trial we will stratify patients according to their 
disease severity based on a theranostic model including classical prognostic factors such 
as the presence of rheumatoid factor, anti-CCP antibodies, erosive status and baseline 
disease activity. In RA patients with a low risk of radiographic progression of a severe 
disease course, we compare a modified version of the COBRA regimen including lower 
dosages of steroids and without sulphasalazine (COBRA slim), with a generally 
accepted step up treatment. In the group of early RA patients with a high risk of severe 
disease we compare the original COBRA regimen (COBRA classic) with modified 
COBRA versions including a MTX-low steroid schedule (COBRA slim) and a 
combination of MTX with leflunomide instead of SSZ (COBRA avant-garde). 
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3.  Study design 
 
3.1.Overall design 
 
In this prospective multicentre randomised controlled trial of 2-year duration, 400 
patients with early active RA (≤1 year), previously untreated with DMARDs, will be 
stratified according to their disease severity and subsequently randomly assigned to 
different treatment strategies (see flow chart).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disease severity will be determined according to a flow chart based on Rheumatoid 
Factor and anti-CCP antibody status, erosive disease or not and disease severity. The 
different randomization options will depend on disease severity (see diagram below). 
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Patients with severe disease 
 
Induction phase: 
 
Patients with severe RA will be randomized to three different remission induction 
regimens including steroids. In all treatment arms patients will initially receive a high 
dose of oral steroids that will be tapered down rapidly on a weekly basis according to 
the timelines of the original COBRA trial (cfr. infra) and from week 28 onwards 
steroids will be further tapered down over 6 weeks till discontinuation. In two treatment 
arms patients will receive initial DMARD combination therapy.  
 
• Group 1a: COBRA classic 
– MTX 15 mg 
– Sulphasalazine 2000 mg 
– Step down steroid full dose: 60-40-25-20-15-10-7.5  mg prednisone, 
each for 7 days 
 
• Group 2a: COBRA slim 
– MTX 15 mg 
– Step down steroid half dose: 30-20-12.5-10-7.5-5 mg prednisone, each 
for 7 days 
 
• Group 3a: COBRA avant-garde 
– MTX 15 mg 
– Leflunomide 10 mg  
– Step down steroid half dose: 30-20-12.5-10-7.5-5 mg prednisone, each 
for 7 days 
 
From week 28 onwards steroids will be tapered down on a weekly basis by leaving out 
one day dose of steroids each week over a period of 6 weeks, till discontinuation. 
 
Maintenance phase: 
 
After the induction phase, from week 40 onwards, the maintenance phase starts.  
Patients will receive a single DMARD maintenance therapy with either MTX or 
leflunomide, except in case the investigators feels it is not possible to switch back to 
mono-therapy due to recent adaptations to the treatment scheme. 
 
At week 40, patients in group 3a will be randomly assigned to maintenance therapy with 
either MTX or leflunomide if their disease activity is acceptably low (DAS 28 CRP ≤ 
3.2).  To evaluate the DAS 28 CRP at this time point, it is allowed to use blood samples 
taken within a timeframe of five days of the visit date.  
Patients in group 1a and 2a will continue MTX as maintenance therapy if their disease 
activity is acceptably low (DAS 28 CRP ≤ 3.2).  
The maintenance dose of MTX is minimally 15 mg per week and the minimum 
maintenance dose of leflunomide is 20 mg daily. Further reduction of DMARD dosages 
during study will only be allowed in case of toxicity. 
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If at the end of the induction phase (week 40) disease activity is not acceptably low 
(DAS28 >3.2), patients can continue in the induction phase depending on the number of 
treatment adjustments already made (section 3.2). 
 
In case no previous treatment adaptations have been made, treatment adjustments as 
described in section 3.2 can be made between week 40 and week 52, preferably 1 
adjustment at week 40 and if necessary another at week 44.  The final evaluation of 
these interventions will take place at week 52.  When disease activity is not acceptably 
low (DAS28>3.2) at week 52, patients are considered treatment failures, if the disease 
activity is below or equal to 3.2, patients will continue the study in maintenance phase. 
 
In case only one treatment adjustment was done before week 40 one extra adaptation 
can be made as described in section 3.2 of the protocol. These patients will be evaluated 
at week 48. If disease activity is not acceptably low (DAS28>3.2 ) at that time point, the 
patients will be considered a treatment failure.  Otherwise if DAS28 ≤ 3.2 patients will 
continue the study in maintenance phase. 
 
If at the end of the induction phase disease activity is not acceptably low (DAS28 > 3.2) 
and 2 previous treatment adjustments were made, patients will be considered as 
treatment failures. 
 
Once patients enter the maintenance phase treatment adjustments from w52 onwards 
will be at the discretion of the physician according to good clinical practice. This means 
that there is no more restriction concerning treatment adaptations and the rule that 2 
adaptations would lead to a treatment failure is no longer applicable. 
 
Patients with less severe disease 
 
Patients with less severe RA will be randomized to either a classic step up regimen 
without steroids, or a remission induction regimen including steroids which will be 
tapered down according to the timelines of the original COBRA trial (see above). 
 
• Group 1b: Tight Step Up 
– MTX 15 mg 
– No additional oral steroids allowed 
 
 
• Group 2b: COBRA slim 
– MTX 15 mg 
– Step down steroid half dose: 30-20-12.5-10-7.5-5 mg prednisone 
 
 
3.2.Treatment adjustments during the induction phase of the study 
 
If patients fail to respond (DAS 28 CRP > 3.2) programmed treatment adjustments will 
be made from 8 weeks of treatment onwards, if desirable and feasible. 
 
The first step in all groups is a MTX dose increase to 20 mg per week. 
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If patients fail to respond (DAS 28 CRP > 3.2) after the first adjustment, further 
adjustments will be made from 8 weeks after the first adjustment onwards (except for 
w40), if desirable and feasible. 
 
 
 
The second step in group 1a is a sulphasalazine dose increase to 3g. 
 
The second step in group 1b, 2a and 2b is to add leflunomide 10 mg. 
 
The second step in group 3a is a leflunomide dose increase to 20 mg. 
 
An intramuscular depot-corticoid injection is allowed together with these treatment 
adjustments, but not within 4 weeks preceding week 16, 28, 40 and week 52 visits.               
As an alternative an oral bridging scheme could be considered, after discussion with the 
coordinating investigator (.Prof. Dr. P. Verschueren, 016 342541, 
patrick.verschueren@uz.kuleuven.ac.be ) 
 
Intra-articular corticosteroids are allowed maximally once every 8 weeks but not within 4 weeks 
preceding week 16, 28, 40 and week 52 visits. 
 
3.3.Treatment failure during study 
 
Treatment failures during the study are defined as failing to respond to the effectiveness 
criteria or as failing to complete a prescribed treatment arm (e.g. toxicities). 
If during the induction phase patients fail to respond (DAS 28 CRP > 3.2) even after 
two predefined treatment adjustments, they will be considered treatment failures from 
week 24 onwards. 
In this case anti-TNF combined with MTX will be the treatment of choice.  
Patients not qualifying the reimbursement criteria for anti-TNF agents will be registered 
and followed up separately.  
Patients who are considered treatment failure will be asked to return for a week 28, 
week 52, week 78 and/or week 104 visit depending on the time point in the trial the 
treatment failure is reached. 
For all patients who failed the treatment (due to effectiveness or toxicity) a strategy 
failure/study completion page will be completed at the time of failure and they will be 
followed up as described above. 
 
3.4.Treatment toxicity during study  
 
General rule for combined DMARD treatment:  
 
If AST or ALT is > 2 times but ≤ 3 times the upper limit of the normal range (ULN) in 
patients receiving combined DMARD treatment, the first measure will be to discontinue 
leflunomide or sulphasalazine treatment.  
Re-evaluation of the blood tests will be done after two weeks. 
Gewijzigde veldcode
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In case of persistent liver disturbances, MTX will be tapered according to schedule and 
a new re-evaluation of the liver function will be scheduled. If after this, liver function is 
not recovered, this will be considered a treatment failure (see section 3.3). If the liver 
function is recovered or recovering MTX should be reintroduced within 4 weeks, other 
DMARDs must be reintroduced gradually within 8 weeks. In case not all medication 
can be reintroduced this will be considered a treatment failure.   
In case of normalization of the liver function after two weeks, leflunomide or 
sulphasalazine can be re-introduced. 
 
Toxicity of MTX in monotherapy: 
 
General rule: dose reduction below 7.5mg for more than 4 weeks will be 
considered a treatment failure. 
 
Dosage reduction:  
 
- in case of gastrointestinal side effects, ulcerative stomatitis or CNS side effects:  
Dose reduction to ≥ 7.5mg (prior switch to IM/SC is preferred in case of GI side 
 effects, ulcerative stomatitis) 
- if AST or ALT > 2 times but ≤3 times ULN:  
 reduce by at least 50% to ≥ 7.5mg/week 
 if after 2 weeks AST or ALT are ≤ 2times ULN,  MTX can be 
maintained at the lower dose or increased gradually up to a maximum of 
20mg/week (rate 2.5mg every 2-4 weeks) 
 if AST or ALT are persistently >2 times ULN: discontinuation of MTX 
 
- if AST or ALT > 3 times ULN: 
 discontinue MTX for 2 weeks 
 if after 2 weeks AST or ALT are ≤ 2 times ULN,  MTX can be 
reintroduced at a lower dose or increased gradually up to a maximum of 
20mg/week (rate 2.5mg every 2-4 weeks) 
 if AST or ALT persistently >2 times ULN: discontinuation of MTX 
 
- Haematological toxicity: according to the decision of the treating physician 
- Renal insufficiency: according to the decision of the treating physician 
- Presumed pulmonary toxicity: discontinuation (treatment failure) 
- Serious infections: temporary discontinuation for not more than 4 weeks is 
allowed 
 
Toxicity of leflunomide in monotherapy: 
 
- in case of diarrhoea or other subjective side effect:  
 dose reduction to 10 mg per week is allowed 
- if AST or ALT is > 2 times but ≤3 times ULN:  
 reduce leflunomide to 10 mg/d 
 if after 2 weeks AST or ALT are ≤ 2 times ULN, leflunomide can be 
maintained at the lower dose or increased up to 20mg/d   
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 if AST or ALT persistent >2 times ULN: discontinuation and wash out 
procedure 
- if AST or ALT is > 3 times ULN: 
 discontinue leflunomide for 2 weeks 
 if after 2 weeks AST or ALT are ≤ 2 times ULN,  leflunomide can be 
started again at 10 mg/d and later increased to 20mg/d 
 if AST or ALT are persistently >2 times ULN: discontinuation and wash 
out 
- Haematological toxicity: according to the decision of the treating physician 
- Renal insufficiency: according to the decision of the treating physician 
- Ulcerative stomatitis or presumed Stevens-Johnson syndrome or TEN (toxic  
epidermal necrolysis): discontinuation and wash out (treatment failure) 
- Presumed pulmonary toxicity: discontinuation and wash out (treatment failure) 
- Serious infections: temporary discontinuation of not more than 4 weeks is allowed 
 
Typical toxicity of sulphasalazine in combination therapy: 
 
Typical cutaneous allergic reaction to sulphasalazine: discontinuation (treatment failure 
for the effectiveness evaluation) 
 
4. Objectives  
 
To study in patients with severe RA, the efficacy and effectiveness of a classic COBRA 
scheme (with 15mg MTX) versus two modified COBRA schemes respectively “slim” 
(without SSZ and with half dose steroids) and “avant-garde” (leflunomide instead of 
SSZ and half dose steroids) in daily practice. 
 
To study in patients with less severe RA, the daily practice efficacy and effectiveness of 
a Tight Step Up regimen (with 15mg MTX) versus a modified COBRA slim scheme 
(without SSZ and with half dose steroids).  
 
A superiority analysis will be performed: in the high risk arm, COBRA classic and 
COBRA avant-garde vs. COBRA slim and in the low risk arm, COBRA slim vs. Tight 
Step Up. 
  
 184 
 
5. Time schedule  
 
 
A maximum of 4 weeks is allowed and a minimum of 1 day is required between 
screening and baseline visit (w0).  In case a baseline visit is done within 5 days of 
screening, the results from the screening blood test can be re-used if no change is 
expected by the investigator. 
 
For key visits (underlined) a time window of one week before and one week after the 
target date is accepted until week 52. 
After week 52 a time window of two weeks before and two weeks after the target date is 
accepted. 
 
At baseline (w0) a list with target dates (+/- window) for each follow up visit will be 
created. 
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6. Study population 
 
6.1.Number of patients and assignment to treatment groups 
 
A total of 400 patients are planned to be included in this study.  
Patients with severe RA will be randomly assigned to one of three treatment groups of 
100 patients each according to a 1:1:1 ratio. Patients with less severe RA will be 
randomly assigned to one of two treatment groups of 50 patients each according to a 1:1 
ratio. 
At randomization, subjects will be stratified according to their erosive status.  
 
 
6.2. Inclusion criteria 
 
Patients enrolled in the study must meet the following inclusion criteria:  
 
- Age 18 years and older 
- Diagnosis of RA as defined by the 1987-revised ACR classification 
criteria or the new ACR/EULAR2010 criteria for early RA 
- Early RA defined by a disease duration ≤ 1 year 
- Use a reliable method of contraception for women of childbearing 
potential 
- Able and willing to give written informed consent and to participate 
in the study 
 
6.3. Exclusion criteria 
 
Patients will be excluded from participating in the study if they meet any of the  
following exclusion criteria: 
 
- Previous treatment with methotrexate or leflunomide 
- Previous treatment with cyclophosphamide, azathioprine or 
cyclosporine 
- Previous treatment with sulphasalazine for more than 3 weeks 
- Previous treatment with hydroxychloroquine for more than 6 weeks 
- Previous treatment with oral corticosteroids at a daily dosage of more 
than 10 mg prednisone equivalent within 4 weeks before baseline 
- Previous treatment with oral corticosteroids at a daily dosage equal to 
or less than 10 mg prednisone equivalent within 2 weeks before 
baseline 
- Previous treatment with oral corticosteroids for more than 4 weeks 
within 4 months before screening 
- Previous treatment with intra-articular corticosteroids within 4 weeks 
before baseline 
- Previous treatment with an investigational drug for the 
treatment/prevention of RA 
- Contraindications for corticosteroids  
- Contraindications for methotrexate, sulphasalazine or leflunomide  
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 known chronic hepatic disease (alcoholic, fibrosis, 
…) 
 known pulmonary interstitial disease or fibrosis 
 known chronic renal failure 
 history of malignant neoplasm within 5 years 
 hematologic problems at the discretion of the 
investigator 
- Psoriatic Arthritis 
- Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal 
conditions, chronic or latent infectious diseases or immune deficiency 
which in the opinion of the investigator places the patient at an 
unacceptable risk for participation in the study 
- Pregnancy, breastfeeding or no use of a reliable method of 
contraception 
- Alcohol or drug abuse 
 
6.4. Concomitant medication 
 
- An extensive list of concomitant medication is recorded at baseline 
- The use of NSAIDs should be recorded for effectiveness evaluation 
- Paracetamol is allowed as long as it is recorded for effectiveness 
evaluation 
- All study patients must receive oral folic acid supplements of 
minimally 1mg daily as well as Calcium and vitamin D (minimal 
1000 mg/800IU daily). 
- All changes in concomitant medication should be registered 
 
7. Outcome measures   
 
7.1. Primary outcome measures 
 
• Proportion in remission (DAS28CRP < 2.6) at 16 weeks 
• Proportion in remission (DAS28CRP < 2.6) at 52 weeks 
• Proportion in remission (DAS28CRP < 2.6) at 104 weeks 
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7.2. Secondary outcome measures 
  
Efficacy at 16 weeks, 52 weeks and 104 weeks:   
• Disease activity:  
– Proportion good EULAR responders 
– Proportion of patients in remission according to the SDAI 
(score ≤ 3,3). 
– Proportion of patients in remission according to the CDAI 
(score ≤ 2 ,8). 
– Proportion of patients in remission according to the 
preliminary Boolean ACR/EULAR criteria. 
– Proportion of patients in remission according to 
DAS28CRP <2.4 
• Functionality: 
– Proportion CM HAQ responders (delta > 0,22) 
– Proportion HAQ = 0 
• X-ray (Sharp Vanderheijde score) (w28, 52 and 104) 
 
Effectiveness at 16weeks, 52 weeks and 104 weeks: 
• Proportion of treatment failures due to efficacy/effectiveness 
problems (only failure due to toxicity at week 16) 
• Proportion with unplanned treatment changes (steroids and 
DMARDs)  
• Proportion lost from follow up 
• Total cumulative steroid dose / mean steroid dose per day 
• Proportion started on biologics (not at week 16) 
 
Safety: number / type of (serious) adverse events (see appendix 1) 
 
 
 
7.3.Other outcome measures 
 
- Recruitment analysis on all consecutive early RA patients 
• Proportion qualifying but unwilling to participate 
• Proportion qualifying but contra-indication 
• Proportion screen failures 
• Proportion in other trials 
- Sensitivity analysis comparing the treatment response in patients 
fulfilling the ACR 1987 classification criteria for RA with those 
fulfilling the 2010 ACR/EULAR RA classification criteria 
- Perception about steroids at baseline, week 16 and week 52 
- Coping (UCL) at baseline and week 16 
- Social support questionnaire at baseline (w0), week 16, week 52 and 
week 104 
- RA QOL questionnaire at baseline, week 16, week 52 and week 104 
- SF36 questionnaire at baseline, week 16, week 52 and week 104 
- IPQ at baseline, week 16, week 52 and week 104 
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- Employment status at baseline, week 16, week 52 and week 104 
- Patient satisfaction questionnaire at week 52 and 104 
- MFI 20 fatigue questionnaire at baseline, week 16, week 52 and week 
104 
- Pittsburgh Sleep Quality Questionnaire at baseline, week 16, week 52 
and week 104 
-  “Patient preference survey” before and during the study (cfr. 
Goekoop) 
- “Doctors preference survey” before and during the study (cfr. Van 
Tuyl) 
 
8. Study duration 
 
This study has a duration of maximally 108 weeks (104 weeks of treatment and a 
maximal interval of 4 weeks between screening and baseline (w0) 
  
9. Enrolment period 
 
The enrolment period will be from 2008-06/2013.   
 
10. Number of investigative sites 
 
• Department of Rheumatology, University Hospital Leuven 
• Cooperating Rheumatology Practices: cfr. supra. 
 
11. Clinical Evaluation 
 
11.1. Screening 
A signed informed consent form must be obtained from each patient prior to any study-
related procedure being performed.  All test results and assessments required to 
establish eligibility of the patient must be obtained prior to enrolment and prior to 
dispensation of the medication. 
 
The following are required at screening: 
 signed informed consent form 
 assessment of inclusion/exclusion criteria 
 RF and anti-CCP 
 X-ray (Sharp Vanderheijde Score) 
 Concomitant Medication 
 TJC, SJC  
 Standard blood sample: ESR, CRP, complet, GOT, GPT and serum creatinine 
 DAS28CRP/ESR 
 VAS GH  
 Determination of the educational level 
 Evaluation of employment status before onset of disease 
 Current employment status / participation 
 Perception Steroids (Questionnaire) 
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11.2. Baseline (w0)  
 
The following are required at Week 0 visit: 
 Concomitant medication. 
 Side Effects 
 TJC and SJC 
 Standard blood sample: ESR, CRP, complet, GOT, GPT and serum creatinine 
(in case screening blood samples were taken within 5 days, these values can be 
used). 
 DAS28CRP/ESR 
(in case screening blood samples were taken within 5 days, these values can be 
used) 
 VAS GH 
 VAS pain and fatigue 
 HAQ questionnaire 
 SF36, RA QoL, IPQ, social support (SSL), fatigue (MFI-20), sleep quality 
(Pittsburgh Sleep Quality Questionnaire) 
 Coping (UCL) questionnaire 
 Serum and urine storage in selected sites only (in case the baseline visit will be 
done within 5 days from screening, these samples can be collected at screening) 
 Genetic sample for consenting patients only (in case the baseline visit will be 
done within 5 days from screening, these samples can be collected at screening) 
 
11.3. Week 4  
 
The following are required at Week 4: 
 Concomitant medication. 
 Side Effects 
 TJC and SJC 
 Standard blood sample: ESR, CRP, complet, GOT, GPT and serum creatinine 
 DAS28CRP/ESR 
 VAS GH 
 Serum and urine storage in selected sites only 
 
11.4. Week 8 and week 40, 65, 78 and 91 
 
The following are required at Week 8, 40, 65, 78 and 91 visits 
 Concomitant medication. 
 Side Effects 
 TJC and SJC 
 Standard blood sample: ESR, CRP, complet, GOT, GPT and serum creatinine 
 DAS28CRP/ESR 
 VAS GH 
 VAS pain and fatigue 
 HAQ questionnaire 
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 Serum and urine storage in selected sites only (only week 8) 
 
11.5. Week 28 
 
The following are required at week 28: 
 X-ray (Sharp Vanderheijde Score) 
 Concomitant medication. 
 Side Effects 
 TJC and SJC 
 Standard blood sample: ESR, CRP, complet, GOT, GPT and serum creatinine 
 DAS28CRP/ESR 
 VAS GH 
 VAS pain and fatigue 
 HAQ questionnaire 
 Serum and urine storage in selected sites only 
 
11.6. Endpoint Visits (week 16, week 52 and week 104) 
 
The following are required at week 16: 
 Concomitant medication. 
 Side Effects 
 TJC and SJC 
 Standard blood sample: ESR, CRP, complet, GOT, GPT and serum creatinine 
 DAS28CRP/ESR 
 VAS GH 
 VAS pain and fatigue 
 HAQ questionnaire 
 Current employment status / participation 
 Perception Steroids (Questionnaire) 
 SF36, RA QoL, IPQ, social support (SSL), fatigue (MFI-20), sleep quality 
(Pittsburgh Sleep Quality Questionnaire) 
 Coping (UCL) questionnaire 
 Serum and urine storage in selected sites only 
The following are required at week 52: 
 RF and anti-CCP 
 X-ray (Sharp Vanderheijde Score) 
 Concomitant medication. 
 Side Effects 
 TJC and SJC 
 Standard blood sample: ESR, CRP, complet, GOT, GPT and serum creatinine 
 DAS28CRP/ESR 
 VAS GH 
 VAS pain and fatigue 
 HAQ questionnaire 
 Current employment status / participation 
 Perception Steroids (Questionnaire) 
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 SF36, RA QoL, IPQ, social support (SSL), fatigue (MFI-20), sleep quality (Pittsburgh 
Sleep Quality Questionnaire) 
 Satisfaction questionnaire 
 Serum and urine storage in selected sites only 
 
The following are required at week 104: 
 RF and anti-CCP 
 X-ray (Sharp Vanderheijde Score) 
 Concomitant medication. 
 Side Effects 
 TJC and SJC 
 Standard blood sample: ESR, CRP, complet, GOT, GPT and serum creatinine 
 DAS28CRP/ESR 
 VAS GH 
 VAS pain and fatigue 
 HAQ questionnaire 
 Current employment status / participation 
 SF36, RA QoL, IPQ, social support (SSL), fatigue (MFI-20), sleep quality (Pittsburgh 
Sleep Quality Questionnaire) 
 Satisfaction questionnaire 
 Serum and urine storage in selected sites only 
 
In case of not reaching the target and recent treatment adjustment or in case of side 
effects the following optional visits can be performed: Week 12, week 20, week 24, 
week 32, week 36, week 44, week 48. 
 
The following are required at these optional visits: 
 Concomitant medication. 
 Side Effects 
 TJC and SJC 
 Standard blood sample: ESR, CRP, complet, GOT, GPT and serum creatinine 
 DAS28CRP/ESR 
 VAS GH 
 
11.7. Strategy failures 
In case of strategy failure, data from the visit at which the decision is taken to consider 
the strategy as ineffective will be recorded.  Radiological evaluation is required in case 
of strategy failure when no radiograph is available within the last 3 months preceding 
the strategy failure visit or expected according to the protocol within 3 months.  
Evaluation of RF and CCP positivity are only required when the strategy failure visit is 
a w52 or a w104 visit. 
Also in case of strategy failure patients will be asked to return for a week 28, week 52, 
week 78 and/or week 104 visit depending on the time point in the trial the treatment 
failure is reached. 
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12. Study discontinuation 
The study may be discontinued by the organizer in case of safety concerns or major 
logistic problems. 
 
13. Withdrawal of patients 
Any patient may withdraw from the study for any reason at any time.  The investigator 
may withdraw any patient from the study if it is not in the patient’s best interest to 
continue. 
When a patient withdraws or is withdrawn from the study, regardless of the reason, the 
date of withdrawal and the reason for termination should be documented on the strategy 
failure/completion page.  To the extent possible all evaluations as required for a strategy 
failure will be recorded: radiological evaluation in case no radiograph is available 
within the last 3 months preceding withdraw and evaluation of RF and CCP positivity. 
Every effort should be made to determine the reason why patients fail to return for the 
necessary visits or withdraw from the study.  If patients cannot be reached by phone, a 
letter should be sent requesting that contact will be made with the investigator to 
confirm the reason for withdrawal from the study. 
 
14. Informed Consent 
Each patient must provide informed consent in order to enrol in the study.  The 
informed consent process will be conducted per institutional protocol and in compliance 
with applicable IEC and regulatory requirements. 
There will be a separate informed consent form for patients not willing to participate to 
the medication study but prepared to provide demographical data for statistical 
comparison between participants and non-participants. 
A separate informed consent form must be signed by patients prepared to give a blood 
sample for genetic analysis. 
 
15. Patient randomisation 
Each clinical site will be assigned a 3 digit site number, the patient numbers will start 
with this site number followed by a 3 digit patient number starting with 001. 
Randomisation will be done within the e-platform after confirmation of the in and 
exclusion criteria. 
 
 
16. Laboratory Tests 
A standard blood sample will be performed.  The testing will be done by an accredited 
laboratory.  The laboratory tests are as follows: ESR, CRP, complet, GOT, GPT and 
serum creatinine. Moreover extra serum and urine samples will be collected at each 
study visit for future scientific analyses. 
At baseline a blood sample for genetic study will be taken only in patients prepared to 
sign a separate informed consent form.  Genetic extractions and storage will be done by 
the CME, University Hospitals Leuven until further analysis. 
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17. Safety 
17.1.  Definition of an adverse event 
An Adverse Event (AE) is defined as any untoward medical occurrence in a patient 
administered a pharmaceutical product.  The occurrence does not necessarily have a 
causal relationship with this treatment.  An AE can therefore be any unfavourable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal product, whether or not related to the 
medicinal product. 
The investigator and/or his study team will examine any patient experiencing an AE as 
soon as possible.  The investigator will do whatever is medically necessary for the 
safety and well-being of the patient.  
 
Severity Grading for Adverse Events: 
Severity should be graded into one of the three classes which describe the clinical 
severity of the event as it occurred: 
 Mild (does not interfere with daily living) 
 Moderate (somewhat interferes with daily living or medications needed to 
relieve event) 
 Severe (incapacitating) 
Laboratory Abnormalities: 
The investigator must assess the clinical significance of all abnormal laboratory values 
as defined by the compendium of normal values for the reference laboratory.  Any 
clinically significant abnormalities should be investigated. 
Collecting and Reporting Adverse Events: 
Patients will be asked at each visit about the occurrence of any adverse events.  Adverse 
events will not be collected or evaluated beyond the patient’s final study visit.  Adverse 
events should be followed by the investigator until they have returned to baseline or 
stabilized. 
 
17.2.  Definition of a Serious Adverse Event 
The definition of a Serious Adverse Event (SAE) is any untoward medical occurrence 
that: 
 Fatal, resulting in death 
 Is immediately life-threatening 
 Requires inpatient hospitalisation or prolongation of existing hospitalisation 
 Results in persistent or significant disability/incapacity 
 Is a congenital anomaly/birth defect 
 
In addition, important medical events that not fulfil above criteria may be considered 
Serious Adverse Events when, based upon appropriate medical judgement, they may 
jeopardize the patient and may require medical or surgical intervention to prevent one of 
the outcomes listed in the definition. 
 
Any SAE that occurs during this study must be reported immediately.  After completion 
of the seriousness criteria in the eCRF a SAE-form will automatically appear and should 
be completed by the investigator.  This SAE reports will then be electronically signed 
and automatically e-mailed to the Department of Rheumatology of the University 
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Hospitals Leuven.  The investigator must complete this form within 24 hours after 
becoming aware of the SAE. 
Follow-up information must be submitted promptly by completing a follow up SAE 
form, which will be submitted by e-mail.  The coordinating physician is available to 
provide medical guidance regarding SAE reporting.   
 
 
17.3.  Safety committee 
A safety committee is installed to regularly review the safety data for the trial.  The 
safety committee acts independently from the steering committee, and consists of 3 
members not participating in the trial: 2 rheumatologists and 1 internal medicine 
specialist. 
On a regular basis, after reviewing the safety data, they will give advice to the steering 
committee. 
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18. Obligations of the investigator 
The investigator must comply with all applicable regulations.  In addition, the 
investigator must follow local and institutional requirements pertaining, but not limited, 
to clinical research, informed consent and IRB/IEC regulations.  The department of 
Rheumatology of the University Hospitals Leuven will provide notification to the 
investigators of protocol and amendment approvals by regulatory authorities, if 
applicable. 
 
Except where the investigator’s signature is specifically required, it is understood that 
the term “investigator” as used in this protocol and protocol related documents refers to 
the investigators and/or appropriate study personnel that the investigators designates to 
perform a certain duty.  The investigator is ultimately responsible for the conduct of all 
aspects of the study. 
 
19. Compliance with Good Clinical Practice 
This study will be conducted in accordance with Good Clinical Practice as required by 
the 1997 International Conference on Harmonization (ICH) Guideline on Good Clinical 
Practice (ICH E6) and the European Directive 2001/20/EC. 
 
The investigator at each clinical site must sign the Protocol Signature Page. 
 
20. Compliance with the Declaration of Helsinki 
This study will be conducted in accordance with ethical principles as described in the 
Declaration of Helsinki. 
 
21. Institutional Review Board/Institutional Ethics Committee 
Prior to enrolment of patients into this study, the final protocol, informed consent form 
(ICF) and any patient recruitment materials will be submitted to, and reviewed and 
approved by an Institutional Ethics Committee (IEC). 
 
Any necessary amendments to the protocol and/or ICF will be prepared by the 
Rheumatology Department of the University Hospitals of Leuven and provided to the 
investigator for submission to the IRB/IEC. 
 
22. Informed Consent Process 
The investigator will choose patients in accordance with eligibility criteria.  The 
investigator will not exercise selectivity so that bias is prevented.  All patients must sign 
an informed consent form that complies with the requirements of ICH E6 before 
entering the study.   
 
Prior to the study, patients will receive a comprehensive explanation of the proposed 
treatment including the nature and risks of the study, alternate therapies, any known 
adverse events, the medicinal product, and the other elements that are part of proper 
obtaining informed consent.  Patients will be allowed sufficient time to consider 
participation in the study, after having the nature and risks of the study explained to 
them. 
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By signing the informed consent form, the patient agrees to complete all evaluations 
required by the study, unless the patient withdraws voluntarily or is terminated from the 
study for any reason. 
 
23. Data acquisition 
For this study an electronic case report form (eCRF) will be used.  Study monitors 
(CRA) will review the eCRFs for completeness and accuracy by comparing them to the 
source documents at the clinical study site.   
 
24. Source Documents 
Documentation of source data is necessary for the evaluation and validation of clinical 
findings, observations and other activities during a clinical study.  Source 
documentation serves to substantiate the integrity of study data, confirms observations 
that are recorded and confirms the existence of study participants.  Data collection is the 
responsibility of the clinical study staff at the site under the supervision of the site 
investigator.  The investigator will maintain complete and accurate documentation for 
the study. 
 
As defined in section 1.52 of the ICH Guideline for Good Clinical Practice (ICH E6) 
source documents may include: original documents, data and records (e.g. hospital 
records, clinical and office charts, laboratory notes, ...) 
All source documents and laboratory reports will be reviewed by the clinical team to 
ensure that they are accurate and complete. 
 
25. Retention of Documentation 
All documents related to the study must be kept as described in the ICH-GCP 
guidelines. 
 
26. Confidentiality 
The study protocol and other written materials provided by the Department of 
Rheumatology of the University Hospitals of Leuven and documentation, data and other 
information generated as part of this study will be held in strict confidence by the 
investigator and site staff.  No information concerning the study or the data will be 
released to any unauthorized third party without prior written approval of the 
Department of Rheumatology of the University Hospitals of Leuven. 
 
27. Deviations from protocol 
In general no deviations to the protocol will be granted, unless there is an agreement and 
approval of the steering committee after discussion with the investigator. 
 
28. Study monitoring 
Prior to the treatment on a patient the monitor shall ensure that the investigator 
understands all requirements of the protocol and his/her regulatory responsibilities as an 
investigator.  The monitor will visit each clinical study site at appropriate intervals to 
ensure compliance with the protocol, to verify accuracy, completeness and correctness 
of data. 
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29. Final Report from investigator 
The coordinating investigator will write a final report after completion of the study in 
accordance with the EudraCT guidelines. 
 
30. Publication 
The results of the main study will be submitted for publication in a peer reviewed 
rheumatology journal. All centres will be entitled to one authorship for the publication 
of the week 16 and week 52 data, depending on the requirements and regulations of the 
journal. Authorships for all other publications will be depending on the contribution of 
an investigator to the manuscript and inclusion of patients. All investigators will be 
mentioned as members of the CareRA study group.  Additional publications concerning 
study data will have to be approved by the CareRA study group. 
 
31. Proposed analysis plan 
A superiority analysis will be performed: in the high risk arm, COBRA classic and 
COBRA avant-garde vs. COBRA slim and in the low risk arm, COBRA slim vs. Tight 
Step Up. In collaboration with the department of biostatistics a power analysis was 
performed based on the primary outcome parameter in the high risk group: proportion 
of patients in remission at month 4. A total of 100 patients per treatment arm is required 
to show a statistical difference between COBRA classic or COBRA avant-garde and 
COBRA slim, with a power of 80% (Alpha 5%), starting from an estimated difference 
in effect size of 20%. The statistical analysis will be performed with SPSS 12 using 
parametric or non-parametric tests, depending on the distribution of the data. 
An interim analysis will be performed on the week 16 and week 52 data of the total 
patient population. 
 
32. Study Material 
32.1. Resources for data analysis 
As this is an investigator initiated trial, the Department of Rheumatology of the 
University Hospitals Leuven will provide the resources for data analysis. 
 
32.2. Medication 
The leflunomide for group 3a will be distributed by the Department of Rheumatology of 
the University Hospitals Leuven.  Sanofi-Aventis will provide this medication without 
any charge.  All other medication used in this study will be prescribed by means of pre-
printed prescription forms, which will be provided by the Department of Rheumatology 
of the University Hospitals Leuven.  The patient will collect this medication at the 
pharmacy as in normal daily practice. 
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Introduction 
The last decades meant a revolution for the treatment of patients with early 
Rheumatoid Arthritis (RA). In the past, patients were treated conservatively and 
treatment was only intensified when disease escalated, leading to structural 
damage and functionality loss in many RA patients. Nowadays, it is clear that 
early, intensive treatment with a clear predefined treatment target leads to 
excellent clinical outcomes for the majority of patients with early RA. First of all, 
it is shown that the earlier the treatment is started in RA, the better outcome the 
patient has. However, no information on the current extent of treatment delay was 
available for Flanders before this thesis. Secondly, many attempts are made to 
tailor treatment to an individual patient based on prognostic factors, to improve 
further disease outcome such as structural damage. However, algorithms 
combining these prognostic factors to aid a physician in his treatment choice were 
not yet tested in daily practice. Thirdly, many intensive treatment options exist 
nowadays to treat a patient with early RA. Yet, debate is ongoing on the exact 
content of this intensive treatment. 
Objectives 
The objectives of this research project were to determine: 
1) the treatment delay, defined as the time between symptom onset and 
treatment initiation in Flanders 
2) the reliability of classical prognostic factors in daily clinical practice 
3) the optimal intensive treatment strategy for every patient with RA 
 
Results 
In chapter 1, we demonstrated that in Flanders only one on five of newly 
diagnosed RA patients are treated in a timely fashion. Patients expressing more 
severe disease characteristics at baseline seemed to present themselves earlier 
to the treating rheumatologist than those without. Moreover, a difference in 
treatment delay between the different types of rheumatology practices was found. 
Patients treated in academic and general hospitals showed longer treatment 
delays than those treated in private practices. Furthermore, patient-related delay 
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contributed the most to overall treatment delay in Flanders. Further research 
showed that aside of clinical characteristics, psychosocial factors also contributed 
to this patient-related delay. More research is needed to unravel the patient’s help 
seeking behaviour. 
In chapter 2, we firstly showed that composite algorithms using classical 
prognostic markers to predict structural damage in patients with early RA could 
not be reliably used in daily practice. No patients that developed rapid structural 
damage could be correctly identified by using these composite algorithms. 
Further in chapter 2, we showed that a combination of classical DMARDs with a 
GC bridging scheme seemed more effective than DMARD monotherapy in 
achieving higher remission rates and less radiographic progression after two 
years of treatment in our observational early RA cohort. Patients in this cohort 
were selected by the treating physician based on the presence of classical 
prognostic factors to receive a more conservative therapy if the RA profile of the 
patient seemed less severe at baseline. Hence, classical prognostic factors seem 
at the moment unreliable to base treatment choice upon in daily practice. 
 
In chapter 3, we presented the results of the CareRA RCT, showing firstly that 
in patients with poor prognosis markers after 16 weeks of treatment DMARD 
combinations with a high or moderate dose glucocorticoid (GC) remission 
induction scheme were not superior to Methotrexate (MTX) only with a 
moderate dose GC remission induction scheme. The efficacy of the three 
compared treatment strategies was similar. Yet, the safety profile was more 
advantageous for MTX only with a moderate GC scheme. Furthermore, we 
showed that MTX monotherapy with a moderate dose GC remission induction 
scheme seems more efficacious than MTX monotherapy without GCs in 
patients presenting without poor prognosis markers after 16 weeks of treatment.  
Most remarkable was the comparable safety profile between both treatments. 
Lastly, we investigated the efficacy and safety in the CareRA trial after one year 
of treatment for both patients with or without poor prognosis. The results 
confirmed the findings at week 16.  
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The overarching conclusion regarding the third objective of this thesis is thus 
that MTX with an initial moderate dose glucocorticoid remission induction 
scheme seems to fit all patients with RA, with a high efficacy and acceptable 
safety profile. 
Conclusion 
Firstly, treatment delay is found to be too long in Flanders. Secondly, current 
classical biomarkers are not reliable in daily practice to guide treatment choice. 
Thirdly, MTX only combined with an initial moderate dose glucocorticoid 
remission induction scheme is very efficacious and safe for all patients with RA. 
We hope to have added essential evidence for an improved treatment outcome 
for every patient with RA with this thesis. 
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Samenvatting 
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Inleiding 
De laatste decennia betekenden een revolutie in de behandeling van patiënten 
met beginnende Rheumatoïde Arthritis (RA). In het verleden werden deze 
patiënten voornamelijk conservatief behandeld. De behandeling werd pas 
opgedreven naarmate de ziekte escaleerde met belangrijke structurele schade 
en verlies van functionaliteit als gevolg voor vele patiënten met RA. 
Tegenwoordig is het duidelijk dat vroege intensieve behandeling met een 
vooropgesteld behandelingsmikpunt leidt tot uitstekende klinische resultaten voor 
de meeste patiënten. Ten eerste is aangetoond dat hoe eerder de behandeling 
wordt opgestart bij een patiënt met vroege RA, hoe beter de resultaten zijn voor 
de patiënt. Er was echter voor aanvang van deze thesis geen informatie 
beschikbaar over de orde van grootte van de behandelingsvertraging in 
Vlaanderen. Ten tweede is onderzocht hoe betrouwbaar de op dit moment 
beschikbare prognostische factoren zijn voor het voorspellen van de ernst van de 
ziekte en de respons op behandeling bij de individuele patiënt om zo nefaste 
ziekteuitkomsten zoals structurele schade te vermijden. Algoritmen die deze 
klassieke prognostiche factoren combineren, om zo de arts bij te staan in zijn 
keuze van een behandeling waren nog niet getest in de dagelijkse praktijk. Ten 
derde bestaan er vele intensieve behandelingsopties bij beginnende RA. Wat de 
exacte inhoud van deze intensieve behandeling is, is nog steeds voer voor debat. 
Doelstellingen 
De doelstellingen van dit onderzoeksproject zijn het bepalen van: 
1) de behandelingsvertraging, gedefinieerd als de tijd tussen de aanvang van 
de symptomen en de start van de behandeling, specifiek in Vlaanderen 
2) de betrouwbaarheid van klassieke prognostische factoren in de dagelijkse 
klinische praktijk 
3) de optimale intensieve behandelingsstrategie voor elke patiënt met RA 
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Resultaten 
In hoofdstuk 1 hebben we aangetoond dat in Vlaanderen slechts één op vijf van 
de nieuw gediagnosticeerde RA patiënten tijdig werd behandeld. Patiënten met 
ernstigere ziektekenmerken leken zich vroeger bij de behandelende reumatoloog 
te presenteren dan degenen zonder. Bovendien werd er een verschil in de 
vertraging op het starten van de behandeling gevonden tussen de verschillende 
vormen van reumatologie praktijken. Patiënten in de academische en algemene 
ziekenhuizen toonden langere vertragingen dan degene in privé-praktijken. Ook 
werd vastgesteld dat de aan de patiënt gerelateerde vertraging het meeste 
bijdroeg tot de totale behandelingsvertraging. 
 
In hoofdstuk 2 bleek dat algoritmen samengesteld op basis van klassieke 
prognostische biomarkers om structurele schade te voorspellen bij patiënten met 
beginnende RA niet betrouwbaar kunnen worden gebruikt in de dagelijkse 
praktijk. Aan de hand van deze algoritmen konden geen patiënten die achteraf 
snelle structurele schade bleken te ontwikkelen, worden geïdentificeerd. Verder 
in hoofdstuk 2 hebben we aangetoond op basis van observationeel onderzoek 
dat een combinatie van klassieke antireumatica met een schema van 
glucorticoïden effectiever leek dan de conservatieve monotherapie na twee jaar 
behandeling. De behandelende arts selecteerde aan de hand van klassieke 
prognostiche factoren voor zijn patiënten met minder ernstige ziektekenmerken 
een meer conservatieve therapie. Patienten met een ogenschijnlijk gunstige 
prognose blijken dus toch minder goed geholpen te worden met een 
conservatieve therapie. 
 
In hoofdstuk 3 rapporteren we de resultaten van de CareRA RCT, waarin we in 
de eerste plaats hebben vastgesteld dat, bij patiënten met markers van slechte 
prognose na 16 weken behandeling, DMARD combinaties met een remissie 
inductie schema startend bij een hoge of matige dosis glucocorticoïden (GC) niet 
superieur waren aan Methotrexate (MTX) met een remissie-inductie schema 
startend bij een matige dosis GC. De doeltreffendheid van de drie vergeleken 
behandelingsstrategieën was vergelijkbaar. Het veiligheidsprofiel was gunstiger 
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voor MTX met een matige dosis GC. Verder toonden we aan dat, bij patiënten 
zonder merkers van slechte prognose na 16 weken behandeling, MTX 
monotherapie met een remissie inductie schema startend bij een matige dosis 
GC effectiever leek dan MTX zonder GC. Het meest opvallende was het 
vergelijkbare veiligheidsprofiel tussen beide behandelingen. Tenslotte 
onderzochten we in de CareRA trial de doelmatigheid en veiligheid van intensieve 
therapieën na één jaar behandeling bij zowel patiënten met of zonder een slechte 
prognose. De resultaten bevestigden de bevindingen van week 16. De algemene 
conclusie van hoofdstuk drie luidt dan ook dat MTX met een remissie inductie 
schema startend bij een matige dosis GC past bij alle patiënten met RA, met een 
hoge werkzaamheid en aanvaardbaar veiligheidsprofiel. 
Conclusie 
Ten eerste is de vertraging alvorens te starten met een behandeling voor RA te 
lang in Vlaanderen. Ten tweede zijn de huidige klassieke prognostische 
biomarkers  niet betrouwbaar voor het sturen van de behandelingskeuze in de 
dagelijkse praktijk. Ten derde is MTX gecombineerd met een remissie-inductie 
schema startend bij een matige dosis GC, zeer doeltreffend en veilig voor alle 
patiënten met beginnende RA. Met dit proefschrift hopen we bij te dragen tot een 
betere behandeling voor elke patiënt met beginnende RA. 
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